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Abstract

MEMBRANE-BOUND MATRIX METALLOPROTEINASES INFLUENCE REACTIVE
SYNAPTOGENESIS FOLLOWING TRAUMATIC BRAIN INJURY
By: Kelly Michelle Warren, MPT
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2010
Major Director: Linda L. Phillips, Ph.D., Professor,
Anatomy and Neurobiology Department

Traumatic brain injury (TBI) produces axonal damage and deafferentation, triggering
injury-induced synaptogenesis, a process influenced by matrix metalloproteinases
(MMP) and their substrates. Here we report results of studies examining the expression
and potential role of two membrane-bound MMPs, membrane-type 5-MMP (MT5-MMP)
and a disintegrin and metalloproteinase-10 (ADAM-10), along with their common
synaptic substrate N-cadherin, during the period of reactive synaptogenesis. Protein
and mRNA expression of MT5-MMP, ADAM-10 and N-cadherin were compared in two
TBI models, one exhibiting adaptive plasticity (unilateral entorhinal cortex lesion; UEC)
and the other maladaptive plasticity (fluid percussion injury + bilateral EC lesions;
TBI+BEC), targeting 2, 7, and 15d postinjury intervals. In adaptive UEC plasticity,
membrane-bound MMP expression was elevated during synaptic degeneration (2d) and
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regeneration (7d), and normalized at 15d. By contrast, N-cadherin expression was
significantly decreased at 2 and 7d after UEC, but increased during 15d synaptic
stabilization. In maladaptive plasticity, 2d membrane-bound MMP expression was
dampened compared to UEC, with persistent ADAM-10 elevation and reduced Ncadherin protein level at 15d. These results were supported by 7d microarray and qRTPCR analyses, which showed transcript shifts in both hippocampus and dentate
molecular layer (ML) for each model. Parallel immunohistochemistry revealed
significant MT5-MMP, ADAM-10 and N-cadherin localization within ML reactive
astrocytes, suggesting a glial synthetic or phagocytotic role for their processing during
recovery. We also investigated the effect of MMP inhibition on molecular,
electrophysiological, behavioral and structural outcome at 15d following TBI+BEC.
MMP inhibitor GM6001 was administered at 6 and 7d postinjury, during elevated MT5MMP/ADAM-10 expression and synapse regeneration. MMP inhibition showed: 1)
reduced ADAM-10 and elevated N-cadherin protein expression, generating profiles
similar to 15d post-UEC, 2) attenuation of deficits in the initiation phase of long-term
potentiation, and 3) improved hippocampal dendritic and synaptic ultrastructure.
Collectively, our results provide evidence that membrane-bound MMPs and N-cadherin
influence both adaptive and maladaptive plasticity in a time and injury-dependent
manner. Inhibition of membrane-bound MMPs during maladaptive plasticity produces
more adaptive conditions, improving synaptic efficacy and structure. Thus, targeting
MMP function and expression have potential to translate maladaptive plasticity into an
adaptive process, facilitating improved recovery.

xv

Chapter 1

Introduction

1

TRAUMATIC BRAIN INJURY
Incidence, Demographics, and Classification
Traumatic brain injury (TBI) is defined as any external force applied to the head
that disrupts the normal function of the brain. Each year, approximately 1.7 million
Americans sustain different severities of TBI, often leading to long-term and life-altering
physical, cognitive and/or psychosocial impairments. Of these 1.7 million cases,
approximately 1.365 million are admitted, treated and released from an emergency
department, 275,000 are hospitalized, and it is estimated that 52,000 cases result in
fatalities (Faul et al., 2010). In addition to these staggering statistics, another cohort of
TBI sufferers are never seen or treated by a medical professional, therefore indicating
an even larger number of annual TBI incidents. In the United States (US), children
aged 0-4 years, adolescents 15-19 years and adults over the age of 65 years are
among the groups most likely to sustain a TBI. In each of these age groups, males
have a higher TBI rate than females, which is often attributed to inherent risky behaviors
(Faul et al., 2010). The leading causes of TBI include falls, motor vehicle accidents,
violence/assault, and sports-related head injuries (NIH, 1999). TBI incidents each year
in the US outnumber cases of multiple sclerosis, breast cancer, and spinal cord injury
combined, making it one of most pervasive medical epidemics facing our society today
(Weber and Maas, 2007). Due to the complicated and patient-specific nature of TBI,
evidence-based diagnostic methods and consistency of standards of care have been
difficult to define and implement across medical institutions. Consequently, TBI remains
a “silent epidemic” that requires continual laboratory and clinical investigation with the
common goal to limit the severity and incidence of persistent deficits that affect the
millions of Americans who are living with the consequences of TBI today.
2

TBI is classified as either mild, moderate, or severe, however the diagnosis and
treatment of patients who fall within this spectrum is not always clear. Within these
broad groups, patients can be further classified based on the type of TBI sustained,
including open vs. closed head injury, contusions, hematomas, ischemic damage,
diffuse axonal injury, and blast injury to name a few. Based on these categories,
patients are often classified as either having a focal or diffuse injury, however these two
types of injury are not exclusive and often found to coexist and contribute to morbidity
(Graham et al, 2000). All aforementioned sub-classifications are determined upon
admission, after patients are put through a battery of tests designed to further delineate
mechanism of injury, determine prognosis, and guide treatment. Postinjury details,
such as duration of loss of consciousness (LOC) and post-traumatic amnesia (PTA), are
collected and used as initial prognostic indicators. A longstanding component of the
initial and ongoing post-traumatic assessment is the Glasgow Coma Scale (GCS),
which was designed in the 1970‟s to quantify injury severity and outcome by scoring eye
opening, motor and verbal responses (Teasdale and Jennett, 1974). Today, the GCS is
still an integral part of initial and follow-up patient assessment however it cannot stand
alone in the postinjury care process, and additional specific tests are necessary to
properly classify TBI severity and outcome. With technological advances, greater
emphasis has been placed on the use of different imaging techniques such as computer
tomography (CT), magnetic resonance imaging (MRI), functional MRI (fMRI), positron
emission tomography (PET), and diffusion tensor imaging (DTI) to improve classification
through identifying different postinjury pathologies and structural changes. Hospitalized
TBI patients also may undergo intracranial pressure (ICP) and Brain Tissue Oxygen
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monitoring as a more sensitive method of determining injury classification, extent and
prognosis. Additionally, the measurement of brain biomarkers in serum and cerebral
spinal fluid (CSF) samples continues to show great promise in improving diagnostic
accuracy following TBI (Povlishock and Katz, 2005). Despite the number of tests and
measurement that have been developed, consistency between medical institutions
remains poor, and a universally accepted protocol for TBI classification, diagnosis, and
treatment has yet to be created.
However, current broad categories of mild, moderate, and severe TBI carry their
own set of postinjury impairments. Depending on the level of severity, patients may
experience acute and chronic neurological, cognitive, behavioral and social
consequences. Neurological consequences of TBI may include acute impairments in
sensory, motor, and autonomic functions, followed by long-term problems such as
movement disorders, seizures, visual impairments and sleep disorders (NIH, 1999).
Cognitively, patients may experience postinjury memory impairment and difficulty with
attending to different tasks for periods of time. If the frontal lobe is involved in the injury,
higher executive skills such as judgment, insight, abstract thinking and information
processing may be affected. Often times, TBI patients exhibit behavioral and social
deficits including increased aggression, agitation, hyper-sexuality, and lack of social
inhibition. Collectively, these consequences leave patients and their families/caregivers
feeling lost, hopeless, and overwhelmed well after the actual TBI incident. Proper
coordination of medical care and involvement in physical, occupational and speech
therapies, family/caregiver training, and social reintegration programs greatly improve
outcomes and quality of life following TBI.

4

TBI Pathophysiology
In order to appreciate the complexity of TBI pathophysiology it is important to
review the elements which contribute to injury mechanism. As indicated above, TBI is
caused by an external force applied to the cranium that causes damage to the brain.
The amplitude, timing, and direction of the force directly relates to the amount and type
of mechanical stress placed on the brain tissue and subsequent injury. It is well
accepted that the primary traumatic insult involves exposure to mechanical force that
exceeds normal tolerable limits of the affected tissue, therefore leading to structural
damage. Mechanical damage caused by the primary injury event triggers a series of
secondary injury responses that invoke additional downstream cellular responses and
tissue damage. The timing and severity of the secondary injury response depends on
the primary injury, as well as the state of the tissue prior to the initial insult. Age and
repetitive traumatic brain injuries have been shown to influence the extent of secondary
injury response and recovery.
Multiple in vivo and in vitro studies have identified a number of intracellular
events that follow the initial traumatic insult. Within the CNS, this response involves not
only neurons, but also astroglia and other supportive cells, microvasculature, and
extracellular matrix molecules, all capable of responding during either primary or
secondary phases of injury. Subsequent to the frank membrane breakdown, principal
pathology develops in metabolic pathways, particularly those related to adenosine
triphosphate (ATP) production. Mitochondria are highly vulnerable and part of the
secondary injury cascade affecting both aerobic and anaerobic mechanisms (Verweij et
al., 2007; Liftshitz et al., 2003; Gilmer et al., 2009). In addition, TBI elicits a significant
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immune response throughout the brain, directly releasing upstream modulators of cell
signaling such as chemokines and cytokines (reviewed by Lenzlinger et al., 2001;
Israelsson et al., 2008; Lloyd et al., 2008). These molecules are also intimately involved
in stabilization of the neuronal/vascular interface within the injured brain, ultimately
affecting cerebral blood flow, intracranial pressure (ICP) and O2/CO2 exchange.
Historically, the primary mechanical disruption of neuronal membrane has been linked
to massive pre-synaptic depolarization and the excessive release of excitatory amino
acids (EAA), especially glutamate and aspartate (Hayes et al., 1992; Yoshino et al.,
1992; Palmer et al., 1993). EAA release activates excitatory neurotransmitter receptors,
such as the N-methyl-D-aspartate (NMDA) type, allowing for dramatic post-synaptic
intracellular shifts in Na 2+, K+ and Ca2+ ions (Faden et al., 1989; Katayama et al., 1990;
Hayes et al., 1992; McIntosh et al., 1994; Wolf et al., 2001). Such excessive
neuroexcitation has been recognized as a major contributor to injury-induced structural
and functional impairments. Other studies have also probed the role of dopamine as a
modulator of the neuroexcitatory cascade following TBI (Zhu et al., 2000; Massucci et
al., 2004; Wanger et al., 2005; as reviewed by Bales et al., 2009). In an attempt to
attenuate the impaired excitatory/inhibitory imbalance generated by TBI, animal studies
first applied N-methyl-D-aspartic acid (NMDA) antagonists as postinjury therapy,
showing protective effects against injury-induced deficits and the facilitation of recovery
following TBI (Faden et al., 1989; Hayes et al., 1992; Hamm et al, 1993; Phillips et al.,
1998). Although NMDA antagonism showed therapeutic efficacy in animal models of
TBI, translation to the clinic has proven difficult, further indicating the complexities and
variation among human TBI cases (Muir, 2006). More recently, dopamine agonists,
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which significantly attenuate the negative effects of excessive neuroexcitation following
rodent TBI (Dixon et al, 1999; Kline et al., 2004; Wanger et al., 2005 and 2007), are
being applied in clinical trials (as reviewed by Warden et al., 2006). Pharmacologically
targeting these different neuropathological mechanisms has potential to improve
outcome following human TBI.
Mechanical neuronal insult induced by TBI also leads to secondary
deafferentation and, in severe cases, neuronal death. Following injury, a subpopulation
of vulnerable neurons also sustains mechanoporation of their axolemmae. This process
is mediated by ionic imbalance, Ca 2+ influx, mitochondrial failure, breakdown in axonal
transport and cytoskeletal compaction, ultimately resulting in the disconnection of
affected axons. These secondary events are observed in both animals and humans,
and are signaled by a number of molecular pathways activated by the primary insult
(Erb and Povlishock, 1991; Povlishock et al., 1992). In certain cases, postinjury
membrane damage can generate both necrotic and apoptotic neuronal death, ultimately
resulting in the loss of susceptible neurons (Farkas and Povlishock, 2007).
Ultrastructural analysis of these dying neurons revealed profiles with pyknotic nuclei,
swollen mitochondria, vacuolated cytoplasm, and membrane disruption (Dietrich et al.,
1994). With diffuse TBI (dTBI), neuronal loss can be demonstrated in the neocortex,
hippocampal fields, dentate gyrus, thalamus, and at scattered sites throughout the
caudate/putamen (Farkas and Povlishock, 2007).

While the mechanically-induced

membrane disruption associated with TBI is generally believed to trigger neuron death
cascades, it is important to note that intact cells with damaged axons are capable of
delayed membrane resealing, therefore eschewing death and exhibiting the potential for
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regeneration (Farkas et al., 2006). The process of regeneration actually begins with
axonal disconnection at the site of injury, resulting from impaired axonal transport,
neurofilament degradation and cytoskeletal compaction (Pettus et al., 1994; Maxwell et
al., 1997; Stone et al, 2004). Several hours to days following injury the proximal
damaged axon segment swells and the distal segment is disconnected, undergoing
Wallerian degeneration (Povlishock, 1992; Povlishock and Pettus, 1996; Kelley et al.,
2005; Buki and Povlishock, 2006). The ultimate effect of such degeneration is the loss
of pre-synaptic terminals at neurons targeted by these damaged axons (Erb and
Povlishock, 1991). This produces deafferentation of post-synaptic sites, inducing the
process of reactive synaptic plasticity at those sites. Because TBI produces diffuse
axonal injury in the context of a complex pathology, it is difficult to study a focal group of
affected axons and their deafferented targets. Our focus has been to better understand
the potential for recovery following such diffuse axonal injury by using a model which
generates this complex pathology in the presence of focal deafferentation. The effects
of TBI-induced axonal injury on synaptic recovery can then be examined in the context
of adaptive neuroplasticity.
Neuroplasticity and TBI
Historically, it was believed that the brain was a hardwired structure, lacking the
capacity to undergo neurogenesis or structural alterations beyond the period of its
development. However, over the course of the last century this theory shifted as
evidence emerged that demonstrated the concept of “plasticity” within the nervous
system, or neuroplasticity. Neuroplasticity refers to the ability of the nervous system to
be altered though processes including neurogenesis and synaptogenesis, often in
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response to some type of activity, experience, or even injury (Keyvani and Schallert,
2002). Injury-induced deafferentation is well documented to induce a regenerative
neuroplasticity within the central nervous system (CNS), producing both new terminal
sprouts from damaged axons and reforming new synaptic connections (Lynch et al.,
1976; Scheff et al., 1977; as reviewed by Steward, 1989; Deller et al., 1996).
Depending upon the injury location and severity, this response may result in favorable
recovery (adaptive neuroplasticity) or unfavorable recovery (maladaptive
neuroplasticity). The process of synaptic neuroplasticity induced by CNS injury is
termed reactive synaptogenesis. In rodent models, reactive synaptogenesis occurs
over a two week period following injury, stepping through a series of phases which
include early degeneration, subsequent regrowth and final stabilization of affected
synapses. Injury-induced synaptogenesis within the hippocampus will be discussed in
detail below. Relative to TBI, animal models which reproduce mild and moderate injury,
along with diffuse axotomy, tend to achieve adaptive recovery over time after injury
(Phillips and Reeves, 2001; Clausen et al., 2005; Gurkoff et al., 2006). It is assumed
that this occurs because sufficient spared axons sprout into deafferented areas and
form new synapses to restore function. Conversely, more severe combined TBI
pathology clearly results in maladaptive recovery, where fewer synaptic connections are
replaced and those generated appear dysfunctional (Phillips and Reeves, 2001; Phillips
et al., 1994). These animal studies suggest that the extent of adaptive and maladaptive
present following human TBI may be correlated with injury severity and the extent of
recovery possible. Although certainly not exclusive, we have shown that modulation of
the extracellular synaptic environment by matrix metalloproteinases (MMPs) occurs
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during both adaptive and maladaptive plasticity, and may be a critical to the
enhancement of recovery following TBI.
Surrounding supportive cells, particularly local astrocytes, are also affected by
the primary TBI insult, which is evident by the morphological and functional changes
that they undergo. Normally, astrocytes support CNS homeostasis through maintaining
ionic balance, interfacing with vessels to stabilize the blood-brain barrier (BBB),
providing nutrition for neurons, and recycling neurotransmitters (Wilhelmsson et al,
2006). Following brain injury, astrocytes undergo a transformation to become
“reactive”, which is characterized by cellular hypertrophy and hyperplasia, thickening
and elongation of main cellular processes, and increased glial fibrillary acidic protein
(GFAP) expression (Baldwin and Scheff, 1996; Amaducci et al, 1981; Wilhelmsson et
al, 2006). These morphologically distinct astrocytes often infiltrate the pericontusional
region and may act to either inhibit or promote recovery. Although infiltrating reactive
astrocytes form a “glial scar” which inhibits regeneration in the nervous system (Liuzzi
and Lasek, 1987; Silver and Miller, 2004; Goldshmit and Bourne, 2010), they have also
been shown to protect adjacent uninjured tissue from further secondary damage and
decrease the inflammatory response (White and Jakeman, 2008; Sofroniew, 2005, Su
et al., 2009; Rasouli et al., 2009), therefore revealing dual roles. As a result of injury,
reactive astrocytes can alter their expression of ion transporters, neurotransmitter
receptors, as well as matrix proteins and proteases which can be membrane bound or
secreted into the extracellular space (Wells et al., 1996; Muir et al., 2002; Falo et al.,
2006; Belanger and Magistretti, 2009). Depending on the injury severity, the expression
of these proteins can determine the role of local reactive astrocytes in the regulation of
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brain pH and neuroexcitability and their influence during injury-induced plasticity (Laird
et al., 2008). For example, secreted and membrane-bound MMPs are upregulated in
reactive astrocytes postinjury, and can influence plasticity through interaction with their
extracellular matrix (ECM) substrates or synaptic junction modulation (Falo et al., 2006;
Kim et al., 2005). Secreted ECM molecules, such as proteoglycans, are critical to the
formation of the glial scar and often are vulnerable to MMP processing after CNS injury
(Pizzi and Crowe, 2007). Reactive astrocytes also play a direct role in the neuroplastic
response by phagocytic removal and degradation of damaged tissue (Sofroniew, 2005).
In some injury models, reactive astrocytes fail to express inwardly reflecting K+
channels, therefore compromising their ability to buffer extracellular K+, maintain ion
homeostasis and dampen neuronal excitation (Bordey and Sontheimer, 1998;
D‟Ambrosio et al., 1999; Bordey et al., 2001). Clearly, the astrocytic response following
TBI appears to be injury specific and shows the capacity to either facilitate or impede
neuroplastic recovery. Despite their often opposing functional roles, reactive astrocytes
are important players in the pathophysiology of TBI. The magnitude and direction of
astrocytic response may correlate with injury severity and outcome, therefore making
them potential therapeutic targets to facilitate adaptive synaptic plasticity.
Based on this brief review, it is evident that postinjury neuropathology is a
complex and dynamic series of events that can result in a wide range of cellular
damage and dysfunction. While each element of the postinjury process is important,
here we choose to focus on the recovery component of injury-induced synaptogenesis,
particularly within the hippocampus of the injured brain.
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PLASTICITY WITHIN THE INJURED HIPPOCAMPAL FORMATION
Multiple studies have shown that CNS injury induces a synaptogeneic response,
particularly in regions of high plasticity, such as the subventricular zone, dentate gyrus
and hippocampus (as reviewed by Taupin, 2006). While there is extensive literature
describing activity, experience and injury-induced plasticity in these different regions,
the focus of this review will be the injury-induced synaptogenesis within the
hippocampus.
Hippocampal Structure
The hippocampus is comprised of two interlocked U-shaped sectors that lie deep
within the temporal lobe and are surrounded by entorhinal (EC), parahippocampal and
perirhinal cortices. The fascia dentata (or dentate gyrus) and the hippocampal
formation (CA1-CA3 laminae) interlock to form a structure that contains a limited
number of neuron types that are tightly packed into distinct layers (Fig. 1.1). Intrinsic
and extrinsic afferent inputs synapse in dendritic fields of the dentate and hippocampus
proper, linking the hippocampus to other limbic structures including the amygdala,
cingulate gyrus, mammilary bodies thalamus, EC, and septal nuclei. The organized
limbic circuitry (discussed below) and functions of the hippocampus are due, in part, to
the structural organization of the dentate gyrus and hippocampal formation (reviewed by
Amaral et al., 2007).
The tri-laminar dentate gyrus is made up of granule, molecular and polymorph
(hilar) layers, and resembles an arrowhead with suprapyramidal and infrapyramidal
blades. The granule cell layer contains small, densely packed excitatory granule cells
along with scattered inhibitory dentate pyramidal basket cells at the interface of the
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Figure 1.1 Hippocampal Structure and Circuitry. Schematic representation of
hippocampal structure and circuitry, including dentate gyrus (DG) and hippocampal
fields CA3- CA1. Primary afferent inputs include lateral and medial perforant path (LPP;
MPP) projections from the entorhinal cortex (EC) and secondary inputs from
contralateral associational-commissural (CA) projections. The tri-synaptic loop circuit
includes PP projections to DG granule cell dendrites, which send mossy fiber (MF)
projections to the CA3 field. CA3 pyramidal neurons send contralateral AC projections
and primary Schaffer collateral (SC) projections to CA1 pyramidal cell dendrites, which
send efferents to the subiculum (Sb) and on to the lateral and medial EC (LED; MEC).
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granule and polymorph layers. The spiny apical dendrites of granule cells extend into
the molecular layer, their outermost processes reaching the hippocampal fissure.
These dendrites receive primarily excitatory input from the EC through the perforant
(ipsilateral EC) and crossed temporodentate (CTD; contralateral EC) pathways, as well
as Commissural-Associational (C/A) and septal projections. The granule cells give rise
to axonal projections called mossy fibers that travel through the hilar polymorph layer
and terminate in the CA3 field of the hippocampus. Along the mossy fiber course, these
axons extend collateral afferents to synapse on the proximal dendrites of the hilar
mossy cells, basal dendrites of the pyramidal basket cells and GABAergic interneurons.
The mossy fibers serve as the initial segment of the hippocampal „trisynaptic loop”,
linking granule neurons with CA3 and CA1 pyramidal neurons.
The hippocampal formation is comprised of two main sectors of pyramidal
neurons, regio superior and regio inferior. The regio superior, or CA1 field, contains
multiple rows of medium-sized to large pyramidal neurons, whose apical dendrites
receive their principal input from the Schaffer collateral axons. The Schaffer collateral
projections arise from large pyramidal neurons located within the regio inferior, or CA3
field. The apical dendrites of CA3 neurons receive afferent mossy fiber projections from
the dentate granule cell layer. CA1 and CA3 fields are arranged in organized layers
similar to those observed in the dentate gyrus, however, additional layers are identified
based on the specific features of pyramidal cell input. These layers include (dorsal to
ventral) the alveus, stratum oriens, stratum pyramidale, stratum radiatum, and stratum
lacunosum/moleculare. The alveus contains pyramidal cell axons that are either
directed towards the fimbria or subiculum. The stratum oriens contains pyramidal and
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basket cell basal dendrites and septal afferents. The stratum pyramidale is made up of
pyramidal cell somas, whose proximal and distal apical dendrites are localized in the
stratum radiatum and lacunosum/moleculare, respectively. There is an additional layer,
stratum lucidum, within the CA3 field which is situated between the stratum pyramidale
and stratum radiatum that contains the mossy fiber projections (as reviewed by O‟Keefe
and Nadel, 1978).
While there are intrinsic connections within the dentate gyrus and hippocampus
proper and between contralateral hippocampal structures, there are also a number of
extrinsic inputs and outputs that link the hippocampus to other brain regions.
Hippocampal afferent inputs and efferent outputs are primarily associated with the
circuit of Papez, and include a number of cortical and subcortical connections.
Subcortically, the hippocampus makes connections with the anterior nucleus of the
thalamus, hypothalamic mammillary bodies and septal nucleus of the basal forebrain
through the fornix, as well as direct connection with the amygdala (Bird and Burgess,
2008). The presubiculum is another subcortical structure that projects to the
hippocampus through the EC. Additionally, many cortical afferent inputs are connected
to the hippocampus through the EC including the perirhinal and parahippocampal
cortices, the superior and middle frontal gyri, superior temporal and cingulate gyri,
precuneus, lateral occipital cortex, occipitotemporal gyri and subcallosal cortical regions
(Bird and Burgess, 2008; Haines, 2004). Collectively, these subcortical and cortical
connections link the hippocampus to a number of functional CNS networks, including
the neuroendocrine, olfactory and visual systems.
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Hippocampal Function and Response to Injury
Based on its structural organization and extensive CNS connections, the
hippocampus has received significant attention in the research community over the past
decades. The hippocampus is among a number of limbic brain structures involved in
emotional, motivational and learning/memory processes. Within the limbic system, it is
believed that the hippocampus plays a major role in long-term memory, however, this is
limited to specific types of memories. While much debate continues to focus on
hippocampal function, most researchers agree that declarative memories are controlled
by the hippocampus (Anderson et al., 2007; LaFerla et al., 2007). Declarative
memories are those based on facts (semantic) or events/episodes (episodic). Within
the category of declarative memory, many theorists agree that the hippocampus is
critical for coding and storage of episodic, rather than semantic memory (Good, 2002;
Bird and Burgess, 2008). Additionally, animal and human studies both show that the
hippocampus plays a role in spatial memory and navigation, as well as temporal lobe
amnesia (Morris et al., 1982; Good, 2002).
Beyond basic neuroscience, many studies have focused on the role of the
hippocampus in neuropathologies such as Alzheimer‟s disease (AD) (Ball et al., 1985),
epilepsy (Kuruba et al., 2009), and TBI (McCarthy, 2003). A common element in all
three conditions is the resultant loss of cognitive function. Following TBI, the
hippocampus is highly vulnerable to cellular damage, a feature considered to be directly
linked with the long-term cognitive deficits observed clinically. Despite theoretical
differences as to the role of the hippocampus in such memory loss, its structural
organization has fostered a more recent, detailed study of synaptic neurophysiology,
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including parameters such as unidirectional excitatory transmission and synaptic
efficacy (Anderson et al., 2007). Initial studies of hippocampal electrophysiology lead to
the discovery of synaptic long-term potentiation (LTP), which evolved into the prominent
cellular model for the processing of functional learning and memory (Bliss and
Collingridge, 1993). Subsequent LTP studies showed that the capacity to evoke such
potentiation was directly associated with the structural and functional efficacy of the
underlying hippocampal synaptic junctions (Steward, 1982 and 1989; Reeves and
Steward, 1986). Further investigation found LTP to be a common synaptic link between
memory processing and injury-induced neuroplasticity (Reeves et al., 1997; Phillips and
Reeves, 2001; Tang and Zhang, 2002; Reeves et al., 2003; Su et al., 2009), serving to
generate a prototype for associating synaptic recovery after TBI with positive cognitive
outcome. In the present studies, we have utilized hippocampal LTP as an outcome
measure to complement molecular, structural and behavioral endpoints, looking for
direct links between ECM/MMP driven mechanisms and functional synaptic recovery
after TBI.
While TBI studies of the hippocampus have principally focused on the loss of
neurons and attenuating cell death, we now know that the affected circuitry is efficient in
its plasticity and, given the right conditions, has the capacity to reorganize and promote
significant cognitive recovery (Dietrich et al., 1994; Hicks et al., 1996; Sifringer et al.,
2007). Although more investigation into the complexity of TBI pathology is certainly
warranted, we feel that the hippocampus is a critical site for understanding
neuroplasticity after brain injury based on its well organized and understood circuitry.
Given that the hippocampus exhibits significant synaptic plasticity in response to stimuli
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such as activity, experience or injury, we have focused on understanding more about its
capacity for synaptic reorganization after TBI. While the literature is vast documenting
activity- and experience-associated plasticity within the hippocampus, here we will
review the area of our focus, reactive or injury-induced synaptogenesis.
Injury-Induced Synaptogenesis
Injury-induced or “reactive” synaptogenesis is a process whereby the nervous
system replaces lost synaptic inputs through growth of local spared afferents into a
dennervated zone (Steward, 1989). As previously described, a traumatic insult to the
brain induces a series of secondary-injury events that often terminate in axonal
disconnect and diffuse deafferentation. Such deafferentation triggers a local
synaptogenic response, where sprouting of spared axon terminals provide new presynaptic input into the denervated region. Reorganized post-synaptic sites emerge in
concert with these axonal sprouts to complete new synapses. While replacement by
proximal spared fibers would most direct, rodent unilateral EC lesion studies show that
homotypic fiber sources are preferred (i.e., CTD fibers from intact contralateral EC), and
that other sprouting axons (i.e., C/A projections) may travel up to 20-40 μm into the
damaged dentate gyrus to replace degenerated axonal terminals (Steward, 1989).
The unilateral entorhinal cortex (UEC) lesion model has been used in multiple
studies to characterize the spatial and temporal profile of reactive synaptogenesis.
UEC eliminates 80-90% of the EC afferent fibers projecting to the dentate molecular
layer, and, over time, synaptogenesis leads to significant structural and functional
recovery. The time course of this process is often described in three distinct postinjury
phases. During the first phase of degeneration (1-5d), damaged axon terminals are
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removed and degraded by reactive glia, while post-synaptic structures are morphed in
shape, often collapsing at their base into the underlying dendritic shaft. This is followed
by the regenerative phase (6-15d), which involves collateral sprouting of spared axons
into the deafferented zone, concomitant with the reformation of post-synaptic spines
and junctions. Finally, a stabilization/maturation phase (15-30+d) follows, where
nascent synapses are either stabilized or pruned away, re-establishing a close match to
the original synaptic profile (Steward and Vinsant, 1983). At the end of these three
phases, synaptic junctions return to a pattern mimicking the uninjured side and synaptic
function is restored. It is important to note that while the above timeline is relevant for
the UEC model in adult rat hippocampus/dentate gyrus, variations will exist between
species, injury type, ages, and brain regions. Therefore, it is important to investigate
the time course of injury-induced synaptic reorganization in each experimental design.
UEC studies also provide evidence of selective pre- and postsynaptic target
specificity and competition between spared sprouting fibers. Within the hippocampus
the C/A afferent projections synapse in the inner third of the dentate molecular layer,
while the outer two thirds of the molecular layer contains EC perforant path afferents.
Additionally, the CTD sends projections to the dentate outer molecular layer from the
contralateral EC (Fawcett et al, 2003). When the ipsilateral EC is 80-90% ablated,
these projections are replaced by CTD, C/A and septal afferents in a hierarchical
fashion. Elimination of the C/A projections entirely, leads to septal afferent growth, but
no EC afferent re-growth, further indicating reinnervation specificity and competition
(Cotman, 1979; Nadler et al, 1980). Additionally, there is dramatic dendritic plasticity
within each molecular layer zone that aids in the restoration of pre-injury synaptic
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density (Deller and Frotscher, 1997; Fawcett et al, 2003). Although these results
illustrate changes in a single model, the spatial and temporal reorganization displayed in
the adaptive UEC are fundamental to our understanding the differences between
adaptive and maladaptive plasticity post-TBI.
Adaptive vs. Maladaptive Plasticity
Based on the above review, the UEC induction of reactive synaptogenesis can
be considered a model of adaptive (successful) plasticity, producing functional recovery.
This recovery involves restoration of synaptic cytoarchitecture, dendritic laminar
organization, and re-emergence of functional efficacy, demonstrated by both
electrophysiological and behavioral measures (Reeves and Smith, 1987; Losche and
Steward, 1977). Therefore, contrasting the UEC conditions with other TBI models
which fail to show synaptic recovery can be quite beneficial. Maladaptive plasticity can
occur when the process is dysregulated, generating disordered neuropil and aberrant
synaptic structure, a situation which is consistent with the severe cognitive impairments
seen in human TBI patients (Phillips et al, 1994, 1997). Our lab has developed an
animal TBI model of maladaptive plasticity that combines the excessive neuroexcitation
of the cFPI with targeted deafferentation of bilateral EC lesions (TBI+BEC). This model
was developed to mimic the complex synaptogenic aspects seen in human TBI, and is
studied in concert with the UEC model of adaptive plasticity. Comparing cellular and
molecular response within these two models provides a better understanding the
underlying mechanisms that contribute to poor synaptic reorganization. Our overall goal
is to characterize recovery-dependent differences in molecular expression during injury-
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induced synaptogenesis and develop therapeutic interventions that will improve
functional recovery following TBI in humans.
Both adaptive and maladaptive plasticity are influenced by the type and timing of
injury, ensuing neuropathology, and the expression, activity, and interaction of different
cellular and matrix proteins that contribute to synaptic reorganization. Of particular
interest is the upregulation of matrix metalloproteinase (MMP) family members and their
paired substrates in different nervous system diseases, including TBI (Yong, 2005;
Rosenberg, 2009). In CNS neuropathologies, MMPs modulate of the extracellular
environment through proteolysis of not only free ECM molecules, but also proteins
which are integral to synaptic adhesion and functional activity (Rosenberg, 2002, 2009;
Kim et al., 2005; Falo et al., 2006; Komori et al., 2004; Wang et al., 2000). Prior studies
have shown that the gelatinases MMP-2 and -9 contribute to BBB breakdown and
exacerbate posttraumatic edema through degradation of the vessel basal lamina
(Truettner et al., 2005; Vilalta et al., 2008; Vajtr et al., 2009). MMP-9 also plays a role in
glial scar formation and cytoskeletal reorganization during axonal regeneration following
spinal cord injury, as well as contributing to TBI neuronal damage and increased infarct
size after stroke (Hsu et al., 2008; Wang et al., 2000; Romanic et al., 1998). In the
context of this dissertation study, our lab has shown that altered MMP-3 expression is
correlated with disorganized ultrastructural synaptic profiles and spatial learning deficits
after TBI+BEC insult (Kim et al., 2005; Falo et al., 2006). MMP-3 appears to influence
the development of synaptic pathology and behavioral impairment through its target
ECM protein agrin, which contributes to receptor organization within the synapse (Falo
et al., 2008). Earlier studies showed hippocampal upregulation of MMP-2, -3, and -9
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expression/activity within the TBI+BEC, paralleled by increased levels of the MMP ECM
substrates collagen IV, chondroitin sulfate proteoglycan (CSPG) and tenascin (Phillips
and Reeves, 2001; Kim et al., 2005). More recently, members of the membrane-type
MMP family and the A Disintegrin and Metalloproteinase (ADAM)/ A Disintegrin and
Metalloproteinase with a Thrombospondin type 1 motif (ADAMTS) subgroup have been
shown to interact with ECM and synaptic molecules during injury-induced
synaptogenesis (Komori et al., 2004; Mayer et al., 2005; Yang et al., 2006). While
these studies linking MMPs to TBI and synaptogenesis are small in number, it is
apparent that MMPs and their paired ECM substrates play an important role in
neuroplastic recovery. However, it is also recognized that their interaction must be
tightly regulated to promote successful synaptic repair. It is our overall hypothesis that
unregulated MMP/substrate interaction contributes to maladaptive post-injury
reorganization and persistent functional impairments following TBI. Therefore, it is
important to continue to investigate MMP/substrate interaction as it relates to the
processes of adaptive and maladaptive injury-induced synaptogenesis.
The following section reviews the general structural and functional features of the
MMP family of enzymes, and takes a closer look at how two membrane-bound MMPs,
membrane-type 5 MMP (MT5-MMP) and ADAM-10 can potentially influence the
postinjury plasticity process through proteolytic interaction with synaptic adhesion
molecule, Neural Cadherin (N-cadherin).
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MATRIX METALLOPROTEINASES
General Classification, Structure, and Function
MMPs constitute a large family of highly regulated zinc and calcium dependent
proteolytic enzymes that play important roles in both development and disease states.
In either secreted or membrane-bound forms, MMPs are collectively capable of
degrading virtually all components of the ECM, as well as cleaving other proteinases,
proteinase inhibitors, growth factors, chemotactic molecules, growth factor binding
proteins, cell surface receptors and cell adhesion molecules (Cawston and Wilson,
2006; Ahmad et. al, 2006; Nagase and Woessner, 1999; Maskos and Bode, 2003;
Cunningham et. al, 2005; Conant and Gottshall, 2005). MMPs first gained recognition
in 1962, when Gross and Lapiere detected collagenolytic activity in involuting tadpole
tales, and revealed collagenase-1 (MMP-1) as the first member of the MMP family.
Subsequent studies revealed new members of the MMP family, often with overlapping
substrate preferences. Until recently, MMPs had been placed into groups such as
collagenases, gelatinases, and stromelysins, based on these similar substrate
preferences. With technological advances, distinct structural variations within these
groups and overlap in substrate specificity led scientists to rethink MMP classification.
A total of 25 vertebrate MMPs have been identified and grouped into the
following 7 subsets, primarily based on domain organization: (1) Minimal domain: MMP7, MMP-26; (2) Simple hemopexin domain (collagenases, stromelysins, and others):
MMP-1, MMP-3, MMP-8, MMP-10, MMP-12, MMP-13, MMP-18, MMP-19, MMP-20,
MMP-22, MMP-27; (3) Gelatinases: MMP-2, MMP-9; (4) Furin activation, secreted:
MMP-11, MMP-28; and Vitronectin insert: MMP-21; (5) Transmembrane
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MMP/Membrane-type (MT-MMP; Type I Transmembrane): MMP-14 [Membrane-type1(MT1-MMP)], MMP-15 (MT2-MMP), MMP-16 (MT3-MMP), MMP-24 (MT5-MMP); (6)
Glycosylphosphatidylinositol (GPI) anchored (Type I Transmembrane): MMP-17 (MT4MMP), MMP-25 (MT6-MMP); (7) Cys/Pro rich with Ig-like domain (Type II
Transmembrane): MMP-23 (Fig. 1.2) (Cawston and Wilson, 2006; Yong, 2005;
Stamenkovic, 2003). Studies reveal that among these subsets and groups, despite
distinct tissue expression patterns of individual MMPs, structural and functional overlap
and interaction occurs, thus revealing a complexity that was once thought to be absent
in MMPs (Cawston and Wilson, 2006; Sternlicht and Werb, 2001). In addition to the
standard eight subsets, there are other families of enzymes that share structural and
functional similarities with MMPs, and are loosely included within the MMP family, such
as the ADAMs motifs. This sub-family of molecules will be discussed in further detail in
a later section.
Structurally all MMPs are multi-domain proteins, with each domain serving a
specific function. Secreted and membrane type-MMPs (MT-MMPs) contain the
following common domains, unless otherwise noted: (1) N-terminal signal domain,
which is removed upon insertion into the endoplasmic reticulum; (2) Propeptide domain
(~80 amino acids) containing a “cystine switch” which helps maintain latency by
blocking the catalytic zinc active site, and is cleaved to activate MMPs; (3) highly
conserved Catalytic domain (~170 amino acids) containing three histadine residues
bound to a zinc ion, calcium ions, and a conserved methionine residue, forming a
structurally supportive “Met-turn” motif beneath the zinc ion active site; (4) Hinge region,
which varies in length and composition and is involved in substrate specificity (absent in
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MMP-7, -23, -26); and (5) C-terminal domain known as the hemopexin-like domain
(~200 amino acids), or HLD, which is also thought to be involved in substrate specificity
(absent in MMP-7, -23, -26) (Hernandez-Barrantes et. al, 2002; Nagase et. al, 2006;
Sternlicht and Werb, 2001; Stramenkovic, 2003). Additional insert sequences are
present and further dictate function in certain secreted and membrane-bound MMPs.
Vitronectin and fibronectin-type II domain inserts are found in MMP-21; and MMP-2 and
-9, respectively, while furin recognition sequences (RR(K/R)R) are found at the Cterminus of the propeptide domain in all MT-MMPs and MMP-11, -28, -21, and -23
(Maskos and Bode, 2003; Nagase et. al, 2006; Cawston and Wilson, 2006; Fillmore et
al, 2001). According to current in vitro literature, this sequence allows for these specific
MMPs to be activated intracellularly by serine proteases of the pro-protein convertase
class (i.e.-furin) (Pei and Weiss, 1995; Illman et al., 2003; Sato et al., 1996; Kang et al.,
2002). Despite slight subgroup variations, these general structural components create
the foundation of the MMP family, and contribute to their multi-functional nature.
As is true in all of science, structure dictates function. MMPs are highly involved in
tissue remodeling and reorganization during both development and disease, such as
spinal cord injury (SCI), TBI, AD, stroke, Parkinson‟s disease (PD), and Multiple
Sclerosis (MS) (as reviewed by Rosenberg, 2002, 2009; Yong et al., 2001; Nagase et.
al, 2006). Proper regulation of MMP function helps maintain a balance between tissue
breakdown and preservation, and primarily occurs by three different mechanisms. The
first line of MMP regulation involves transcriptional control. Generally, MMPs are
expressed at low levels, but can be transcriptionally upregulated in response to
increased tissue remodeling and events such as inflammation, injury, and cancer
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progression (Nagase and Woessner, 1999). Synthesis of all MMPs as inactive
zymogens (proMMP form) also serves as a regulatory mechanism. Therefore, in order
to achieve full function, MMPs must be activated by removal of the pro-domain (Sounni
and Noel, 2005; Sternlicht and Werb, 2001). Finally, MMP activity can be regulated by a
collection of endogenous tissue inhibitors of metalloproteinases (TIMPs), which bind
and inactivate all MMPs in a 1:1 (MMP: TIMP) ratio. Currently there are four identified
TIMPs (TIMP-1, -2, -3, -4), each of which has different affinities for individual MMPs.
These regulatory mechanisms act to balance MMP activation and inhibition, therefore
maintaining normal development and remodeling in a healthy state (Nagase et. al,
2006; Cawston and Wilson, 2006).
While endogenous mechanisms are in place to ensure a physiological balance of
secreted and membrane-bound MMP activity, regulation of MMPs has been shown to
become unbalanced during pathological states. Within the CNS, detrimental effects of
persistent MMP activity include tumorigenesis, BBB disruption, neuroinflammation,
demyelination, and neuronal death. Therefore, MMPs have been shown to occur in
neuropathologies such as SCI, TBI, AD, stroke, PD, MS (Rosenberg, 2002, 2009; Yong
et al., 2001). Laboratory and clinical studies have the used blocking/knockdown
techniques and synthetic inhibitors in an attempt to control persistent MMP activity in
these different neuropathologies. Blocking antibodies, knockout or knockdown methods
(transgenic mice, short interfering RNA), antisense methods, and pharmacological MMP
inhibitors have all been used to not only investigate the roles of MMPs but to also limit
disease progression and improve recovery. For example, administration of broad-
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Figure 1.2 Matrix Metalloproteinase (MMP) Structure and Subgroups. a) Variable
structure of MMPs including general domains (signal peptide, propeptide, catalytic,
hinge region, and haemopexin) and unique inserts/domains (furin cleavage site, type II
fibronectin repeats, MT-loop, transmembrane domain, cytoplasmic tail, N-terminal signal
anchor, cysteine array, Ig-like domain, and GPI anchor; b) Seven subgroups based on
MMP structure. Note membrane-type MMPs possess additional structural
domains/inserts that dictate position and function.
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spectrum MMP inhibitor GM6001 in a stroke model produced a significant reduction in
infarct size following focal ischemia (Amantea et al., 2007). Acute administration of
GM6001 improved functional recovery following SCI and significantly limited the amount
of apoptotic brain damage following TBI (Noble et al., 2002; Sifringer et al., 2007). In
most laboratory studies, inhibition or knockdown of overexpessed and active MMPs at
appropriate times has limited their detrimental effects and pathology progression.
Clinical MMP inhibition studies have not produced the same results, and have often
been stopped early due to poor side effects in patients. Both laboratory and clinical
studies have historically focused on the inhibition of secreted MMPs such as MMP-2, -3,
and -9. However, the role of membrane-bound MMPs in development and disease has
gained increased attention over the past decade due to the subgroup‟s unique structural
features and ability to be an upstream mediator of other MMP activity.
Membrane-bound MMPs
Within the family of MMPs important structural differences have been uncovered,
especially between the secreted and membrane-bound MMPs. Membrane-bound
MMPs possess unique structural features that dictate cellular localization and enzymatic
function. It is important to note the structural features that set this group apart from
soluble MMPs, in order to better understand the roles they play in physiological and
pathological processes.
A truly unique feature of membrane- bound (membrane-type; MT) MMPs is the
presence of a membrane anchoring domain following the HLD. This domain consists of
a stem region (~30 amino acids) and a hydrophobic tether region (~20 amino acids).
The tether region either exists as a transmembrane domain (TMD) with a short
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cytoplasmic tail, as in MT1-, MT2-, MT3-, and MT5-MMP, or as a GPI anchor, as in
MT4- and MT6-MMP (Hernandez-Barrantes et. al, 2002). The cytoplasmic tail in all MTMMPs, except MT4-MMP, may serve as a possible phosphorylation site, as is contains
a cystine residue, with adjacent tyrosine and serine residues (Parks and Mecham,
1998).
All MT-MMPs, with the exception of MT4-MMP, contain an additional 8-amino
acid insertion between β-strand II and III that forms a “MT-loop” within the catalytic
domain, that is essential for proMMP-2 activation (Sounni and Noel, 2005; English et. al,
2001). The ability of MT-MMPs to activate proMMP-2 is best illustrated by the research
focused on MT1-MMP activation of pro-MMP2. The activation occurs through a series
of specific bonds, where MT1-MMP, TIMP-2, and proMMP-2 form a ternary complex on
the cell surface (Itoh and Seiki, 2005; Itoh, 2006; Itoh et. al, 2001). The process begins
with the expression of an active, full length MT1-MMP protein (~60 kDa) on the cell
surface binding to TIMP-2 at the “MT-loop”. Three dimensional analysis of the “MT-loop”
structure reveals a pocket-like region which matches up with the Tyr-36 residue in the
AB loop on the N-terminal domain of TIMP-2 (Fernandez-Catalan et. al, 1998).
Mutations of MT1-MMP‟s “MT-loop” alter enzymatic activity of proMMP-2, further
indicating its functional importance (Fernandez-Catalan et. al, 1998). The binding of
TIMP-2 inhibits any catalytic activity of MT1-MMP, which appears to be functioning
more as a docking station rather than an enzyme in this situation. TIMP-2 possesses a
C-terminal domain with a high affinity for the HLD domain of proMMP2. The proMMP-2
“substrate” docks to the C-terminus of TIMP-2 and forms the ternary complex (Strongin
et. al, 1995; Maskos and Bode, 2003). The binding of these three proteins is insufficient
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to activate proMMP-2, thus an adjacent TIMP-free MT1-MMP is needed to initiate the
first pro-MMP-2 cleavage. The primary cleavage site in proMMP-2 is not typically
susceptible to MMPs, but a series of loops within the MT1-MMP catalytic domain may
act to embrace this site and allow cleavage (Maskos and Bode, 2003). Following the
initial cleavage, an additional MMP-2 molecule removes the remaining propeptide
domain from the intermediate MMP-2 to yield a mature and fully-active MMP-2 molecule
(Deryugina et. al, 2001). While the majority of the current literature of is focused on
MT1-MMP, other MT-MMPs are believed to carry out the same function (MT2-MMP,
MT3-MMP, and MT5-MMP). The unique “MT-loop” feature further implicates this
subgroup of MMPs in physiological and pathological processes that require MMP-2
activity.
As previously mentioned, all MT-MMPs have a furin recognition sequence at the
C-terminus of the propeptide domain, which serves as a cleavage site for activation (as
reviewed by Cawston and Wilson, 2006). A second site in the propeptide, described as
a stretch of 5 homologous amino acids, is present in addition to the furin recognition
sequence in all MT-MMPs. This site may be essential to enzymatic functioning and act
as an intramolecular chaperone by maintaining protein conformation (Fillmore et. al,
2001; Cao et. al, 2000). Collectively, these structurally characteristics make MT-MMPs
unique proteolytic enzymes within the MMP family (see again Fig 1.2).
Based on advances made in uncovering these structural variations, MT-MMPs
have emerged as important new players in ECM regulation due to their unique cellular
localizations, structure, and involvement in a variety of physiological and pathological
processes, such as tissue remodeling, tumor growth and metastasis, angiogenesis,
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synaptic plasticity, and even activation of secreted proMMPs (Sato and Seiki, 1996;
Jaworski, 2000, as reviewed by Sounni and Noel, 2005). Although MT-MMPs possess
functions similar to those of secreted MMPs, and cleave some of the same substrates,
such as collagen, gelatin, laminin, glycoproteins and proteoglycans, they do possess
structural and functional characteristics which set them apart from their secreted
counterparts (Hernandez-Barrantes et. al, 2002). In contrast to secreted MMPs, which
can migrate away from the cell to affect distant targets, MT-MMPs are specialized to
affect a very focal area of the pericellular microenvironment. As a result of their focal
concentration, MT-MMPs have additional unique functions, some of which have direct
and indirect effects on secreted MMP activity.
In general, MT-MMPs contribute to the proteolysis of ECM components and the
activation of proMMPs (proMMP-2, -13) or other zymogens (ADAMTS-4 p68), as well as
influence a variety of extracellular and intracellular signaling pathways, alter cell-to-cell
and cell-to-matrix relationships, control gene expression, and promote cell survival,
migration and invasion, and angiogenesis, during phases of health and disease
(Hernandez-Barrantes et. al, 2002; Sounni and Noel, 2005; Deryugina and Quigley,
2006). MT-MMPs are able to influence the above processes because of the different
structural domains that make them unique. The most distinguishing feature of an MTMMP is its position within the plasma membrane. Prior to inserting in the membrane,
most often the furin recognition sequence is cleaved by proprotein convertase in the
Golgi during protein trafficking, and the MT-MMP becomes activated intracellularly.
Blocking MT-MMP intracellular activation has been shown to be a prerequisite for MTMMP membrane insertion and position. For example, when intracellular MT1-MMP
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activation is blocked in vitro, MT1-MMP fails to be trafficked to the membrane and
remains localized proximal to the Golgi compartment (Wu et al., 2007). This level of
intracellular regulation is thought to allow for proper protein folding and activation prior
to membrane insertion, therefore ensuring that when the enzyme is upregulated, it is
ready to function when and where it is needed in a timely manner. There is also
evidence of alternative methods of MT-MMP activation, including autoproteolysis,
cleavage by a non-furin protease and extracellular activation by plasmin (Okumura et.
al, 1997). This characteristic of primary intracellular activation is in contrast to most
secreted MMPs which are primarily activated extracellularly.
Following activation, the cytoplasmic tail (domain) may be an important player in
intracellular events such as trafficking and cell surface localization of the MT-MMP,
therefore affecting MT-MMP functions such as sheddase activity and subsequent cell
migration (Nakahara et. al, 1997). For example, in cancer cells MT1-MMP is localized at
higher concentration in lamellipodia and invadopodia, possibly due to cytoplasmic tail
activity (Nakahara et. al, 1997). This specific localization of MT1-MMP leads to an
increase in pericellular ECM degradation and surface receptor cleavage, therefore
enhancing cell migration (Hotary et. al, 2000; Mori et. al, 2002; Nakahara et. al, 1997).
The mechanism of cell migration is not fully understood, but may involve MT1-MMP
directed shedding of the membrane glycoprotein CD44, a widely expressed major
hyaluronan receptor involved in cell-cell interactions, adhesion, and migration.
Releasing the ectodomain of CD44 from the cell surface may alter the cell-matrix
adhesion properties and permit cell migration (Naor et. al, 1997). In order to fully
promote cell migration, MT1-MMP must also be internalized by a clathrin-dependent
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pathway, a process that is also mediated by the cytoplasmic tail (Anilkumar et. al,
2005). Other MT-MMPs may also be able to influence cell migration in a similar fashion.
In addition, the cytoplasmic tail may influence cell signaling pathways, as well as MTMMP dimerization and trafficking (as reviewed by Souni and Noel, 2005; Wang P et. al,
2004).
Once tethered to the membrane, the transmembrane or GPI anchor domains are
responsible for maintaining the position of MT-MMPs, which in turn concentrates
proteolytic activity to specific regions of the cell surface (Sternlicht and Werb, 2001). In
this position, the catalytic domain is the integral structural component, and is necessary
to carry out many MT-MMP functions. MT-MMPs membrane localization, along with
influence from the cytoplasmic tail domain, may also affect cell signaling pathways that
involve cell survival, migration and invasion, and angiogenesis. In pathological states,
the spatial relationship of MT-MMPs and their cell surface substrates facilitates
cleavage and shedding of either whole or fragmented proteins, resulting in modification
of cell signaling pathways (Itoh and Seiki, 2006). An example of this is the indirect
activation of epidermal growth factor receptor (EGFR) signaling by MMP-2, -9 and MT1MMP. EGFR activation affects downstream oncogenic pathways, such as the Sac,
Ras, and extracellular signal-regulated kinase (ERK) pathways, and may also lead to
increased expression of MT1-MMP in cultured glioma cells. This suggests that EGFR
and MT1-MMP may function together as mediators of glioma malignancy (Roelle et. al,
2003). MT-MMPs may also be involved in intracellular signaling through interaction with
integrins. Integrins are cell adhesion molecules that mediate bi-directional signal
transduction through the plasma membranes of neighboring cells. Interaction between
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MT1-MMP and αvβ3 integrin promotes cell adhesion and migration in vitro through the
phosphorylation of the focal adhesion kinase (FAK) pathway (Deryugina et. al, 2002).
In addition, MT2-MMP plays a role in the protection of tumor cells in vitro by altering
apoptotic signals, therefore suggesting that it may protect tumor cells in vivo as well
(reviewed by Deryugina and Quigley, 2006). Through these signaling pathways and
other mechanisms, MT-MMPs play very crucial roles in pathological states (Wang R et.
al, 2004).
Apart from its membrane-bound activities, the catalytic domain of some MTMMPs can be cleaved autocatalytically or non-autocatalytically, thereby releasing it into
the surrounding microenvironment as a soluble enzyme. Shedding of the catalytic
domain from the membrane may be a point of MT-MMP regulation, and possibly result
in further pericellular proteolysis and alteration of enzyme-inhibitor balance through
TIMP binding (Osenkowski et. al, 2004; Hernandez-Barrantes et. al, 2002; Wang and
Pei, 2001). Further investigation of cleaved and shed MT-MMP catalytic domains is
needed to better define how they function as soluble proteinases.
Membrane-bound-MMPs and the Nervous System
Although MMPs are highly involved in both physiological and pathological events
throughout the body, their involvement in nervous system development, remodeling,
and repair remains at the forefront of scientific investigation. During nervous system
development, MMPs are involved in dendritic and axonal formation and growth,
synapse formation and stabilization, neuronal and glial migration, and structural
reorganization. (Komori et. al, 2004; Sekine-Aizawa et. al, 2001; Monea et. al, 2006;
Jaworski, 2000). In addition to their roles in development, MMPs act as major players in
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a variety of neuropathological processes such as cancer, neurotoxicity,
neuroinflammation, cerebral ischemia, TBI, AD, and MS (Sekine-Aizawa et. al, 2001;
Sounni and Noel, 2005; Cunningham et. al, 2005; Yong et. al, 2001; as reviewed by
Rosenberg, 2002). While several soluble MMPs (e.g., MMP-2, -3, -9) have been shown
to influence these processes, membrane-bound MMPs have emerged as important
players based on their localization and ability to concentrate enzymatic activity. Here
we will detail a specific membrane-bound MMPs, MT5-MMP, in relation to central
nervous system development and plasticity.
MT5-MMP
Nearly a decade ago, the fifth member of the MT-MMP subset was cloned,
sequenced, characterized, and appropriately named MT5-MMP (MMP24) (Pei, 1999;
Llano et. al, 1999). Structurally, MT5-MMP shows the greatest homology with MT3MMP, followed by MT1-MMP and MT2-MMP, maintaining overall sequence identities at
64.4%, 53%, and 52.1%, respectively (Pei, 1999). Llano et al (1999), found similar
homology between MT5-MMP and MT3-MMP at 63%. The molecular mass is ~65 kDa
for the full inactive form of MT5-MMP, ~58 kDa for the full active form, ~52 kDa for the
transmembrane-lacking form, and 28-34 kDa for shed forms (Pei, 1999; Sekine-Aizawa
et. al, 2001, Wang X et. al, 1999).
A few structural variations are present in MT5-MMP, and may influence its
functional abilities. Llano et al (1999) found a series of repeated sequences (CCG,
CTG, and GCG) in the signal and propeptide domains of MT5-MMP. These sequences
generate stretches of 8 Pro residues and 6 Leu residues in the signal sequence, and 6
Ala residues in the propeptide domain, therefore making the N-terminal region of MT5-
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MMP significantly longer than the other membrane-bound MMPs. In the human
genome, these nucleotide sequences are highly unstable and therefore usually
polymorphic, which may suggest the existence of MT5-MMP protein variants with
alternative structures and functions (Llano et. al, 1999; Ross and Fillmore, 2007).
Another variation is present within the stem domain of MT5-MMP in mouse, rat, and
human, where there is an additional furin recognition site, RRKERR. The RRKERR
motif is necessary for cleavage and shedding of the soluble MT5-MMP form (Wang and
Pei, 2001). Rapid shedding or fragmenting of MT5-MMP appears to be common at
physiological temperatures, perhaps due to enzymatic instability (Pei, 1999; Wang X et.
al, 1999). These structural differences influence MT5-MMP‟s functional role within the
nervous system.
Aside from structural additions, MT5-MMP has a very unique pattern of tissue
expression when compared to the other membrane-bound MMPs, which are expressed
in a variety of tissue types (Bernal et. al, 2005). MT5-MMP appears to be preferentially
expressed in both rodent and human nervous systems, with mouse and human MT5MMP 95% homologous (Pei, 1999; Sekine-Aizawa et. al, 2001; Conant and Gottschall,
2005). Within the rat brain MT5-MMP accounts for ~60% of all non-gelatinase type
MMPs, whereas MT1-MMP and MT2-MMP account for 22.7% and 13%, respectively
(Sekine-Aizawa et. al, 2001). Through reverse transcriptase polymerase chain reaction
(PT-PCR) technology, MT5-MMP expression has been tested in a variety of tissues.
Although expression remains the highest in the developing and adult brain and spinal
cord, weak expression has been detected in tissues such as testis, liver, bone,
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pancreas, lung and kidney (Pei, 1999; Llano et. al, 1999; Sekine-Aizawa et. al, 2001;
Bernal et. al, 2005).
Expression of MT5-MMP in the developing and adult CNS is primarily in regions
that exhibit high neuronal plasticity, such as the hippocampus, olfactory bulbs, dentate
gyrus (DG), ventricular zone, and cerebellum (Jaworski, 2000; Sekine-Aizawa et. al,
2001; Hayashita-Kinoh et. al, 2001). MT5-MMP has also been detected in PNS
structures such as, isolated dorsal root ganglion neurons (DRG) and the trigeminal
ganglion (Jaworski, 2000; Hayashita-Kinoh et. al, 2001). Within these regions, MT5MMP is primarily expressed in neurons, including cerebellar purkinje and granule cells,
hippocampal and cortical pyramidal cells, and granule cells in the DG (Hayashita-Kinoh
et. al, 2001; Sekine-Aizawa et. al, 2001). In the developing rat cerebellum, MT5-MMP is
specifically localized in the soma and dendrites of Purkinje cells (Sekine-Aizawa et. al,
2001). Within isolated DRG cells of the developing mouse, MT5-MMP is localized in the
soma and growth cone of neurites (Hayashita-Kinoh et. al, 2001). The localization and
expression patterns of MT5-MMP in the nervous system suggest that MT5-MMP may
be involved in normal development, morphogenesis, and neural plasticity. In addition,
MT5-MMP is indicated in neuropatholgies such as AD, brain cancer, and neurotrauma
(Sekine-Aizawa et. al, 2001; Ahmad et. al, 2006; Llano et. al, 1999; Pei, 1999; Wang P
et. al, 2004; Komori et. al, 2004).
MT5-MMP‟s role in development has been investigated in both the rat and
mouse nervous systems (Sekine-Aizawa et. al, 2001; Jaworski, 2000; Hayashita-Kinoh
et. al, 2001). Using in situ hybridization, MT5-MMP mRNA is first detected in the rat at
embryo day 16 (E16), and is clearly expressed in neocortical areas by E20. Levels peak
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at postnatal day 0 (P0), and although there is a steady decline into adulthood, MT5MMP remains highly localized to regions of postnatal plasticity (Jaworski, 2000). In
Purkinje cells of the postnatal rat cerebellum, Western blot analysis reveals a gradual
increase in MT5-MMP protein levels between P1 and P35, with a dramatic increase
during P14-35. Immunohistochemistry supports these observations at different
postnatal time points. At P5, MT5-MMP is expressed in mature post-mitotic neurons
within the inner granule cell layer, especially in the soma. At P14, a time-point during
which dendritic trees are developing, MT5-MMP protein is highly present in dendrites.
MT5-MMP remains present in developed dendritic trees and cell bodies at P35, and is
densely expressed within the Purkinje cells, as far out as postnatal week 10 (P10W)
(Sekine-Aizawa et. al, 2001). A varied expression pattern of MT5-MMP mRNA is
observed within the developing mouse cerebellum. Northern blot analysis reveals weak
MT5-MMP mRNA expression at E14. Levels increase in the mouse cerebellum from
E18 through P0, at which time levels drop sharply and are practically undetectable at
P30 (Hayashita-Kinoh et. al, 2001). During this timeline of mouse development, several
neocortical morphogenic events are occurring, including active neurogenesis, neuronal
migration and differentiation, neurite outgrowth, and synaptic pruning (Brumwell and
Curran, 2006). Collectively, MT5-MMP‟s pattern of expression during rat and mouse
brain development suggests that it may be involved in nervous system morphogenesis
and plasticity, possibly through ECM degradation and remodeling.
In the adult brain, MT5-MMP is an important player in both physiological and
pathological processes. As a member of the MMP family, MT5-MMP has inherent
proteolytic abilities, and is active within the nervous system. MT5-MMP cleaves and
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fully degrades gelatin, chondroitin sulfate proteoglycans (CSPG), heparin sulfate
proteoglycans (HSPG) and dermatan sulfate proteoglycans (DSPG), and partially
degrades fibronectin in vitro (Hayashita-Kinoh et. al, 2001; Wang X et. al, 1999; as
reviewed by Hernandez-Barrantes et. al, 2002). In situ zymography shows MT5-MMP
gelatinolytic activity in post-mitotic cells migrating to the cerebellar inner granule layer in
P9 mice, and in adult cerebellar Purkinje and granule cells. In mouse DRG cells of the
PNS, recombinant MT5-MMP degrades CSPG and HSPG, both of which play an
inhibitory role in neurite outgrowth (Hayashita-Kinoh et. al, 2001). Cleavage of some
proteoglycans is thought to release reservoirs of factors such as amphoterin and
pleiotrophin, which may promote neurite outgrowth (Quinn et. al, 1999). MT5-MMP is
responsible for this proteolytic activity in vitro, because the activity is blocked by MMP
inhibitors such as ethylenediamine tetraacetic acid (EDTA), BB94 and TIMP-2
(Hayashita-Kinoh et. al, 2001; Wang X et. al, 1999). MT5-MMP appears to be unable to
degrade laminin and type I collagen (Wang X et. al, 1999). The degradation of specific
MT5-MMP substrates may contribute to normal tissue remodeling and reorganization,
as well as influence synaptic plasticity within the nervous system.
In addition to playing a role in normal tissue reorganization, MT5-MMP may be
involved in pathologies such as cancer and AD. The activation of proMMP-2 by MT1MMP/TIMP-2 is a key event in a variety of human carcinomas, including brain cancer.
As previously mentioned, MT5-MMP is capable of activating proMMP-2 in vitro, and is
believed to function similarly to MT1-MMP (Wang X et. al, 1999; Pei, 1999; Llano et. al,
1999). Therefore, MT5-MMP activation of proMMP-2 could play a role in tumor cell
migration and invasion within the brain. It is speculated that MT5-MMP forms a
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homodimer, similar to that of MT1-MMP, during proMMP-2 activation as previously
described. This is supported by in vitro immunoprecipitation experiments that reveal
what is thought to be a dimerized MT5-MMP 130 kDa form (Pei, 1999). In human tissue
samples, MT5-MMP mRNA is significantly over-expressed in brain tumors such as
astrocytomas, anaplastic astrocytomas, and glioblastomas (Llano et. al, 1999).
Recently, investigators have tried to target different proteins that interact with MT5MMP, as a possible means of treating these types of cancer. For instance, activation of
proMMP-2 appears to take place at the cell surface, therefore mechanisms that regulate
MT5-MMP position and localization on the membrane may also be involved in cancer
progression. Typically, MT5-MMP proteins are internalized from the membrane and
sent back through the Trans Golgi Network (TGN), and are then retrieved and
repositioned on the cell surface. Mint-3, which is capable of binding membrane
proteins, is required for retrieval of internalized MT5-MMP back to the membrane,
through interaction with the EWV motif in the carboxyl-end of MT5-MMP. Theoretically,
if Mint-3 were inhibited or knocked down, fewer internalized MT5-MMP proteins would
be repositioned in the membrane, less proMMP-2 would be activated, and tumor cell
migration and invasion would diminish (Wang X et. al, 2004). Further investigation into
the actual mechanism and efficiency of proMMP-2 activation by MT5-MMP is needed to
gain greater insight into its role in human carcinomas of the nervous system.
In addition to involvement in cancer progression, MT5-MMP may also play a role
in neurodegenerative diseases, such as AD. One of the hallmarks of AD is the
presence of senile plaques, which primarily consist of mis-folded aggregates of amyloid
β (Aβ), a proteolytic product of amyloid precursor protein (APP). MT5-MMP interacts
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with both Aβ and APP in the brain. In human brains, MT5-MMP is co-localized with Aβ
deposits near senile plaques, suggesting that cells may utilize MT5-MMP proteolytic
abilities to remove fibrillar forms of Aβ peptides (Sekine-Aizawa et. al, 2001). MT5MMP also induces cleavage and shedding of APP from the membrane in vitro, but only
in the presence of the adapter protein Fe65. MT5-MMP sheds a 120 kDa APP fragment
from the membrane and induces Fe65-dependent transactivation, where Fe-65 remains
bound to the cytoplasmic tail of APP and is translocated to regulate gene expression
associated with APP (Ahmad et. al, 2006). While Fe-65 is considered a scaffolding or
adapter protein rather than a transcription factor, it has been found to influence protein
expression and interact with a number of molecules, including APP, that are involved in
nervous system development and tissue specific functions (Araki et al, 2004). In
relation to APP, MT5-MMP may either function to decrease the amount of Aβ
aggregates and possibly protect against AD, or it may contribute to the progression of
AD by cleaving APP into smaller fragments, ultimately leading to senile plaque
formation. Further investigation will help characterize MT5-MMP‟s involvement in AD.
Aside from membrane bound activities, MT5-MMP may possess the ability to
process ECM components and other proteins as a soluble species (Pei, 1999). When
membrane-bound, MT5-MMP has a very short half-life, of ~ 30 min at 37°C in vitro, and
is constantly being shed at rates higher than other MT-MMPs. The full length
membrane-bound form is autocatalyzed into smaller fragments, which are released into
the pericellular space. Of these fragmented species, the ~28 kDa fragment retains the
catalytic domain, and therefore may have new proteolytic abilities within the
extracellular space (Wang X et. al, 1999). The activity of the cleaved catalytic domain
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of MT5-MMP is not fully understood, but may ultimately expand MT5-MMP‟s substrate
profile in vivo.
Based on previously discussed expression pattern within highly plastic regions of
the brain, and specific localization in developing neurites and dendritic processes, MT5MMP is also thought to play a very important role in neural plasticity, or synaptogenesis,
within the CNS and peripheral nervous system (PNS) following injury. In the PNS,
injury induced plasticity involves both collateral and regenerative axonal sprouting into
the damaged or denervated regions (Fawcett et. al, 2003). Following a peripheral nerve
injury, such as transection of the sciatic nerve, it is normal to observe nerve fiber
sprouting into Lamina II of the dorsal horn of the spinal cord. MT5-MMP knockout mice
are unable to structurally reorganization sprouting Aβ-fibers within the dorsal horn of the
spinal cord following sciatic nerve injury (Komori et. al, 2004). However, wild-type (WT)
MT5-MMP mice exhibit the typical injury induced neuronal plasticity. As a result of the
lack of axonal sprouting into Lamina II, which contains a high percentage of nociceptive
neurons, MT5-MMP knockout (KO) mice also do not develop the neuropathic pain with
mechanical allodynia that typically accompanies such an injury. Mechanical allodynia is
feature of neuropathic pain, and is evoked by non-noxious mechanical stimuli. The lack
of Aβ-fiber sprouting and mechanical allodynia in KO MT5-MMP mice suggests that
MT5-MMP plays an important role in laminar reorganization following peripheral nerve
injury (Komori et. al, 2004). MT5-MMP may influence reorganization through ECM
degradation, or possibly through interaction with cell signaling pathways involved in
nerve fiber outgrowth and migration to the appropriate target.
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Following CNS injury, certain neurons retain their ability to sprout and form new
synaptic connections within injured regions to enhance functional recovery, a process
commonly referred to as reactive synaptogenesis (Hamori, 1990; Fawcett et. al, 2003;
Phillips and Reeves, 2001). MMPs and their substrates are major contributors to the
process of reactive synaptogenesis, which involves collateral sprouting and synaptic
reorganization and stabilization (Yong et. al, 2001; Fawcett et. al, 2003). MT5-MMP is
emerging as an important player in developmental and injury induced synaptogenesis.
One mechanism of synapse modulation may involve the interaction between the
enzyme-substrate pair of MT5-MMP and cadherin, which has mainly been studied in
vitro (Monea et al, 2006). Cadherins are cell-cell adhesion molecules that are present
at a number of cell junctions, including synapses (Takeichi and Abe, 2005).
Specifically, cadherins are present in extending dendritic filopodia and mature synapses
of cultured hippocampal pyramidal cells (Togashi et. al, 2002). During synaptogenesis,
cadherins are active in pre- and post-synaptic terminals and help guide and stabilize
new connections (Takeichi and Abe, 2005). Interestingly, blockage of cadherin activity
at the synaptic junction results in abnormalities in synaptic formation, suggesting that
cadherins also regulate morphological changes within dendritic spines (Togashi et al,
2002). MT5-MMP shares a similar localization pattern to that of cadherin, and is
present at the growth cone tips of developing cortical neurons, in both axons and
dendrites, and remains present in the synapses of mature neurons, when bound to the
palmitoylated α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor
binding protein (ABP). Palmitoylated ABP, which can be linked to cell-adhesion
complexes, guides MT5-MMP to these locations and facilitates the interaction between
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MT5-MMP and cadherins at the synapse (Monea et al, 2006). Therefore, MT5-MMP
may also affect synaptic stability though interaction with cadherins and other cell-cell
adhesion complexes. Based on the current literature, MT5-MMP is considered an
important factor in the process of synaptogenesis. However, additional in vivo and in
vitro studies are needed to fully understand MT5-MMP‟s role in both developmental and
injury-induced synaptogenesis.
ADAMs
ADAMs are type I transmembrane proteins of the adamylisin family that posses
both proteolytic and adhesive functional capabilities (Black and White, 1998; White et
al., 2003). Due to similar domain structures and proteolytic capabilities, ADAM proteins
are included within the MMP family of proteases previously described. Currently, 40
gene members of the ADAM family have been identified, 21 of which are thought to be
functionally active in humans (Duffy et al., 2009). The ADAM genes are divided into
sub-families, based on their ability to exhibit or not exhibit proteolytic activity, and then
further divided into smaller subsets based on specific tissue/cell expression (testis
specific vs. non-testis specific). ADAMs that exhibit proteolytic activity in humans
include, ADAMDEC-1 (decysin), ADAM-8, -9, -10, -12, -15, -17, -19, -20, -21, -28, -30,
and -33. The remaining human ADAM proteases, ADAM-2, -7, -11, -18, -22, -23, -29,
and -32 lack one or more essential features in the catalytically active site, and are
therefore grouped into the non-proteolytic sub-family (Edwards et al, 2008; White et al.,
2003). These two sub-families are further divided based on tissue/cell expression
patterns. Studies have shown that ADAMs are expressed during development in
different tissue and cell types throughout the body including, testis, lungs, intestines,
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muscle, central and peripheral nervous system tissue, somatic tissue, bone, and
hematopoietic cell types (Edwards et al., 2008). Although the majority of expression
studies investigate levels during development, selective ADAMs do remain present and
functional throughout adulthood.
Structurally, ADAMs are traditionally composed of eight basic domains: 1) Nterminal signaling-domain; 2) pro-domain; 3) metalloproteinase domain; 4) disintegrin
domain; 5) cysteine-rich domain; 6) EGF-like domain; 7) membrane-spanning domain;
and 8) cytoplasmic domain (Fig. 1.3) (Black and White, 1998). While most domains are
present in all ADAMs, studies have indicated that in special cases some either remain
inactive or are absent entirely. Despite slight variations in structure, these general
domains each have individual functions that dictate the role(s) ADAMs play during
biological and pathological states.
The N-terminal signaling domain is responsible for directing the protein through
the secretory pathway. The pro-domain, much like that of the MMPs, maintains enzyme
latency through the same cysteine-switch mechanisms previously detailed, and also
acts as an intramolecular chaperone (Roghani et al., 1999). Removal of the pro-domain
by a proprotein convertases (i.e.-furin or PC7) in the secretory pathway produces an
active enzyme (Lum et al., 1998; Anders et al., 2001). The metalloproteinase and
disintegrin domains are the most studied of the ADAM domains, and are respectively
responsible for the protease and adhesive properties that characterize most ADAMs.
The metalloproteinase domain contains a Zn+2 dependent catalytically active site that is
held latent by the pro-domain. Sixty percent of ADAMs possess this domain, which
contains the same HEXGHXXGXXHD sequence found in the catalytic domains of most
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MMPs, indicating the ability for proteolytic activity (Takeda, 2009). Major substrates that
are proteolytically processed by the metalloproteinase domain include, signaling ligands
and their receptors, cell-cell adhesion molecules, cell-matrix adhesion molecules,
cytokines, and growth factors (White et al., 2003; Seals and Courtneidge, 2003). The
disintegrin domain contains a 14 amino acid stretch (CRXXXXXCDXXEXC) called the
“disintegrin loop” which is believed to be responsible for integrin interaction and
therefore the adhesive property of many ADAM molecules (White et al., 2003).
Interaction with integrins has been shown to influence cell adhesion and cell-cell
interactions. It is important to note that not all ADAM family members have protease
and/or adhesive capabilities.
Unlike the metalloproteinase and disintegrin domains, the cysteine-rich domain is
present in all ADAM molecules, and is found to be continuous with the disintegrin
domain. It has recently been described as having two segments, a “wrist” (Cw) and
“hand” (Ch). While Cw is continuous with the disintegrin domain, Ch is the most
divergent and variable segment in the ADAM structure and therefore posses what has
been termed a hyper-variable region (HVR). The HVR is believed to be involved in
substrate specificity, and may play a role in substrate binding to facilitate ectodomain
shedding of the substrate by the metalloproteinase domain, therefore influencing
protease activity (Takeda, 2009). As a whole, the cysteine-rich domain has also been
shown to interact with different molecules to promote cell spreading and migration
(Hooper and Lendeckel, 2005). The function of the EGF-like domain, which is absent in
both ADAM-10 and -17, is not well understood in the current literature, but is thought to
act as a rigid spacer connecting and orienting the metalloproteinase/disintegrin/cysteine
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domains to the membrane-spanning domain (Takeda, 2009). The membrane-spanning
domain tethers the ADAM protein to the cell surface, which makes these molecules very
similar to the MT-MMPs. Therefore, they are presented with a limited pericellular
environment which ultimately concentrates their activity to a specific zone. It is
important to note that although the majority of ADAMs are found tethered to the cell
surface, ADAM-11, -12, -17, and -28 are susceptible to slicing that eliminates the
membrane-spanning domain (Cerretti et al, 1999; Roberts et al, 1999; Howard et al.,
1999; Galliano et al., 2000). These sliced variants are released as soluble proteins, and
able to act at a distance from the cell surface. It is not yet fully understood if all ADAMs
are susceptible to this type of alternative splicing. Nonetheless, the production of
membrane-bound and soluble ADAM forms permits both focal and diffuse extracellular
activity. Among the membrane-bound ADAMs, the cytoplasmic domain varies in both
length and composition and is often subject to alternative splicing. At least one Src
homology region-3 (SH3) binding site is present on the cytoplasmic domain for
serine/threonine or tyrosine phosphorylation. Phosphorylation of these sites and/or
binding of other proteins to the cytoplasmic domain have been shown to influence
ADAM maturation, trafficking, membrane localization, proteolytic activity, and
association with cytoskeletal elements (Seals and Courtneidge, 2003). Taken together,
the general domains of ADAM molecules permit a variety of functions that have been
shown to influence processes in development and pathology.
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Fig 1.3 A Disintegrin and Metalloproteinase (ADAM) General Structure. Schematic
representation of ADAM structure including prodomain, metalloproteinase domain,
disintegrin domain, cysteine-rich region, EGF-like domain, transmembrane domain, and
cytoplasmic tail domain.
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Duffy et al., 2009

51

Functionally, ADAM proteins are known primarily to proteolytically process the
ectodomains of a variety of cell surface receptors and signaling molecules, and are
often referred to as “sheddases". Secondary to protease abilities, ADAMs possess
adhesive properties that also influence their functional roles during biological processes.
Expression patterns implicate ADAMs in biological processes such as neuronal cell
migration, axon guidance, cell adhesion, fertilization, neurogenesis, myogenesis,
branching morphogenesis in lung, and heart and bone development (as reviewed by
Hooper and Ledeckel, 2005). ADAMs have also been shown to play important roles in
disease states including, cancer, rheumatoid arthritis, AD, Muscular Dystrophy, cardiac
disease, and Multiple Sclerosis (Hooper and Lendeckel, 2005).
It is evident that ADAMs play important functional roles in development and
pathology. During biological processes, ADAM activity has been shown to promote
both extracellular and intracellular signaling (Reiss et al., 2005; Janes et al., 2005;
Borggrefe and Oswald, 2009). Ectodomain shedding of growth factors or cytokines by
ADAMs can stimulate and/or inhibit extracellular signaling pathways, which in turn
influence a number of biological processes. This ectodomain cleavage of substrates by
ADAMs has also been shown in many cases to be a prerequisite for intracellular
signaling, involving molecules such as Notch and β-catenin (Pan and Rubin, 1997;
Marambaud et al., 2003). This process, referred to as Regulated Intramembrane
Proteolysis (RIP) is a sequential proteolytic cascade that involves the primary
ectodomain cleavage of a membrane-bound protein, followed by a secondary cleavage
within the membrane by intramembrane-cleaving molecules such as presenilins (Brown
et al., 2000; Buckingham, 2003). The secondary cleavage can lead to subsequent
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processing of intracellular fragments which act in intracellular signaling pathways to
influence gene transcription. Currently, ADAM-10 is the primary RIP molecule in the
ADAM family (Saftig and Hartmann, 2005). In addition to extracellular and intracellular
signaling, ADAMs also influence cell adhesion and migration through binding to
integrins and modulation of cell-cell and cell-matrix connections, respectively. Cell
adhesion and migration can also be affected by cleavage of cell adhesion or ECM
molecules. Therefore, in many cases, the metalloproteinase and disintegrin domains
can work in concert to influence different biological processes.
Successfully carrying out these functions requires a certain level of regulation.
ADAMs are tightly regulated by a variety of means. Regulation of these biological
processes often involves controlling the protease activity, which can be influenced by
adjacent and downstream domains. Structural modifications such as Pro domain
removal and alternative splicing of cysteine-rich and cytoplasmic domains can
drastically affect the activity of ADAMs. Binding of surrounding adapter proteins to or
phosphorylation of the cytoplasmic domain may also impact protease activity. Due to
the homology of the catalytic site between MMPs and ADAMs, several ADAM family
members have been shown to be regulated by the binding of endogenous TIMPs.
While much regulation is in place to limit the proteolytic activity of ADAMs, other lines of
regulation act to promote sheddase activity. For example, ADAM-mediated shedding
can be stimulated as a result of G-protein coupled receptors or protein kinase C (PKC)
activation, changes in intracellular Ca2+ levels, and natural or experimental stimuli.
Additionally, alterations to ADAM cell surface placement and localization can influence
sheddase activity as well as change the pericellular environment of potential substrates
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(Reiss and Saftig, 2009). These levels of regulation of ADAMs influence the
spatiotemporal expression and function of ADAMs, which is necessary during biological
processes. Loss of ADAM regulation has the potential to disrupt ADAM/substrate
balance, and may lead to the progression of disease.
The importance of ADAMs in development and disease has been confirmed
however specific nuances for each ADAM family member remain to be fully detailed.
While ADAMs within small subsets may have overlapping structural and functional
characteristics, it is important to delineate specific biological roles. For the purposes of
this study, we have chosen to highlight ADAM-10, and emphasize its expression and
activity patterns within the nervous system.
ADAM-10 and the Nervous System
ADAM-10 was first isolated in 1989 in bovine brain myelin samples, but did not
get its original vertebrate designation until 1996 (Howard et al., 1996). Today, ADAM-10
has been identified as an essential protein in a number of vertebrates and is considered
the principle „RIPing‟ sheddase of cell surface proteins such as APP and Notch. Among
the family of ADAMs, ADAM-10 shares the greatest sequence homology with ADAM-17
(Maskos et al., 1998). Both ADAM-10 and -17 lack the EGF domain and calcium I and
III binding sites in the disintegrin domain, and possess additional disulfide bonds within
their metalloproteinase and a shorter Ch segment in the cysteine-like domains (Takeda,
2009). Due to their sequence similarities, ADAM-10 and -17 have been shown to play
compensatory roles in both development and disease. While structural and functional
similarities exist between ADAM-10 and -17, ADAM-10 appears to be expressed at
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higher levels in the nervous system, therefore suggesting a greater role in nervous
system development and disease (Marcinkiewicz and Seidah, 2000).
Early vertebrate studies investigated expression patterns of ADAM-10 in
developing and mature systems. During development, ADAM-10 mRNA was found to
be expressed ubiquitously throughout the dermatome, myotome, epidermis, gut
ectoderm, epithelial tissue of the kidney and liver, heart and in neural crest cells of the
chick embryo (Hall and Erickson, 2003). In the developing mouse brain, ADAM-10
mRNA was detected at E13 in cranial ganglia, and at E17 and P4, primarily
concentrated within the superficial cortical layers and hippocampus. In adult mouse
brain, ADAM-10 mRNA expression was dampened, however more specifically localized
to pyramidal cells in cortical layers II-VI, throughout the CA1 hippocampal region,
dentate gyrus, and dorsal thalamus, and within non-neuronal cells including
oligodendrocytes within the corpus callosum and choroid plexus cells (Marcinkiewicz
and Seidah, 2000). In human tissue, ADAM-10 was found to be highly expressed
throughout the brain, in both neurons and glial cells, as well as in mesenchymal stem
cells, placenta, bone marrow and blood myeloid cells, and bladder (Karkkainen et al.,
2000; Marcinkiewicz and Seidah, 2000; Edwards et al, 2008). These expression
patterns suggested a potential functional importance of ADAM-10 within the developing
and adult nervous systems. Further functional studies confirmed ADAM-10 as the
principle sheddase involved in the Notch signaling pathway, and revealed it to be
among a small group of ADAMs responsible for α-secretase cleavage of APP. Although
substrates Notch and APP have dominated ADAM-10 literature, there are additional
potential substrates, including Ephrins, CD44, L1 adhesion molecule, N-cadherin, and
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EGF, that may also influence nervous system physiology and pathology (Janes et al.,
2005; Nagano et al., 2004; Mechtersheimer et al., 2001; Reiss et al., 2005; Sahin et al.,
2004). In the following sections, selective ADAM-10 substrates will be highlighted to
demonstrate the involvement of ADAM-10 in development and disease.
ADAM-10 involvement in the Notch signaling cascade has garnered much
investigation due to the importance of Notch in a number of biological processes.
Within the nervous system, Notch is present from birth to death, and actively influences
processes including neurogenesis, axonal and dendritic growth, synaptic plasticity, and
neuronal death. Notch has also been implicated in different neuropathologies, including
ischemic stroke, AD, PD, Huntington‟s disease, and brain cancer through the Notch
signaling pathway (Lathia et al., 2008). Therefore, understanding ADAM-10/Notch
interaction not only gives insight to nervous system development and maintenance, but
it may also shed light on possible treatment options for the involved neuropathologies.
The Notch signaling pathways involves the binding of the Notch receptor to its
appropriate ligand (Delta-like, Jagged in mammals), which induces a set of proteolytic
cleavages, the release of an intracellular Notch fragment, and subsequent regulation of
gene transcription. The released intracellular domain of Notch does not bind directly to
DNA but rather acts as a transcriptional coactivator by binding recombination signal
sequence-binding protein Jκ (RBP-J) and activates the transcription of genes that
contain binding sites for RBP-J (Borggrete and Oswald, 2009). Notch target genes
include: transcription factors such as Hes and Hey proteins; developmental and immune
genes such as CD25 and GATA3; genes associated with cell survival, proliferation, and
migration such as c-myc and cyclinD1; and a variety of others such as NFκB2, bcl-2,
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and ADAM-19 (as reviewed by Borggrefe and Oswald, 2009). The downstream effects
of Notch signaling on both development and disease are widespread, and partially
dependent on ADAM activity. ADAM-10 is capable of cleaving Notch at its first
cleavage site, which in turn allows for additional cleavage by γ-secretase and release of
an intracellular fragment (Pan and Rubin, 1997; Borggrefe and Oswald, 2009). Without
the ADAM-mediated cleavage event, Notch deficiency would occur, leading to a
breakdown in gene transcription and downstream CNS processes. Interestingly,
ADAM-10 knockout mice exhibit multiple developmental malformations, including
defective CNS and heart development, vasculogenesis and somitogenesis, similar to
those seen in other Notch deficiency models such as Notch1/Notch4 and
presenilin1/presenilin2 double knockout mice (Hartmann et al., 2002; Krebs et al., 2000;
Herreman et al., 1999). Based on these finding and observations it can be posited that
ADAM-10 and Notch interaction is essential for CNS development, and may also be
important in CNS disease processes.
Amyloid precursor protein (APP) is another well-studied substrate of ADAM-10
that is involved in cell motility and axonal vesicular transport under normal conditions
(Sabo et al., 2001; Kamal et al., 2001). Like Notch, APP is susceptible to proteolytic
processing by a variety of secretases, and releases fragments that can act on
downstream gene targets. Within the brain, APP can be processed by α- (ADAM-10, 17), β- (BACE1), and γ- (presenilin) secretases, and each cleavage product acts
differently. Cleavage of APP by ADAM-10 results in the release of an extracellular
APPsα fragment, which has been shown to be neuroprotective and promote
neuroplasticity (Bell et al., 2008). This preliminary cleavage induces an intramembrane

57

γ-secretase cleavage and release of an intracellular fragment believed to have nuclear
signaling functions. In contrast, cleavage by β-secretase results in the release of an Aβ
fragment that has been associated with AD plaques, neurotoxicity, and abnormal
neurite size (LaFerla et al., 2007; Sastre, 2010). Due to the protective qualities of the
APPsα fragment and the detrimental nature of the Aβ fragment within the brain, ADAM10 has recently been targeted in AD studies. In human post-mortem studies, ADAM-10
mRNA was detected by northern blot analysis in AD brains throughout the frontoparietal
cortex (Marcinkiewicz and Seidah, 2000). ADAM-10 also showed moderate granular
and vesicular staining in pyramidal and non-pyramidal neurons in cortical layers I-V and
also around diffuse neuritic plaques (Bernstein et al., 2003). Recall that MT5-MMP was
also found to localize around neuritic plaques, which may indicate functional overlap
between the two membrane-bound MMPs. While ADAM-10 was present in AD brains,
protein expression was significantly reduced when compared to age matched controls,
indicating that perhaps a reduction in ADAM-10 results in decreased APPsα release,
therefore giving way to Aβ processing and AD progression. In vivo AD/ADAM-10
studies support this hypothesis. When AD mice were crossed with mice that
moderately overexpressed ADAM-10 (APPV7171/ADAM10mo), results indicated
decreased Aβ peptide levels, reduced plaque formation and improved LTP and
cognitive scores when compared to singly transgeneic AD parent mice (Postina et al.,
2004). In a separate study looking at excitotoxic stress induced by kainate injection,
moderate ADAM-10 expression was shown to provide neuroprotection against
excitotoxic stress in AD parent mice, but failed to protect against seizures and
neurodegeneration. Additionally singly transgeneic dominant negative ADAM-10 mice
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showed shorter seizing times and less neuronal cell death and glial cell invasion
following kainate injection when compared to wild-type mice. These results suggest
that while overexpression of ADAM-10 may limit excitotoxicity in mice that also
overexpress APP, inhibition of ADAM-10 may be beneficial in controlling seizure activity
and neuroinflammation in this model (Clement et al., 2008). While these studies
indicate a role for ADAM-10 in APP processing, it should also be noted that when
ADAM-10 is deleted in cells, APP processing still occurred (Deuss et al., 2008).
Although these are in vitro results, it is important to recognize the functional overlap
between ADAM-10 and other ADAMs or MMPs.
While much of the work done to investigate ADAM-10 interaction with ephrins
has been conducted in Drosophila it may still reveal an important functional relationship
that has potential influence on vertebrate nervous system processes. Ephrins act with
Eph receptors to form bi-directional signaling systems between membrane proteins
involved in tissue compartmentalization processes such as somitogenesis,
angiogenesis and axonal guidance (Saftig and Hartmann, 2005). Within the nervous
system, axonal guidance requires axon repulsion, which is activated when Eph
receptor/ephrin connections are disrupted (Pasquale, 2005). Studies indicate that
ADAM-10 is capable of ephrin ectodomain cleavage, and disruption of Eph
receptor/ephrin binding. In Drosophila, KUZ (ADAM-10 orthologue) was found to be
required for proper axonal extension during development (Fambrough et al., 1996).
These observations were further investigated in primary cultured neurons that showed
ectodomain cleavage of ephrin-A2 when full-length KUZ was present and inhibited
cleavage when dominant negative KUZ was present (Hattori et al., 2000). ADAM-10
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was also found to associate with Eph3A and cleave ephrin-A5 to ensure signal
termination and complex internalization in cultured cells (Janes et al., 2005). These and
other studies implicate ADAM-10 as a primary sheddase of ephrins within the nervous
system, and suggest an important role for ADAM-10 in plasticity changes associated
with axonal guidance and nervous system development.
Finally, ADAM-10 can be tightly linked to nervous system development and
plasticity through interaction with N-cadherin. This interaction is similar to that between
MT5-MMP and N-cadherin. N-cadherin, which will be discussed in greater detail in the
following section, is a transmembrane synaptic adhesion molecule that homophilically
binds across the synaptic cleft to connect and stabilize pre- and post-synaptic elements
(Benson and Tanaka, 1998). In addition to maintaining synaptic structure and integrity,
N-cadherin is important for synaptic efficacy and signaling. ADAM-10 has been shown
to regulate cell surface expression and availability of N-cadherin through ectodomain
shedding (Uemura et al., 2006; Reiss et al., 2005). Release of the extracellular Ncadherin fragment has been shown to promote neurite outgrowth (Paradies et al, 1993;
Utton et al., 2001). N-cadherin ectodomain shedding not only promotes neurite
outgrowth and modulates the synaptic stability extracellularly, but it also triggers
downstream intracellular cytoskeletal changes and transcriptional events through the
activity and translocation of β-catenin (Reiss et al., 2005).
While MT5-MMP and ADAM-10 mediated N-cadherin cleavage, along with the
downstream events will be detailed in later sections, these studies may be taken as
evidence that these membrane-bound MMPs play a critical role in the process of
synaptic plasticity. To better understand the potential effects of N-cadherin proteolytic
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cleavage, the following section will review characteristics of classic cadherins and
highlight N-cadherin‟s role in the nervous system.

CADHERINS
Classic cadherins
Classic cadherins constitute a well-established family of Ca+2 dependent, cell
adhesion molecules, with as many as 20 members in a single vertebrate species
(Takeichi and Abe, 2005). Cadherins are classified as single-pass transmembrane,
type I glycoproteins that typically form strong homophilic bonds in the presence of Ca +2,
and are known to be associated with adherins junctions in a variety of cell types (Heupel
et al., 2008; Benson and Tanaka, 1998). Cadherin mediated cell-cell adhesion plays an
important role in development and maintenance of tissue integrity in multicellular
organisms (Halbleib and Nelson, 2006). In addition to their adhesive properties,
cadherins dynamically influence different intracellular signaling pathways that in turn
affect downstream transcriptional events during embryological and adult processes
(McCusker and Alfandari, 2009).
Structurally, these cell-adhesion molecules possess a large extracellular segment,
made up of tandemly repeated extracellular cadherin domains (Fig 1.4). Based on
extracellular domain number and organization, classic cadherins are further subdivided
into two distinct groups: type I/II or type III cadherins. Type I/II cadherins are found
solely in vertebrates and ascidians and possess five extracellular domains. Of the five
extracellular domains, the distal most is responsible for specific binding, which is
typically homophilic. However, heterophilic binding can occur through formation of cis-
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and trans-heterodimers between similar cadherins (Shan, WS et al., 2000). This group
can be further divided into type I: epithelial (E-), neural (N-), placental (P-), and retinal
(R-) cadherins, and type II cadherins, which are designated numerically (ex: Cadherin11). Type I cadherins possess a conserved HAV (histadine alanine valine) adhesion
recognition sequence that is crucial for homophilic cadherin interactions (as reviewed by
Suzuki and Takeichi, 2008; Noë et al., 1999). Type II cadherins lack this HAV
sequence, and are often found to bind heterophilically between cells. Finally, type III
cadherins exist in invertebrates and vertebrates such as fish and birds, but are not
found in mammals. In contrast to type I/II, their extracellular segment typically possess
greater than five extracellular domains, as well as a unique primitive class cadherin
domain (PCCD) that is situated between the extracellular domains and the plasma
membrane (Oda and Tsukita, 1999; Tanabe et al., 2004).
Despite variations in extracellular arrangement, all classic cadherins possess a
highly conserved intracellular segment that contains juxtamembrane and cytoplasmic
tail domains. The juxtamembrane domain (JMD) contains a GGGEED sequence that
permits interaction with members of the p120 catenin family. The JMD also plays an
important role in cell-cell adhesions and cell physiology by influencing cadherin
clustering, cytoskeletal modifications, and the influx of calcium (Benson et al., 2000;
Brusés JL, 2006). The cytoplasmic tail domain (CD) serves as a binding site for
catenins, such as β- and γ-catenin. This protein cluster is linked to the actin
cytoskeleton through α-catenin to not only ensure structural integrity of the tissue and
full adhesive activity, but also to influence intracellular signaling pathways (see again
Fig. 1.4) (Togashi et al., 2002; Lilien et al., 1999).

62

Figure 1.4 Classic Cadherin Structure and Interaction with Cytoplasmic Proteins.
Classic cadherin structure includes tandemly repeated extracellular (EC) domains, a
membrane spanning domain, and an intracellular domain that is further divided into
juxtamembrane and cytoplasmic tail domains. The intracellular domain interacts with
cytoplasmic proteins such as β- and α-catenin, which anchor cadherin to the actin
cytoskeleton.
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Having knowledge of the general structure and function of classic cadherins
allows us to understand the role they play in tissue development, maturation and
maintenance. While cadherins influence a variety of processes throughout an
organism‟s lifespan, their role in nervous system development and disease has
garnered tremendous attention and fostered important scientific inquiry. In order to
highlight the importance of cadherins in the nervous system, we will shift the focus of
this review to the role that N-cadherin plays in nervous system development,
neurophysiology and neuropathology.
N-cadherin and the Nervous System
Successful nervous system development requires coordinated temporal and
spatial synthesis, regulation, and interaction of a number of essential proteins. Of these
proteins, N-cadherin (130 kDa) is one of the first present during the onset of nervous
system development. In vivo studies show that N-cadherin mRNA is typically
expressed in two phases, an early embryonic phase and a late embryonic/postnatal
phase. In the early embryonic phase, N-cadherin mRNA is ubiquitously expressed
throughout undifferentiated neuroepithelium. During this phase the neuroepithelium is
proliferating in the ventricular zone and the first neurons begin differentiation in the
marginal zone (lamina I) of the cerebral cortex. During the late embryonic/postnatal
phase, when more neurons have differentiated and fiber tracts begin to form, Ncadherin mRNA expression becomes restricted to particular subsets of neurons in cellrich layers or lamina within specific regions of the brain. These specific brain regions
include: deep neocortical layers, internal nuclear layer of the retina, parietal cortex,
olfactory bulb, cerebellum, and several limbic system structures such as the
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hippocampus proper and dentate gyrus (Bekirov et al., 2002; Redies and Takeichi,
1993). Within the rat hippocampus, the highest observed N-cadherin mRNA expression
occurs from postnatal day 0-2, within cell-rich areas such as the granule cell layer of the
dentate gyrus and the pyramidal cells of CA1 and CA3 fields. It has also been observed
that although N-cadherin is initially localized to both inhibitory and excitatory synapses,
with time it selectively localizes to excitatory synapses within the hippocampus (Benson
and Tanaka, 1998). In addition to neuronal localization, N-cadherin mRNA has also
been shown within the neuropil of the dentate gyrus molecular layer, which is
suggestive of astrocytic or oligodendrocyte localization (Bekirov et al., 2002). This
observation is consistent with both in vivo and in vitro studies that have shown Ncadherin mRNA within supportive cells of the nervous system, such as glial and
Schwann cells (Wilby et al., 1999; Letourneau et al., 1990). In the postnatal/adult
phases of life, the distribution of N-cadherin is basically maintained, while its intensity of
expression tends to decrease with age.
N-cadherin expression patterns indicate that it is functionally important during
nervous system development, and remains necessary into later phases of life. Studies
show that N-cadherin is functionally involved in neural tube morphogenesis,
development of left to right asymmetry through the Wnt signaling pathway, and
formation of the alar region of the midbrain, hindbrain and posterior spinal cord (Lele et
al., 2002; Thiery JP, 2003). Interestingly, null-N-cadherin homozygotes display multiple
nervous system defects, including malformations of somites and the neural tube, and
typically die by day 10.5 of gestation due to heart defects (Thiery JP, 2003; Lou et al.,
2001). Despite the cause of death, the nervous system malformations observed in
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these animals would ultimately be detrimental to the process normal development, thus
indicating the importance of N-cadherin during this stage.
As nervous system development persists neurons differentiate, migrate to their
final destination and extend axonal and dendritic processes in order to form synaptic
connections and circuits within the brain. Once established and throughout their
existence, synapses experience a variety of modifications and changes. Together
these processes can be characterized as either activity-independent, which includes the
“hard wired” events leading up to and including synaptogenesis, or activity-dependent,
which can also include synapse formation as well as further synaptic modification (ex:
strengthening; weakening; deletion). N-cadherin plays important and distinct roles in
both activity-independent and dependent processes.
During the activity-independent phase of development, N-cadherin is upregulated
and recruited to both pre- and post-synaptic compartments, as well as along axonal
shafts. Specifically, N-cadherin is recruited and inserted into the membrane of the
symmetrical zone on the synapse, or puncta adherentia, which lies laterally to the
asymmetric synaptic neurotransmitter release zone (Uchida et al., 1996). Studies show
that recruitment of N-cadherin to these compartments during development is important
for neurite outgrowth, axon target recognition, pre-synaptic assembly, dendritic spine
morphogenesis, and synaptic formation and specificity (Jontes et al., 2004; Bozdagi et
al., 2000; Lilien et al., 1999). In addition to a synaptic role, N-cadherin controls growth
cone migration to Schwann cells, therefore influencing the process of axon myelination
(Letourneau et al., 1990).
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The aforementioned processes are guided and/or influenced by specific
structural components of N-cadherin. Studies have investigated the role(s) extracellular
and intracellular domains of N-cadherin play in these processes. As previously
mentioned, the extracellular domain of cadherin is necessary for cell-cell adhesion. It is
not only responsible for the physical bond formed between cells, in this case neurons,
but also is important for recruitment of N-cadherin to proper sites within the neuronal
compartments. Studies that look at the effect of mutant N-cadherin in both young and
old neurons illustrate the importance of the extracellular domain. For example, in older
neurons, with pre-established synaptic contacts, extracellular domain deletion did not
lead to synapse disassembly, but instead resulted in dendritic spine morphology
changes (elongated or bifurcated spines) and significantly smaller synapses. In both
sets of neurons, although less dramatic in older transfected neurons, disruption of presynaptic vesicle recycling and Synapsin and PSD-95 distribution was observed
(Togashi et al., 2002). These findings highlight the importance of the N-cadherin‟s
extracellular domain for proper synaptic assembly, and potentially function.
The intracellular domain of N-cadherin can also influence activity-independent
events during neural development and synaptogenesis. Recall that the intracellular
domain possesses two distinct regions, the JMD and CD. These regions serve primarily
as binding sites for different synaptic proteins that are essential for synaptic formation
and function. A majority of these synaptic proteins belong to the catenin family. The
interaction between catenins and N-cadherin‟s intracellular domain is not only essential
for the creation and maintenance of synaptic structure, but also important for
intracellular signaling.
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It is important to note that the JMD and CD have distinct roles when it comes to
carrying out these essential synaptic functions. The JMD has been shown to influence
processes such as neurite outgrowth, functional coupling between pre- and postsynaptic elements, synaptic adhesion, and synaptic stabilization through cadherin
clustering. These events are believed to involve the coupling and uncoupling of p120
catenin to/from its surface (as reviewed by Brusés, 2006). The relationship between the
JMD and p120 catenin has also been implicated in intracellular signaling. When p120
becomes uncoupled from the JMD, it has been shown to influence transcription through
nuclear translocation and subsequent interactions with a zinc finger transcription factor
(Daniel and Reynolds, 1999).
The CD appears to have more of a structural role during neural development and
synaptogenesis, through its interaction with catenins and the actin cytoskeleton.
Studies have implicated the CD/catenin complex in events such as neurite outgrowth,
pre-synaptic vesicle assembly, dendritic spine stabilization, and synaptic adhesion and
maturation (as reviewed by Brusés, 2006; Benson and Tanaka, 1998). Proper
orientation of N-cadherin, β-catenin, αN-catenin and cytoskeletal components is
necessary for these events to occur successfully. Multiple studies have shown that
alterations to any one of the complex proteins during synaptogenesis in young neurons
can lead to dendritic morphological changes and synaptic destabilization (Togashi et al.,
2002; Abe et al., 2004; Bozdogi et al., 2004). More mature neurons tend to be affected
less by these changes, which may indicate compensation by similar cadherins/catenins.
The CD is also involved in intracellular signaling, primarily through interaction with βcatenin which is influenced by phosphorylation. β-catenin is in a dephosphorylated
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state while bound to the CD, but is released into the cytoplasm when phosphorylated
(Lilien et al., 1997). Uncoupled β-catenin, which is well established as a Wnt signaling
molecule, has the potential to influence a variety of signaling pathways and downstream
transcription (McCusker and Alfandari, 2009). For example, β-catenin can combine with
the Tcf/LEF family of transcription factors to alter gene expression (Huber et al., 1996;
Moon et al., 2004). It is clear that both the JMD and CD play important roles in synaptic
formation, structural integrity, and intracellular signaling during activity-independent
developmental and synaptogenic events.
Beyond development, N-cadherin has been found to be involved in activitydependent events, mainly activity-dependent synaptic plasticity. Activity-dependent
synaptic plasticity is a dynamic process that involves periods of neural activity at the
synapse that have the potential to change synaptic structure and strength, and is
essential to normal brain function. Activity-dependent plasticity is also crucial in
synaptic circuitry rewiring following CNS injury (Benson et al., 2000). Neural activity has
been shown to increase adhesive forces of N-cadherin and also recruit more N-cadherin
to existing and nascent synapses at different stages of synaptic plasticity (Tanaka et al.,
2000; Bozdogi et al., 2000). Decreasing or increasing neural synaptic activity using
pharmacological agents can also alter the expression and localization of catenins that
are associated with N-cadherin intracellularly (Abe et al., 2004). Recall that the
alteration of any of the cadherin-catenin components has been shown to correlate with
changes in synaptic structure and function.
The experimental model most often used to illustrate N-cadherin‟s involvement in
synaptic plasticity is LTP. To understand N-cadherin‟s role in synaptic plasticity, it is
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important to first describe the LTP model. LTP is the cellular model of long-lasting
synaptic plasticity that is believed to contribute to learning and memory (Nagy et al.,
2006). Because the hippocampus is crucial for learning and memory formation,
hippocampal slice preparations is the dominant model used in these experiments,
where the CA3 field Schaffer collateral afferent fibers are stimulated, and recordings of
field excitatory postsynaptic potentials (fEPSP) are taken from the dendrites of the CA1
field (Squire, 1992). The high frequency stimulation administered to the slice triggers
strong depolarization of neurons, which can lead to both short and long-lasting synaptic
plasticity. Short-lasting plasticity is fast and occurs during the induction and early
phases of LTP (E-LTP), often lasting for approximately 60 minutes post-stimulation. ELTP does not require new protein synthesis, but rather relies on modification to the
synapse using existing and available stored proteins (Malenka and Bear, 2004). Longlasting plasticity is slower to develop, occurs during the late phases of LTP (L-LTP), and
involves gene transcription and protein synthesis, as well as the formation of new
synaptic connections. L-LTP can last hours to days, and sometimes weeks poststimulus (Benson et al., 2000; Bozdogi et al., 2000). N-cadherin has been shown to
play important and distinct roles in both E-LTP and L-LTP.
Based on the synaptic localization of N-cadherin and its role in synaptic
assembly and adhesion, it is clear to see how it can influence short- and long-term
activity-dependent synaptic plasticity. Alterations in short-term synaptic plasticity
properties have been demonstrated in N-cadherin knockout embryonic stem cells,
which displayed functional impairments in high-frequency pre-synaptic vesicle
exocytosis (Jüngling et al., 2006).
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In the case of E-LTP, which includes LTP post-stimulus induction, studies have
shown an important role for N-cadherin. In hippocampal slices pre-treated with Ncadherin blocking antibodies, antagonists, or recombinant fragments, E-LTP either fails
to be induced or displays a decreased E-LTP response that quickly returns to baseline
(Tang et al., 1998). N-cadherin also has been shown to be important in strengthening
of existing and assembly of new synapses during L-LTP. In a study by Bozdogi et al.,
spCAMP induced LTP resulted in a significant increase of N-cadherin protein levels at
synaptic labeled puncta (2000). In contrast to N-cadherin LTP studies, cadherin-11
knockout mice display enhanced LTP in hippocampal neurons that appeared
structurally sound. This finding suggests that cadherins may influence different
signaling cascades that contribute to synaptic plasticity, and that there are unique roles
for cadherins localized within this region (Manabe et al., 2000).
How does N-cadherin strengthen synapses during neural activity? A possible
mechanism involves the association for N-cadherin with N-methyl-D-aspartic acid
(NMDA) type glutamate receptors (NMDAR). Following strong stimulation of NMDAR,
N-cadherin dimerizes and becomes increasingly resistant to being processed by MMPs.
Dimerization promotes strong synaptic adhesion and therefore allows additional
synaptic changes to take place without compromising synaptic stability (Tanaka et al.,
2000). However, another study indicates that neural activity may decrease N-cadherin
adhesive forces due to changes in [Ca+2]. It is well established that a threshold of
neural stimulation causes an influx of Ca+2 through NMDAR channels, and leads to a
decrease [Ca+2] at the synaptic cleft. This decrease in extracellular Ca+2 limits the
available Ca+2 needed for homophilic N-cadherin binding, therefore weakening its
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adhesive properties and permitting structural remodeling. It is estimated that [Ca+2]
drops from 1.3mM to 0.8-.03 nM upon LTP induction, which in some cases may be
sufficient to weaken N-cadherin synaptic adhesion (Heupel et al., 2008). Despite
varying reports, opposing N-cadherin responses to neural activity may be due to
involvement of different signaling pathways that are activated during specific stages of
development and disease.
Neural activity can also lead to N-cadherin extracellular domain cleavage by
enzymes such as MT5-MMP and ADAM-10, an event that is triggered by NMDAR
stimulation (Fig 1.5) (Monea et al., 2005; Reiss et al., 2005; Uemura et al., 2006).
Extracellular domain cleavage decreases N-cadherin‟s adhesive capabilities across the
synapse, which may be beneficial during period synaptogenesis when the flexibility of
synaptic elements is necessary. Release of a 90 kDa N-cadherin N-Terminal Fragment
(NTF) into the extracellular space can influence different biological events. For
example, NTF can associate with ECM molecules and potentially influence cell
adhesion and neurite outgrowth. In addition, extracellular cleavage of N-cadherin
activates a cascade of events that results in additional cleavage and signaling
intracellularly (McCusker and Alfandari, 2009). Intracellular C-terminal Fragment 1
(CTF1; 40 kD), which contains the transmembrane and entire intracellular domain of Ncadherin, is generated following NTF shedding. CTF1 is further modified by Presenilin1 (PS-1), which releases the intracellular domain from the transmembrane domain, and
is renamed CTF2 (35 kD) (Uemura et al., 2006). CTF2 can interact with both β-catenin
and cAMP response element-binding (CREB) binding protein (CBP) to prevent their
degradation, and in turn either promote or limit gene transcription (Marambaud et al.,
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2003; Reiss et al., 2005). While the exact function(s) of these fragments remains
elusive, it is clear that neural activity alters N-cadherin structure and function, and in
turn affects different synaptic processes.
Based on the current literature, N-cadherin serves a number of functions during
synaptogenesis and throughout the life of a synapse. N-cadherin is important during
activity-independent events, such as neurite outgrowth and axon targeting, and during
activity-dependent events such as synaptic plasticity and intracellular signaling. Many
of these studies have focused on the role(s) of N-cadherin during normal nervous
system development and neurophysiological events. There appears to be a need for
further investigation of N-cadherin expression and function during various
neuropathologies, such as TBI. Therefore, we have designed this study to investigate
the interaction between N-cadherin and two membrane-bound MMPs, MT5-MMP and
ADAM-10, during injury-induced synaptogenesis following TBI.
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Figure 1.5 Cleavage Products of N-cadherin. MMP extracellular cleavage of fulllength (130 kDa) N-cadherin releases a 90 kDa N-terminal fragment (NTF).
Extracellular cleavage is followed by intracellular processing of N-cadherin. Intracellular
fragments include a ~40 kDa C-terminal fragment 1 (CTF1) and a second ~35 kDa
fragment (CTF2).
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EXPERIMENTAL HYPOTHESES
The following set of experiments and their results are divided into two main
chapters. The first chapter describes the spatial and temporal hippocampal expression
of MT5-MMP, ADAM-10, and N-cadherin in models of adaptive (UEC) and maladaptive
(TBI+BEC) synaptogenesis. The second chapter describes the effects of in vivo
pharmacological MMP inhibition on protein expression, physiological response, synaptic
structural integrity and cognitive behavior during maladaptive synaptogenesis induced
by (TBI+BEC). The general hypotheses for both sets of experiments are:

Hypothesis 1: Hippocampal MT5-MMP, ADAM-10 and N-cadherin protein and
mRNA expression will be altered in UEC and TBI+BEC models during each phase
of reactive synaptogenesis (2, 7, and 15d postinjury). The comparison of spatial
and temporal expression profiles for MT5-MMP, ADAM-10 and N-cadherin will
reveal differences between models of adaptive (UEC) and maladaptive (TBI+BEC)
plasticity, identifying aberrant changes linked to the extent of recovery achieved.

To test Hypothesis 1, the spatial and temporal profile of hippocampal protein and mRNA
expression was characterized using Western blot analysis, immunohistochemistry and
qRT-PCR over select postinjury time intervals (2, 7, and 15d for protein; 7d for mRNA).

Hypothesis 2: MMP inhibition during periods of enhanced MT5-MMP/ADAM-10
expression will alter N-cadherin protein levels, as well as improve both synaptic
efficacy and structure during synapse stabilization when examined 15d post-
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TBI+BEC. These effects on synaptic plasticity will be reflected in progressive
abrogation of injury-induced cognitive deficits when tested at 12-15d postinjury.

To test Hypothesis 2, TBI+BEC cases were treated with either MMP inhibitor GM6001
or vehicle at 6-7d postinjury. The GM6001 treated and vehicle groups were then
sacrificed during the period of synapse stabilization at 15d after injury. Hippocampal
protein expression was determined using Western blot analysis, while synaptic function
was analyzed by in vitro electrophysiological measures, and synaptic cytoarchitecture
determined using electron microscopic techniques. A separate group of TBI+BEC
animals was subdivided for either the same GM6001 or vehicle treatment and tested for
cognitive performance in the Morris Water Maze at 12-15d postinjury.
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Chapter 2

Classification of MT5-MMP, ADAM-10 and N-cadherin during Adaptive and Maladaptive
Injury-Induced Synaptogenesis
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ABSTRACT
Traumatic brain injury (TBI) leads to long-term impairments, often resulting from
excessive neuroexcitation and axonal insult within vulnerable brain regions (Okonkwo
and Povlishock, 2003; Povlishock and Katz, 2005). Axon damage produces
deafferentation and triggers an injury-induced synaptogenic response, involving matrix
metalloproteinase (MMP) interaction with paired substrates within the deafferented
region. Two such MMPs are Membrane-Type 5 Matrix Metalloproteinase (MT5-MMP)
and A Disintegrin and Metalloproteinase-10 (ADAM010), which are highly expressed in
the brain and may influence injury-induced synaptogenesis via cleavage of a shared
substrate, neuronal cadherin (N-cadherin) (Reiss et al., 2005; Monea et al., 2006). The
present study examined the spatial and temporal profiles of hippocampal protein and
mRNA for MT5-MMP, ADAM-10 and N-cadherin. Models of adaptive (unilateral
entorhinal cortex lesion; UEC) and maladaptive (combined central fluid percussion with
bilateral entorhinal cortex lesion; TBI+BEC) plasticity were contrasted in order to identify
differences in the expression of these matrix proteins during reactive synaptogenesis.
Rats were subjected to UEC or TBI+BEC and hippocampal protein extracts prepared at
2, 7, and 15d postinjury. Western blot results showed significant elevation of MT5-MMP
and ADAM-10 expression at 2 and 7d in both models, however, model differences were
observed at 15d. Each enzyme was decreased at 15d after UEC, but only MT5-MMP
showed reduction following TBI+BEC, while ADAM-10 exhibited a persistently elevated
expression . Adaptive UEC recovery reduced N-cadherin at 2d, which returned to
control levels at 7d, and increased expression at 15d. Maladaptive plasticity induced by
TBI+BEC also caused a significant decrease N-cadherin at 2 and 7d, but failed to show
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the increase at 15d as was seen with UEC. Preliminary qRT-PCR experiments
sampling 7d deafferented molecular layer revealed increases in UEC transcript for MT5MMP and ADAM-10 consistent with the observed protein change, while in TBI+BEC
only ADAM-10 transcript was altered, with an elevation matching 7d protein rise. Ncadherin mRNA showed an increase at 7d after UEC, prior to 15d protein increase. By
contrast, N-cadherin transcript was not altered at 7d after TBI+BEC, supporting absence
of any rise in N-cadherin protein. These inter model differences support distinct roles
for each molecule in generating the maladaptive plasticity observed post-TBI+BEC. In
parallel immunohistochemical experiments, MT5-MMP, ADAM-10 and N-cadherin
showed strong signal within reactive astrocytes of the deafferented dentate molecular
layer, suggesting either a glial synthetic or phagocytotic role for processing matrix
proteins during recovery. Collectively, these results reveal spatio-temporal differences
in MT5-MMP, ADAM-10 and N-cadherin expression when adaptive and maladaptive
synaptic plasticity are compared, identifying specific molecules and times which might
be targeted for improvement of synaptic recovery following TBI.

INTRODUCTION
Traumatic brain injury (TBI) is a widespread, commonly under-diagnosed
neuropathology that affects roughly 1.7 million people each year in the United States
alone (Faul et al., 2010). Following TBI, many patients experience long-term physical,
cognitive, and/or psychosocial impairments, which arise as a result the primary
traumatic insult, as well as the subsequent cascade of secondary neuropathological
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events (Povlishock and Katz, 2005; Langlois et al., 2006). These secondary events
often result in diffuse axonal damage, neuronal death, and deafferentation within the
damaged brain region (Povlishock and Christman, 1995; Hayes et al., 1992; Okonkwo
and Povlishock, 2003). In an attempt to repair the damaged tissue and regain function,
the brain exhibits properties of synaptic plasticity, where surrounding non-injured
neurons sprout to create new synaptic connections. However, the success of functional
recovery is based on a variety of factors, including the complexity and severity of the
injury.
Experimental models of TBI have been designed to mimic the neuropathology
and downstream reactive synaptogenesis observed following injury in humans.
Following experimental TBI successful synaptic reorganization is evident, and postinjury
events can be divided into three specific phases: degradation of injured axons (1-5 days
post-lesion); regeneration of new synapses (6-15 days post-lesion); synaptic maturation
(15-30+ days post-lesion) (Steward and Vinsant, 1983). Of these models, the unilateral
entorhinal cortex lesion (UEC) is well-established as a model of adaptive injury-induced
synaptogenesis within the hippocampus (Steward et al., 1988). The UEC eliminates 8090% of the afferent fibers that synapse in the outer molecular layer (OML) of the rat
dentate gyrus. It is an appropriate model for studying adaptive injury-induced
synaptogenesis, because it results in predictable remodeling of the deafferented zone
and recovery. However, plasticity and functional recovery in the human TBI patient is
less organized and predictable, and therefore the use of more complex and clinically
relevant models is warranted. In an attempt to reproduce the complex neuropathology
and persistent cognitive deficits similar to those seen in human TBI, our lab developed a
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rodent injury model that combines central fluid percussion with bilateral entorhinal
cortex lesions (TBI+BEC). This model results in diffuse neuroexcitatory injury with
bilateral focal hippocampal deafferentation, leading to maladaptive synaptic plasticity
and persistent structural, functional and behavioral deficits (Phillips et al., 1994; Phillips
and Reeves, 2001). By contrasting models of adaptive and maladaptive plasticity (UEC
vs. TBI+BEC), we can determine the expression profile of different proteins over time
postinjury, focusing on candidates which may be responsible for the failure of
successful synaptogenesis and functional recovery seen in the TBI+BEC model.
Of the many proteins that change following injury, matrix metalloproteinases
(MMPs) are among those upregulated in several models of central and peripheral
nervous system injury (Truettner et al., 2005; Rosenberg et al., 2007; Falo et al., 2006;
Komori et al., 2004; Yong et al., 2001). MMPs constitute a large family of zinc and
calcium-dependent enzymes responsible for cleavage of a variety of extracellular matrix
(ECM) substrates in response to different neuropathologies, including TBI (SekineAizawa et al., 2001; Sounni and Noel, 2005; Cunningham et al., 2005; Yong et al.,
2001). During the early postinjury stages, MMPs play important roles in ECM
degradation which can foster synaptic reorganization. However, persistent MMP
expression and activity has the potential to produce excessive ECM/substrate
breakdown and poor synaptic functional recovery following TBI (Suehiro et al., 2004;
Rosenberg et al., 1996a, 1996b, 1998, 2001; Kim et al., 2005; Shigemori et al., 2006).
To better understand the role of MMPs in synaptic plasticity, we have characterized
different MMP/substrate pairs in the adaptive UEC and maladaptive TBI+BEC models.
We found that MMP expression after UEC was temporally correlated with different
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phases of adaptive synaptogenesis. However, selective secreted MMPs were
persistently upregulated during post-TBI+BEC synaptogenesis, and failed to show
consistency with expression patterns characteristic to adaptive plasticity (Falo et al.,
2006; Kim et al. 2005). These findings reveal the importance of MMPs in the process of
reactive plasticity, and suggest that manipulation of their expression may improve
functional recovery following injury.
While our lab and others have historically investigated the post-TBI role of
secreted MMPs, the role of membrane-bound MMPs had not been studied in TBI
synaptic plasticity models. In contrast to their secreted counterparts, membrane-bound
MMPs are specifically positioned adjacent to their substrates, which may permit lytic
activity at neuronal membrane sites targeted for synaptic function. In this novel study,
we characterized the hippocampal protein profiles of two membrane-bound MMPs,
Membrane-type 5 matrix metalloproteinase (MT5-MMP) and A disintegrin and
metalloproteinase-10 (ADAM-10), along with their mutual substrate neural cadherin (Ncadherin) during the period of reactive synaptogenesis induced by UEC and TBI+BEC.
MT5-MMP and ADAM-10 are localized in and around hippocampal synapses and have
been shown to cleave N-cadherin. N-cadherin functions at synapses via homologous
N-terminus interaction with adjacent cadherins to guide developing synapses and
stabilize and strengthen mature connections (Jaworski, 2000; Marcinkiewicz and
Seidah, 2000; Takeichi and Abe, 2005; Monea et al., 2006; Reiss et al., 2005). Ncadherin also forms intracellular complexes with catenin molecules, which are ultimately
anchored to cytoskeletal structural elements to further ensure synaptic structural
integrity (Takeichi and Abe, 2005). Therefore proteolytic extracellular cleavage of N84

cadherin by MT5-MMP and/or ADAM-10 activity may potentially modify synaptic
structure and function during injury-induced synaptogenesis.
In the present study, we investigated the spatio-temporal protein profiles of MT5MMP, ADAM-10 and N-cadherin within the deafferented hippocampus at 2, 7, and 15d
postinjury. This time course encompasses the three phases of injury-induced
synaptogenesis previously described. We hypothesized that the protein profiles of all
three molecules would be significantly altered after TBI, and that these profiles would
show differences between adaptive and maladaptive recovery, particularly during the 715d period of synapse generation and stabilization. Parallel changes in mRNA
production for each molecule were also posited. Finally, we also hypothesized that
hippocampal MT5-MMP and ADAM-10 protein distribution would be altered during
synaptogenesis, showing an elevation within the deafferented outer molecular layer.
This elevation was posited to include increases within reactive astrocytes, positioned in
close proximity to synaptic N-cadherin (Fig. 2.1).
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Figure 2.1 Proposed Synaptic and Peri-Synaptic Protein Localization. Schematic
representation of ADAM-10 (red) localization in post-synaptic density and surrounding
glial processes; MT5-MMP (blue) in surrounding glial processes; and N-cadherin
(yellow) spanning the synaptic cleft and localized in both pre- and post-synaptic
elements. Proximity of MMPs to N-cadherin favors molecular interaction/processing
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METHODS
Experimental Animals
Adult male Sprague-Dawley rats (300-400g) were used in this study. Two rats
were housed per cage, with food and water ad libitum, and subjected to a 12 hr darklight cycle at 22°C. All protocols for injury and use of animals were approved by the
Institutional Animal Care and Use Committee of Virginia Commonwealth University. At
2, 7 and/or 15d postinjury time intervals, four randomly divided animal groups were
used for biochemical assessment: (1) Unilateral Entorhinal Cortex (UEC, total n=41), (2)
Combined Injury (TBI+BEC, total n=58), (3) Sham-injured (total n=53). For all
biochemical analysis, the contralateral hippocampus served as a paired-control for the
UEC, while sham-injured animals served as controls for the TBI+BEC animals.
Unilateral Entorhinal Cortex Lesion
The entorhinal cortex lesion (UEC) protocol was a modification of the method of
Loesche and Steward (1977). A group of rats were anesthetized with isoflurane (4% in
carrier gas of 70% N2O and 30% O2) delivered via nose cone and placed in a
stereotaxic frame for surgical preparation. During all surgeries, animal body
temperature was maintained at 37°C via thermostatic heating pad (Harvard Apparatus,
Holliston, MA). Additionally, animal heart rate (beats per minute, bpm), arterial oxygen
saturation (%), breath rate (breath per minute, brpm), pulse distention (µm), and breath
distention (µm) were monitored via pulse oximeter during all surgical preparation
(MouseOx; Starr Life Sciences, Oakmont, PA). Briefly, an approximately 3 mm x 5mm
portion of the skull was removed on the right side to expose the dura mater superior to
the entorhinal cortex. Electrolytic lesions were made by passing a 1.5 mA current (40
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second duration) via 0.2 mm Teflon-insulated wire electrode, positioned 10° to the
perpendicular plane, at eight separate stereotaxic sites: 1.5 mm anterior to the
transverse sinus, and 3, 4, and 5 mm lateral to midline, 2 , 4 and 6mm ventral to the
brain surface for the first two lateral measurements (3 and 4mm) and only 2 and 4mm
ventral to the brain surface for the last lateral measurement (5mm) (see Appendix A, Fig
A-1). After lesioning, the electrode was removed, the scalp was sutured over the
surgical site, and Bacitracin was applied. Rats were closely monitored for recovery from
anesthesia and lesion and then returned to their home cages.
Surgical Preparation for Central Fluid Percussion TBI
Animals were anesthetized (as above) and placed in a stereotaxic frame for
surgical preparation 24hrs prior to injury. Body temperature and physiological
measurements were monitored throughout surgical preparation (as above). As
previously described (Phillips et al., 1994), rats received a 4.8 mm midline craniectomy
midway between bregma and lambda, exposing but not breaching the underlying dura
(see Appendix A, Fig A-2). Two steel screws were implanted 1 mm caudal to the
coronal suture on the left and 1mm rostral to lambdoidal suture on the right. A modified
Leur-Loc hub (2.6 mm inside diameter) was implanted in the craniectomy site and fixed
with cyanoacrylate adhesive. Dental acrylic was added around the hub and screws to
secure the complex. The scalp was sutured closed to cover hub and Bacitracin was
applied to the wound. Rats were monitored for recovery and returned to their home
cages.
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Central Fluid Percussion TBI
Moderate central fluid percussion injury (2.0+0.1 atm) was performed as
described by Dixon et al. (1987). The fluid percussion injury device is made up of a
Plexiglas cylinder (60cm long, 4.5 cm diameter) filled with double distilled water. One
end of the cylinder has a rubber-covered Plexiglas piston mounted on O-rings, and the
opposite end is closed by a metal extra-cranial pressure transducer (Entram Devices,
Inc., model EPN-0300-100A). The end of the metal transducer (5mm tube, 2.6 mm
inside diameter) has a male Leur-loc fitting that connects to the exposed female Leurloc hub implanted in the rat skull. A metal pendulum is dropped from a determined
height that coincides with injury severity, and strikes the rubber-covered piston, forcing
a small injection of 2x distilled water into the closed cranial cavity, briefly displacing
brain tissue (see Appendix A, Fig A-2). Injury level is recorded by the extra-cranial
transducer, and visualized and reported (atmospheres, atm) on an oscilloscope
(Tektronix 5111: Beaverton, OR). Twenty-four hours after surgical preparation, rats
were re-anesthetized, connected to the fluid percussion device through the exposed
hub, and subjected to injury. Animals were monitored for recovery from anesthesia and
injury by observation and timing of multiple reflexes (paw, tail, corneal, righting, pinna),
and then returned to their home cages.
Combined Central Fluid Percussion +Bilateral Entorhinal Lesion
Animals that received the combined injury were surgically prepared for fluid
percussion injury, and twenty-four hours later received moderate (2.0+0.1 atm) central
fluid percussion injury. These animals recovered for another twenty-four hour time
period, and were then re-anesthetized and subjected to bilateral entorhinal cortex
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lesions (Phillips et al., 1994). Bilateral lesions were performed as described above in
UEC protocol (see Appendix A, Fig A-2). After lesioning, electrodes were removed, the
scalp sutured, and Bacitracin was applied. Animals were transferred to a recovery cage
and monitored for at least 1 hr to ensure adequate recovery, and were then returned to
their home cages.
Western Blotting
At 2, 7, and 15d following UEC or TBI+BEC a subset of animals (UEC n=24;
TBI+BEC n=39; Sham-injured n=35) were selected for hippocampal protein analysis.
Rats were anesthetized (4% isoflurane in carrier gas of 70% N2O and 30% O2) and
sacrificed by decapitation. Whole hippocampi were removed, homogenized in ice-cold
TPER (Pierce), and centrifuged (8,000xg) for 5 min at 4°C. Supernants were removed
and assayed for protein concentration (Shimadzu UV-160, Shimadzu Scientific,
Columbia, MD; FLUOstar Optima, BMG Labtechnologies, Inc., Durham, NC). For blot
preparation, a 1:5 dilution (5 μg sample:20 μg H2O) of each sample was mixed with XT
Sample Buffer/Reducing Agent (Bio-Rad Laboratories, Hercules, CA) and heated at
95°C. Proteins were resolved on a 4-12% Bio-Tris gel (Bio-Rad) and transferred to
PVDF membranes. Post-blotted gels were stained and analyzed for even protein load
and transfer. Membranes were washed in dH2O twice and TBS once for 5 min each,
and then blocked in 5% milk TBS-Tween (TBS-T) for 1 hour. Membranes were then
probed with primary antibody (MT5-MMP rabbit polyclonal n-terminus: 1:1,000, Abcam,
Cambridge, MA; N-Cadherin mouse monoclonal c-terminus: 1:1,000, BD Transductions
Laboratories, San Jose, CA; ADAM-10 rabbit polyclonal c-terminus: 1:1,000, Sigma, St.
Louis, MO) in 5% Milk TBS-T. After overnight incubation at 4°C, blots were washed six
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times with Milk TBS-T for 5 min each, incubated in secondary antibody (IgG goat antimouse: 1:20,000, Rockland, Gilbertsville, PA; IgG bovine anti-rabbit: 1:20,000, Santa
Cruz, Santa Cruz, CA; ) for 1 hour, and washed six times with TBS-T for 5 min each.
Antibody binding was visualized with enhanced chemiluminescence substrate,
SuperSignal (Thermo Scientific, Rockford, IL). Positive blot bands were imaged on the
Syngene G: BOX and densitometry was performed by GeneTools (Syngene, Frederick,
MD). β-actin (mouse monoclonal: 1:3,000, Sigma, St. Louis, MO) was used as a load
control for TBI+BEC Western blot experiments (see Appendix B, Fig B-8), while postblot staining was used to assess loading consistency for UEC Western blot
experiments.
Immunohistochemistry
At 2, 7 and 15d following UEC or TBI+BEC a subset of animals (UEC, n=7;
TBI+BEC, n=13; Sham-injured, n=13) were selected for qualitative analysis. Rats were
anesthetized with a lethal dose of sodium pentobarbital (90 mg/kg, i.p.) and perfused
first with 0.9% NaCl followed by aldehyde fixative (4% paraformaldehyde in 0.1M
NaHPO4 Buffer or PBS, pH=7.4). Brains were removed and stored in buffer overnight
at 4°C. Coronal vibratome sections (30-40 μm) of the hippocampus and dentate gyrus
were prepared for immunofluroescent visualization. Briefly, vibratome sections were
pre-incubated in 0.5% peroxidase for 30 min, and washed three times with PBS for 10
min each. PBS was removed, sections were placed in blocking buffer (fish gelatin in
PBS + 0.05 % Triton X-100) for 30 min and then incubated overnight at 4° C in primary
antibody (MT5-MMP rabbit polyclonal n-terminus: 1:250, Abcam, Cambridge, MA; NCadherin goat polyclonal n-terminus: 1:100, Santa Cruz, Santa Cruz, CA; ADAM-10
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goat polyclonal c-terminus: 1:500, Santa Cruz, Santa Cruz, CA; GFAP mouse
monoclonal: 1:20,000, Millipore, Billerica, MA; CD-11 mouse monoclonal: 1:500, BD
Biosciences, San Jose, CA; Iba-1 rabbit polyclonal: 1:250, Wako, Osaka, Japan).
Antibody signal was optimized in preliminary experiments, and selected sections were
incubated overnight in primary antibody in each experiment. After overnight incubation,
sections were washed three times in PBS for 10 min each, and then blocked for 30
minutes in buffer. In a dark room, the secondary fluorescent antibody (Alexa 488
donkey anti-goat or donkey anti-rabbit: 1:1,000; Alexa 594 donkey anti-mouse: 1:1,000,
Invitrogen, Carlsbad, CA) was applied for 1-2 hours, followed by three PBS washes for
10 min each. Sections were then float-mounted in PB onto Probe On Plus glass slides
(Fisher Scientific, Pittsburgh, PA) and cover-slipped (1.5 um thickness) using
Vectashield (Vector Laboratories, Burlingame, CA). Tissue was qualitatively analyzed
for MT5-MMP, N-cadherin, and ADAM-10 co-localization with GFAP and CD-11 using
the Leica TCS-SP2 AOBS confocal laser scanning microscope.
Microarray Analysis
At 7 d following UEC or TBI+BEC, subsets of animals (UEC n=5; TBI+BEC n=3;
Sham n=3) were anesthetized (4% isoflurane in carrier gas of 70% N20 and 30% O2)
and sacrificed via decapitation. Both whole hippocampal (UEC n=1; TBI+BEC/Sham
n=1) and dendrite-rich dentate molecular layer (ML) (UEC n=4 pooled; TBI+BEC/Sham
n=2 pooled for each group) samples were prepared. Following decapitation,
hippocampi and dissections of enriched dentate molecular layers were quickly frozen in
liquid nitrogen. At the time of analysis, RNA extracts were prepared from frozen
samples placed directly in Trizol reagent (InvitrogenTM, Life Technologies, Carlsbad,
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CA). A subsequent cleanup process with RNAeasy (QIAGEN, Valencia, CA) was
performed according to the manufacturer‟s protocol. RNA purity was judged by
spectrophotometry (260, 270, 280 nm). RNA integrity, as well as that of cDNA and
cRNA synthesis products, was assessed by running 1µl of each sample in RNA 6000
Nano LabChips® on a 2100 Bioanalyzer (Aligent Technologies, Foster City, CA).
Affymetrix GeneChip Rat Genome 230 2.0 Arrays (Santa Clara, CA) were then used to
screen for genomic transcript changes, including MT5-MMP, ADAM-10, and N-cadherin
mRNA expression (see Dumur et al., 2009 for detailed methods description). Once
data was collected, background correction, normalization, and estimation of probe set
expression summaries were performed using the log-scale Robust Multi-array Analysis
(RMA) method. Identification of altered gene expression for injured compared to control
samples was assessed by applying the Significance score (S-score) method. The Sscore method uses an error-based model to determine the variances for probe pair
signals and follows a normal standard distribution. The procedure produces scores
centered at “0” (no change) with a standard deviation of 1. Benjamin-Hochberg
correction method was then used to correct for multiple testing and to obtain adjusted
alpha-levels for each probe set (MT5-MMP, ADAM-10, and N-cadherin).
qRT-PCR
The 7d UEC and TBI+BEC samples used for microarray analysis were also
analyzed using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
methods to assess gene expression levels for MT5-MMP, ADAM-10 and N-cadherin
using TaqMan® chemistry. Probes and primer sets for detection of MT5-MMP
(Rn00582114 m1), ADAM-10 (Rn01530753 m1), and N-cadherin (Rn00580099 m1)
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were obtained from Inventoried Assays (Applied Biosystems, Foster City, CA). These
gene specific probes were labeled in the 5‟ end with FAM (6-carboxyfluorescein) and
the 3‟ end with a dark quencher. Cyclophilin A from the Pre-developed TaqMan® Assay
Reagents (Applied Biosystems) was used as an endogenous control for all samples.
Experiments were performed in the ABI Prism 7500 Sequence Detection System
(Applied Biosystems) using the TaqMan® One-Step PCR Master Mix Reagents Kit. All
samples were tested in triplicate under cycling conditions of 48°C for 30 minutes, 95°C
for 10 minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute. To calculate
fold changes in expression levels for each gene, the 2-ΔΔCt method was used. To
calculate the efficiency of amplification for MT5-MMP, ADAM-10, and N-cadherin, 10fold serial dilutions of template samples were run (Dumur et al., 2009)
In situ Hybridization
At 7d following UEC or TBI+BEC, a subset of animals (UEC, n=5; TBI+BEC, n=3;
Sham-injured, n=2) were selected for in situ hybridization (ISH) analysis. Rats were
anesthetized with a lethal dose of sodium pentobarbital (90 mg/kg, i.p.) and perfused
first with 0.9% NaCl followed by aldehyde fixative (4% paraformaldehyde in 0.1M
NaHPO4 Buffer or PBS, pH=7.4). Brains were removed and stored in buffer overnight
at 4°C. Coronal vibratome sections (20-30 μm) of the hippocampus and dentate gyrus
were prepared for ISH. Sections were mounted on slides and stored at -20°C until
riboprobe preparation was complete. A rat MT5-MMP cDNA was generated by PCR
cloning from nucleotides 408-931 of mouse MT5-MMP and using the following primers:
F: 5‟-ATGTGGCGTCCCTGAT-3‟, R: 5‟-TGAAGTTGTGTGTCTCC-3‟ (Jaworski, 2000).
Sense and antisense riboprobes were generated against a 500bp fragment of MT5-
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MMP using digoxigenin (DIG) labeled dNTPs (Roche, Mannheim, Germany) and the
MAXI-Script In Vitro Transcription Kit (Ambion, Austin, TX). Probes were hydrolyzed to
~250 nt. Mounted vibratome sections were prepared and hybridized at 65°C as
previously described (Yamagata et al., 2002). Briefly sections were fixed with PFA,
incubated in Proteinase K, acetylated, permeabilized in 1% Triton-X and hybridized.
Bound riboprobes were detected by horseradish peroxidase (POD)-conjugated anti-DIG
antibodies and fluorescent staining with Tyramide Signal Amplification (TSA) systems
(PerkinElmer, Shelton, CT). For immunofluroescent labeling, sections were blocked
and primary antibody applied overnight at 4° C (GFAP rabbit anti-cow polyclonal
antibody, DAKO; 1:1000). Secondary antibody was applied to sections, which were
coverslipped and sealed. Images were obtained on a Leica TCS-SP2 AOBS confocal
laser scanning microscope.
Statistical Analysis
Results were expressed as percent change from paired control samples. The
significance of differences in densitometric measures of Western blot immunobinding
was analyzed using the Student‟s t-test. Computer-based SPSS software was used for
all analyses. A probability of less than 0.05 was considered statistically significant for all
experiments.

RESULTS
Physiological Measurements
During surgical preparation and lesioning, all animals were monitored for heart rate (350
+ 20bpm), arterial oxygen saturation (> 93%), breath rate (45 + 5bpm), pulse distention
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(15 + 5µm), and breath distention (12 + 5µm) with pulse oximeter (MouseOx; Starr Life
Sciences, Oakmont, PA). Surgical procedures on all experimental animals produced no
significant change in these physiological measures.

Western Blot Analysis
MT5-MMP, ADAM-10, and N-cadherin Protein Forms in Hippocampus
Western blot (WB) results revealed predominant and additional lesser forms of
MT5-MMP, ADAM-10 and N-cadherin following UEC and TBI+BEC (Fig. 2.2). A
predominant band was present for MT5-MMP at 80 kDa. The active form of MT5-MMP
is ~58 kDa, however this band was not detected in our MT5-MMP protein analysis.
When the MT5-MMP membrane was re-probed, the 80 kDa band was found to comigrate with TIMP-2 (~24 kDa), the endogenous inhibitor of MT5-MMP (see Appendix B
Fig.B-1). Additionally, a less prominent and unbound TIMP-2 band was observed at 24
kDa. This result suggests that active MT5-MMP was bound to TIMP-2, and like other
MT-MMPs, may participate in the downstream activation of other MMPs (e.g.- proMMP2). An additional 85 kDa MT5-MMP form was present, which has yet to be
characterized in the literature, but may represent a glycosylated form. Immunopositive
bands for ADAM-10 were observed at 100 kDa, 80 kDa, and 70 kDa. These ADAM-10
bands most likely represent an alternative TIMP-1 bound form (100 kDa), a “pro” or
latent form (80 kDa), and a predominant active form (70 kDa), as described in the
ADAM-10 literature. Finally, bands for N-cadherin were visualized at 130 kDa and ~40
kDa. These N-cadherin bands represent a predominant full-length form (130 kDa) and
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its intracellular fragment that includes the transmembrane domain (~40 kDa), which is
produced following ectodomain cleavage.
MT5-MMP, ADAM-10 and N-cadherin Protein Expression Post-UEC
Western blot analysis of whole ipsilateral hippocampal extracts revealed significant
injury-induced changes in MT5-MMP, ADAM-10 and N-cadherin protein between 2 and
15d post-lesion, when compared to contralateral uninjured controls (Fig. 2.3). The
TIMP-2 associated 80 kDa form of MT5-MMP was significantly elevated at 2 and 7d
postinjury (177.23 ±20.77, p<0.01; 202.06 ± 21.90, p<0.01). The active 70 kDa form of
ADAM-10 also showed significant elevation over control at 2 and 7d postinjury (213.15
± 8.26, p<0.01; 200.89 ± 34.62, p<0.05). Full length N-cadherin expression was
significantly decreased at 2d (68.39 ±6.94, p<0.01), and increased at 15d (128.27 ±
9.00, p<0.05). At 7d, there was a trend towards a significant decrease in N-cadherin
expression (74.23 ± 11.77, p=0.079). At all three postinjury intervals, an inverse
relationship was noted between both enzymes and N-cadherin, suggesting possible
enzyme/substrate interaction during injury-induced synaptogenesis. These results
showed an up-regulation of two key MMPs during the degenerative (2d) and early
regenerative (7d) phases of synaptogenesis, followed by a return to baseline during the
stabilization phase (15d). These changes in MT5-MMP and ADAM-10 protein
expression may correlate with changes in enzymatic activity, which could influence the
early phases of injury-induced plasticity through interaction with N-cadherin following
UEC.

98

Figure 2.2 Potential Hippocampal Molecular Forms of MT5-MMP, ADAM-10 and Ncadherin Observed in Protein Analysis. Schematic membrane-bound, structural
depiction of active (58kDa) and TIMP-2 bound (80kDa) forms of MT5-MMP; TIMP-1
bound (100kDa), pro- (80kDa) and active- (70kDa) forms of ADAM-10; Full-length form
(130kDa) and cleaved intramembrane-cytoplasmic fragment (40kDa) of N-cadherin.
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Figure 2.3 Hippocampal MT5-MMP, ADAM-10 and N-cadherin Protein Expression
following UEC. Values expressed as percent of contralateral hippocampus over 2, 7,
and 15d postinjury time intervals. Following UEC insult, significant increases in MT5MMP (MT5) and ADAM-10 protein expression were observed at 2 and 7d with
normalization of both MMPs at 15d. By contrast, N-cadherin showed significant
reduction at 2 and 7d and elevation at 15d. Note inverse relationship between enzymes
and substrate over postinjury time course. Representative blots shown below.
I=ipsilateral hippocampus (injured); C=contralateral hippocampus (control); 2d: n=4-7;
7d: n=4-7; 15d n=4-6. *p<0.05, **p<0.01.
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In addition to the predominant protein forms of MT5-MMP, ADAM-10, and Ncadherin, other alternative/minor bands were also visualized following UEC (see
Appendix B, Fig B-2 through B-6). Analysis of MT5-MMP showed that an 85 kDa
species was significantly decreased over all time points (2d: 19.34 ± 3.15, p<0.02; 7d:
22.84 ± 1.92, p=0.001; 15d: 60.25 ± 5.79, p<0.05) following injury. This 85 kDa form
has not been previously reported for MT5-MMP, and may represent an uncharacterized
bound form or a post-translationally modified form that migrates differently in the gel
system. ADAM-10 protein analysis revealed two additional bands, 100 kDa and 80
kDa. The 100 kDa band, an apparent TIMP-1 bound form, was significantly decreased
at all time points (2d: 80.84 ± 1.69, p<0.01; 7d: 77.73 ± 5.18, p=0.05; 15d: 76.15 ± 6.19,
p<0.05), as was the latent 80 kDa pro-form (2d: 32.03 ± 3.64, p<0.01; 7d: 45.85 ± 10.4,
p<0.01; 15d: 67.11 ± 6.95, p<0.05). These results showed that two regulated forms of
ADAM-10, a TIMP-1 bound and latent form, were reduced with deafferentation
remaining below control levels through all phases of reactive synaptogenesis. With Ncadherin, we also observed a ~40 kDa fragment at 2 and 15d, which was significantly
decreased at 2d (65.27 ± 6.40, p<0.001). These results show the presence of a
cleaved form of N-cadherin, which may represent a product of acute postinjury ADAM10 and/or MT5-MMP proteolysis.
MT5-MMP, ADAM-10 and N-cadherin Protein Expression Post-TBI+BEC
Whole hippocampal extracts were also examined to determine changes in MT5MMP, ADAM-10 and N-cadherin protein expression, when compared to sham control
(Fig. 2.4). Western blot analysis revealed significant differences across all groups over
the examined time intervals. The 80 kDa form of MT5-MMP was significantly elevated
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above sham at 2 and 7d postinjury (126.73 ± 9.85, p=0.05; 195.72 ± 11.01, p<0.001).
The 70 kDa active-form of ADAM-10 showed significant elevation over control at all
three intervals (2d: 156.34 ±18.18, p<0.01; 7d: 267.17 ±23.54, p<0.001; 15d: 230.78 ±
30.41, p<0.001). Full- length N-cadherin expression was significantly decreased at 2
and 7d (75.11 ± 6.91, p<0.05; 81.03 ±4.80, p<0.05). These results were similar to those
found following UEC, including the inverse relationship between enzymes and substrate
and similar MT5-MMP protein profiles. Nevertheless, two important differences were
observed when comparing adaptive to maladaptive expressional changes. Notably, the
significant up-regulation of ADAM-10 across all time intervals and the failure of Ncadherin to significantly increase above control levels at 15d.

These results suggest

that, of the two metalloproteinases, ADAM-10 and its proteolytic interaction with Ncadherin may preferentially contribute to the maladaptive synaptic plasticity observed 715d following TBI+BEC insult.
Consistent with the UEC results, additional WB bands for all three proteins were
also visualized after TBI+BEC. For MT5-MMP, an 85 kDa species was found to
significantly decrease over all time points (2d: 40.98 ± 6.84, p<0.001; 7d: 46.55 ± 6.46,
p<0. 001; 15d: 59.23 ± 5.81, p<0.001) following injury. ADAM-10 protein analysis
revealed that a 100 kDa ADAM-10 form was significantly decreased at 2d (82.43 ± 3.36,
p<0.001), and returned to sham levels at 7 and 15d. An 80 kDa latent form of ADAM-10
was also significantly reduced, but only at 2 and 15d (52.76 ±7.45, p<0.001; 79.66
±4.98, p=0.05). These additional forms of both MT5-MMP and ADAM-10 showed
similar profiles to those in the UEC study, suggesting that they may be regulated and/or
function similarly in both injury models. Although a 40 kDa form of N-cadherin was
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Figure 2.4 Hippocampal MT5-MMP, ADAM-10 and N-cadherin Protein Expression
following TBI+BEC. Values expressed as percent of sham controls over 2, 7, and 15d
postinjury time intervals. Following TBI+BEC, a significant increase in MT5-MMP (MT5)
protein expression was observed at 2 and 7d, while ADAM-10 was significantly
increased at all time-points. By contrast, N-cadherin showed significant reduction at 2
and 7d, and failed to elevate above control levels at 15d. Note inverse relationship
between enzymes and substrate over post-injury time-course. Representative blots
shown below. I=Injured; S=Sham (control); 2d: I=6-10, S=8; 7d: I=7-16, S=9-10; 15d
I=7-8, S=8; *p<0.05, **p<0.01.
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present over all post-TBI+BEC time intervals, there was no significant change from
sham, whereas this form was significantly decreased at 2d after UEC. Because this 40
kDa form may be further cleaved into fragments that influence intracellular signaling
pathways, such intermodel differences suggest that N-cadherin regulated cell signaling
may contribute to the aberrant plasticity observed after the combined insult.
Immunohistochemistry
Immunofluorescent labeling was used to characterize cellular ADAM-10, MT5MMP and N-cadherin localization, as well as overall protein distribution within the
dentate gyrus following UEC and TBI+BEC. Tissue was double stained with MT5MMP/ADAM-10/N-cadherin and markers for astrocytes (GFAP) and microglia (CD11/Iba-1). MT5-MMP, ADAM-10 and N-cadherin co-localized with the astrocytic marker
in each injury model at 2, 7 and 15d postinjury (Fig. 2.5 and 2.6), but failed to show colocalization with either microglial marker (see Appendix C, Fig. C-8). Images double
stained with GFAP and MT5-MMP/ADAM-10/N-cadherin from the 7d postinjury time
interval are presented here to show protein localization and distribution. Additional
images for the 2 and 15d time intervals are shown in Appendix C (Fig. C-2 through C-6).
ADAM-10 Immunohistochemistry following UEC and TBI+BEC
Confocal imaging of hippocampus showed increased ADAM-10 signal throughout
the deafferented molecular layer (ML) of both 7d UEC and TBI+BEC cases when
compared with paired controls (Fig. 2.5 and 2.6). The antibody signal was present as
diffuse punctate sites within the neuropil, but the primary staining was localized within
reactive astrocytes, co-labeled with GFAP. The overall intensity of ADAM-10 was
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greater in the combined insult cases. In both models, ADAM-10 uniformly filled the cell
bodies and processes of reactive astrocytes. Diffuse staining was also present in glial
processes surrounding granule cell (GC) somata. When 2, 7, and 15d cases were
compared, the greatest signal and cellular labeling was observed at 2 and 7d postinjury
in both models, consistent with WB results showing greatest expression of ADAM-10 at
those times. While these experiments cannot confirm whether ADAM-10 is produced by
astrocytes or simply being degraded within them, it is clear that astrocytes play a role in
the processing of ADAM-10 following during both adaptive and maladaptive
synaptogenesis.
MT5-MMP Immunohistochemistry following UEC and TBI+BEC
In contrast to ADAM-10, hippocampal confocal imaging showed a different
pattern for MT5-MMP ML distribution in 7d UEC and TBI+BEC animals relative to paired
controls (Fig. 2.5 and 2.6). Overall intensity of signal was lower in the UEC than for
TBI+BEC, where, in the latter, MT5-MMP showed a strong diffuse staining throughout
the ML. Like ADAM-10, the overall intensity of MT5-MMP was also greater in the
combined insult cases. In both models the primary signal was again localized within
GFAP positive astrocytes. Following UEC, the MT5-MMP signal filled the somata and
processes of these reactive astrocytes. By contrast, MT5-MMP labeling in the
combined model formed a cluster-like staining pattern within astrocytic cell bodies and
their primary processes. A dense punctuate MT5-MMP labeling was seen surrounding
granule cells.

Comparison of all three postinjury time intervals showed the greatest

labeling at 2 and 7d in both models. WB results did show greatest increase in MT5MMP at 7d, approximately equivalent for each injury. Interestingly, our
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Figure 2.5 Molecular Layer Localization of ADAM-10, MT5-MMP and N-cadherin
with GFAP at 7d following UEC. Confocal imaging revealed co-localization of ADAM10, MT5-MMP and N-cadherin with astrocytic marker GFAP in molecular layers. Singlechannel confocal images showed pronounced signal within the deafferented OML, with
a cell-filling pattern for ADAM-10 and N-cadherin. MT5-MMP displayed a punctate
staining throughout the neuropil and clustered signal within reactive astrocytes.
Contralateral (control) overlays display a dampened injury response, but similar
expression pattern for each protein. ADAM-10, MT5-MMP and N-cadherin (green);
GFAP (red). 40x magnification. OML = outer molecular layer; IML= inner molecular
layer; GC= granule cell layer. Arrowheads indicate examples of co-localization for each
protein.
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Figure 2.6 Molecular Layer Localization of ADAM-10, MT5-MMP and N-cadherin
with GFAP at 7d following TBI+BEC. Confocal imaging revealed co-localization of
ADAM-10, MT5-MMP and N-cadherin with astrocytic marker GFAP in combined injured
animals. Overlays of injured animals showed pronounced astrocytic response and
signal within the deafferented outer molecular layer. ADAM-10 exhibited a cell-filling
pattern, while MT5-MMP revealed punctate neuropil staining and somatic clustered
intracellular signal reaching into proximal processes. N-cadherin had similar punctate
neuropil pattern, and primarily astrocytic somatic clustering. Sham-injured (control)
overlays display a dampened injury response, but similar spatial expression pattern.
ADAM-10, MT5-MMP and N-cadherin (green); GFAP (red). 40x magnification. OML =
outer molecular layer; IML= inner molecular layer; GC= granule cell layer. Arrowheads
indicate examples of co-localization.
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immunohistochemistry supported the higher ML MT5-MMP signal for combined cases.
As for ADAM-10, strong glial labeling suggests a possible role of the reactive astrocyte
in either MT5-MMP synthesis or phagocytotic processing.
N-cadherin Immunohistochemistry following UEC and TBI+BEC
Confocal imaging of hippocampal N-cadherin revealed more subtle model
differences at 7d postinjury (Fig 2.5 and 2.6). Following UEC, N-cadherin and GFAP
were co-localized within the ML, with increased signal throughout the deafferented
neuropil relative to paired controls. Fine, punctate label was seen around GC somata.
The overall pattern of N-cadherin staining was similar for the 7d post-TBI+BEC cases,
however, signal was more punctuate and concentrated within the astrocyte cell bodies
with minimal process labeling. These subtle model differences may indicate variations
in astrocytic processing of N-cadherin during adaptive and maladaptive synaptogenesis.
The results of these experiments show an increase in ML expression of N-cadherin at
7d postinjury. This is in contrast to the reduced expression assessed by WB
measurements. It is important to note that due to technical limitations, antibody
recognizing an N-terminal sequence of N-cadherin was used for immunohistochemical
experiments, while a C-terminal recognizing antibody was employed for WB analysis.
Application of the different antibodies most likely accounts for differences in N-cadherin
expression detected by the two methods. We interpret our WB results as illustrating a
decrease in overall C-terminal signal due to MT5-MMP or ADAM-10 cleavage of intact
N-cadherin. By contrast, the confocal experiments appear to show cleaved and shed Nterminal fragments of N-cadherin, which are potentially internalized for processing within
reactive astrocytes of the ML.
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DNA Microarray analysis
At 7d post-UEC and TBI+BEC, RNA extracts of whole hippocampus (UEC n=1;
TBI+BEC/Sham n=1) and enriched molecular layer (ML) (UEC n=4 pooled;
TBI+BEC/Sham n=2 pooled) were used to generate cDNAs for microarray gene
expression screening. The 7d postinjury time interval was selected because it was the
period exhibiting greatest WB MT5-MMP and ADAM-10 hippocampal protein expression
and we wanted to determine if this protein peak was matched by an elevation in mRNA
synthesis. A rise in mRNA expression at 7d would also help us interpret changes in
protein expression occurring during the subsequent synaptic stabilization phase of
recovery at 15d. For this study, changes in gene expression of ±50% or more from
control were considered significant. Results did reveal potential injury effects in some
cases, although overall changes in MT5-MMP, ADAM-10, and N-cadherin transcripts at
7d postinjury were not significant using our ±50% cutoff (Table 1). Among the three
genes, the most pronounced UEC transcript shift occurred with ADAM-10, where we
found a 45% and 47% increase relative to control in ML and hippocampus, respectively.
MT5-MMP and N-cadherin transcripts at 7d after UEC revealed no significant change
(0-5%). For post-TBI+BEC gene expression, the greatest shifts were seen in ML
samples, where ADAM-10 and N-cadherin transcripts increased 20% and MT5-MMP
decreased 20% in expression. In the whole hippocampus, ADAM-10 mRNA was 15%
higher than control, while MT5-MMP and N-cadherin transcripts were not altered.
Microarray results revealed potential transcript changes in both hippocampus and ML
for each model. These indications of possible mRNA shifts after injury were
subsequently probed and verified in the ML samples using qRT-PCR methods.
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Table 1. Microarray Analysis of MT5-MMP, ADAM-10 and N-cadherin Transcripts
at 7d post-UEC and TBI+BEC. Transcript values reported as a relative change from
control (UEC: contralateral molecular layer or whole hippocampus; TBI+BEC: sham).
Post-UEC values show greatest change in ADAM-10 for molecular (+45%) and whole
hippocampal (+47%) sample(s), while N-cadherin and MT5-MMP show no change (NC).
Post-TBI+BEC values show small shifts in transcript for MT5-MMP (-20%) molecular
layer, ADAM-10 molecular layer (+20%) and whole hippocampal (+15%), and Ncadherin molecular layer (+20%) samples. UEC molecular layer n=4 rats, ipsilateral
sides pooled and contralateral sides pooled; whole hippocampus n=1 rat ,ipsilateral
and contralateral side separately analyzed; TBI+BEC molecular layer n=2 rats, all
pooled from both animals; Sham molecular layer n=1rat, two sides pooled; n=2 rats;
TBI+BEC whole hippocampus n=1rat , injured hippocampi pooled; Sham hippocampi
n=1 rat, two sides pooled.
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Table 1. Microarray Analysis in Adaptive & Maladaptive TBI models

UEC
Molecular layer
(n=4, pooled)

Whole Hippocampus
(n=1) .

MT5-MMP

NC

NC

ADAM-10

1.45+

1.47+

N-cadherin

NC

NC

TBI+BEC
Molecular layer

Whole Hippocampus

(n=2, pooled)

(n=1 injured, 1 sham)

MT5-MMP

1.20-

NC

ADAM-10

1.20+

1.15+

N-cadherin

1.20+

NC
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Quantitative RT-PCR
Aliquots from the same 7d UEC and TBI+BEC ML RNA extracts used for
microarray analysis were subjected to qRT-PCR with specific primers to MT5-MMP,
ADAM-10, and N-cadherin mRNA (Fig. 2.7).
MT5-MMP, ADAM-10 and N-cadherin mRNA Expression after UEC
Quantitative RT-PCR analysis of ipsilateral ML samples at 7d post-UEC revealed
higher mRNA expression for MT5-MMP, ADAM-10 and N-cadherin when compared to
contralateral control. While experimental design prevented statistical analysis in this
situation, MT5-MMP transcript did show a modest 31% increase, while ADAM-10 mRNA
was elevated 112% over control. These results are temporally consistent with our WB
results which showed significant elevation in both MT5-MMP and ADAM-10 protein at
7d postinjury. N-cadherin mRNA had the most pronounced change, a 117% elevation
over control, indicating active transcription during a period of reduced N-cadherin
protein expression, and just prior to the 15d increase in N-cadherin during UEC synapse
stabilization.
MT5-MMP, ADAM-10 and N-cadherin mRNA Expression after TBI+BEC
In 7d TBI+BEC ML samples subjected to qRT-PCR we observed an apparent
elevation of ADAM-10 mRNA expression compared to sham-injured control. Transcript
was increased by 83% during the period of sprouting and synaptogenesis, consistent
with post-TBI+BEC WB protein expression. These results suggest that matched
changes in ADAM-10 transcript contribute to the large 7d rise in protein seen after
combined insult, and may also support the persistent elevation of ADAM-10 protein at
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Figure 2.7 Quantitative RT-PCR Molecular Layer mRNA Expression of MT5-MMP,
ADAM-10 and N-cadherin post-UEC and TBI+BEC. Values expressed as a percent
of control (UEC: contralateral ML; TBI+BEC: Sham) at 7d following injury. ML samples
showed elevated MT5-MMP, ADAM-10, and N-cadherin transcript post-UEC, and only
elevated ADAM-10 transcript post-TBI+BEC. Shifts in initial ADAM-10 microarray data
(see Table 1) consistent with ADAM-10 ML transcript expression in both models. ML
=Molecular Layer. UEC ML n=4 rats, ipsilateral sides pooled and contralateral sides
pooled; TBI+BEC ML n=2 rats, all pooled from both animals; Sham molecular layer
n=1rat, two sides pooled.
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15d with maladaptive plasticity. MT5-MMP and N-cadherin mRNA expression in the ML
were not different from control at 7d. These results suggest that if transcript elevation
was responsible for the 7d WB rise in MT5-MMP protein, it likely occurred prior to the
time of tissue sampling. Absence of change in N-cadherin transcript at 7d after
TBI+BEC would be consistent with the observation that the protein was not elevated
over controls at either 7 or 15d after injury.
In situ hybridization
MT5-MMP RNA localization at 7d following UEC and TBI+BEC
Preliminary in situ hybridization experiments were conducted to determine the
cellular site of MT5-MMP synthesis within the hippocampus. The MT5-MMP probe
used in this experiment was a gift generously provided by Dr. Diane Jaworski. This
probe was designed for the characterization of MT5-MMP expression within the
developing brain (Jaworski, 2000). Based on results from immunohistochemical
experiments, we predicted that MT5-MMP synthesis occurs within hippocampal glial
cells, specifically reactive astrocytes. Preliminary trials using 20-30 μm thick coronal
brain sections revealed MT5-MMP anti-sense signal within reactive astrocytes in the
deafferented dentate ML at 7d after UEC and TBI+BEC, as indicated by MT5-MMP
probe co-localization with astrocytic marker GFAP (see Appendix D Fig. D-1). Antisense signal was found predominantly within astrocytic processes and around the cell
body perimeter, closely matching the distribution of the protein in our
immunohistochemical study. While MT5-MMP signal was present in both injured and
control slices, increased labeling and astrocytic response was also observed in both
UEC and TBI+BEC animals.
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Unfortunately, we also observed non-specific fluorescent signal with the sense
control sequence in some of our experiments. This signal was found within the same
reactive astrocytes targeted by the antisense label. In troubleshooting this result, we
identified several possible sources of the aberrant control signal: 1) the use of different
restriction enzymes for cDNA cuts than those of the original published technique,
potentially causing non-specific binding of the extended vector DNA sequences, 2) the
use of 20-30 µm thick vibratome tissue slices as opposed to thinner 8-10 µm frozen
sections, and 3) insufficient permeability of probe into the tissue, generating surface
adhesion artifact. We plan to conduct additional experiments to address these possible
complications, and will generate clean sense controls before proceeding with further in
situ hybridization analysis of MT5-MMP, ADAM-10 and N-cadherin mRNA in our injury
models.
DISCUSSION
The current study examined the spatial and temporal profile of MT5-MMP,
ADAM-10 and N-cadherin protein expression during reactive synaptogenesis (2-15d
postinjury) within the dennervated hippocampus. Expression of the membrane type
MMPs and their common ECM substrate were compared in two different TBI models,
directly contrasting adaptive (UEC) versus maladaptive (TBI+BEC) synaptic plasticity.
These protein data were complemented by assessment of mRNA expression for each
molecule at 7d postinjury, the period of active sprouting and synapse formation. In our
Western blot analyses, we found that MT5-MMP and ADAM-10 protein was elevated at
the 2 and 7d postinjury intervals for both models, times marking acute degenerative
change and early synaptic growth. The greatest increase in MMP expression was seen
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with ADAM-10 at 7d. This data was supported by large 7d elevations in ADAM-10
versus MT5-MMP transcript in both models. We also observed a consistent decrease in
N-cadherin expression at 2 and 7d after injury in each model. Notably, the main
differences between adaptive and maladaptive plasticity were seen at 15d, when
synapse stabilization is underway. Here, adaptive UEC plasticity showed reduced MMP
protein and an increase in N-cadherin expression over that of controls. By contrast, the
maladaptive plasticity of TBI+BEC was marked by a persistently elevated ADAM-10
protein level and the absence of any rise in N-cadherin expression. Interestingly,
immunohistochemistry for each MMP and N-cadherin showed primary localization in
reactive astrocytes of the deafferented molecular layer and the intensity of this
localization was increased following injury. These results show that membrane-bound
MMPs are involved in the both adaptive and maladaptive synaptic plasticity and, given
the distinct recovery-dependent differences in MT5-MMP, ADAM-10, and N-cadherin
expression, likely participate through interaction with N-cadherin to affect synapse
stabilization. Elevated ADAM-10 and reduced N-cadherin expression was most
correlated with the maladaptive response. Such enzyme/substrate interactions could
critically influence cell-cell and ECM-cell interaction and the organization of intact
synapse structure. Overall, these results confirm that membrane-bound MMP response
is influenced by the type and complexity of neuropathology induced by TBI.
Postinjury Time Course of Membrane-bound MMPS and N-cadherin Expression
Our Western blot analysis of hippocampal MT5-MMP, ADAM-10 and N-cadherin
protein expression during reactive synaptogenesis revealed the following: 1) both
membrane-bound MMPs were increased early postinjury (by 2d) and peaked in
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expression at the 7d sprouting period, suggesting a prominent role in the earlier phases
of recovery, 2) both membrane-bound MMPs were matched by a reduction in their
target substrate N-cadherin, observed for adaptive and maladaptive conditions alike,
and 3) the principal forms of these proteins indicate different roles for each enzyme,
MT5-MMP expressed in a TIMP bound, non active form and ADAM-10 changes
primarily linked to the 70 kDa active enzyme. Overall, the profiles of MT5-MMP and
ADAM-10 expression in the adaptive UEC model are consistent with our previous
analyses of secreted MMPs, where both transcription and translation of MMPs 2, 3 and
9 are rapidly elevated at the onset of synaptogenesis (Kim et al., 2005, Falo et al.,
2006). In contrast to those studies, where released MMPs were reduced at later stages
of synaptic recovery, our current results suggest that persistent expression of active
membrane bound ADAM-10 can aberrantly influence the long-term stabilization of new
synapses generated after TBI. A prominent role for ADAM-10 during TBI-induced
synaptic plasticity would be expected from the literature, where it has been shown to
influence axonal guidance, cortical synapse development and synaptic modulation
through interaction with molecules like ephrin, APP, and N-cadherin (Hattori et al., 2000;
Bell et al., 2006; Reiss et al., 2005). The active form of this enzyme appears to target
the synaptic adhesion protein N-cadherin during the early, more plastic phases of
synapse regeneration, but this enzyme/substrate interaction is attenuated during
synapse maturation and stabilization. Such interaction would be predicted since
reduced adhesion would be required for the morphing of synaptic structure in the acute
postinjury period, and elevated N-cadherin needed for transmembrane anchoring of the
synaptic junction complex and binding of synaptic proteins to the pre- or postsynaptic
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cytoskeleton. The presence of high levels of ADAM-10 would foster the cleavage of Ncadherin at its extracellular/membrane interface, resulting in shedding of the N-terminal
sequence into the matrix space. Other studies have also demonstrated that synaptic
stabilization and functional efficacy are mediated through N-cadherin extracellular
binding, transmembrane placement, and intracellular association with catenin molecules
(Gottardi and Gumbiner, 2004). In addition, the intracellular N-cadherin fragmentation
can signal the transcription of genes involved in cell survival, migration and synapse
adhesion/stabilization (McCusker and Alfandari, 2009). Thus, N-cadherin is involved in
synaptogenesis, through direct physical binding and indirect effects on downstream
transcription. Our results provide further evidence that these membrane-bound MMPs
and N-cadherin are an important enzyme/substrate pairing for successful synaptic
reorganization following TBI.
From the literature, MT5-MMP can be linked with neuroplasticity, where
reorganization of Aβ fibers after sciatic nerve injury, synaptic modulation through Ncadherin cleavage, and neurite outgrowth with proteoglycan cleavage are all promoted
by its activation (Komori et al., 2004; Monea et al., 2006; Hayashita-Kinoh et al., 2001).
By contrast, we did not find MT5-MMP in its active form, rather expressed at a higher 80
kDa band, a size predicted for enzyme bound to endogenous inhibitor. Blot re-probing
experiments suggest that this high kDa band represents active MT5-MMP bound to its
endogenous inhibitor TIMP-2. Such a result opens the possibility that the enzyme may
play a very different role from the predicted N-cadherin modulation during reactive
synaptogenesis. Rather, TIMP-2 bound MT5-MMP may be part of a ternary complex
that activates pro-MMP-2, and leads to downstream gelatinase activity. Activated MMP124

2 would then be available to interact with ECM molecules present in the damaged
neuropil to influence early phases of reactive synaptogenesis. We know that shifts from
pro- to active MMP forms occur following CNS injury (Ashi et al., 2000; Noble et al.,
2002; Li et al., 2009) and that focal activation of these enzymes can occur in a complex
formed by TIMP/MT-MMP/pro-MMP binding at the cell membrane (Strongin et. al, 1995;
Sternlicht and Werb, 2001; Maskos and Bode, 2003; Nagase et al., 2006). Such focal
MMP activation could be particularly important when new synaptic sites are being
organized along reforming dendrites within the deafferented molecular layer.
In addition to the significant changes found in predominant forms of MT5-MMP,
ADAM-10 and N-cadherin, secondary signals for each protein were also observed
following injury. These additional forms showed temporal shifts consistent with the
expression of the principal kDa forms. For example, ADAM-10 probed blots contained
both 100 kDa TIMP-1 bound and 80 kDa pro-enzyme forms which were significantly
reduced in tandem with the elevation of active ADAM-10 enzyme. Further, we also
observed a 2d increase in a 40 kDa N-cadherin form, consistent with the intracellular Cterminal fragment produced by ADAM-10 cleavage. Generation of a 35 kDa N-cadherin
C-terminal fragment has been associated with intracellular signaling pathways which
facilitate gene transcription (Marambaud et al., 2003; Reiss et al., 2005; McCusker and
Alfandari, 2009; Jang et al., 2009). While our peptide did not migrate exactly at 35 kDa,
it remains possible that injury has generated the same intracellular fragment, although
not fully processed for its role in downstream cell signaling. Given the known roles for
MMP and N-cadherin interaction, these findings are not surprising, however, they are

125

novel in the context of reactive synaptogenesis, providing further insight into the time
and recovery-dependent roles of these two membrane-bound MMPs.
Model Differences in Membrane-bound MMP and N-cadherin Expression
Direct comparison between adaptive and maladaptive models of reactive
synaptogenesis revealed three major differences in MT5-MMP, ADAM-10 and Ncadherin expression. Compared to adaptive synaptic recovery, the maladaptive
condition showed: 1) attenuated MT5-MMP and ADAM-10 expression at 2d after injury,
2) a higher level of ADAM-10 protein at 7d, which remained significantly elevated at 15d
postinjury and 3) a failure to generate elevated full-length N-cadherin at 15d during
synapse stabilization.
Following UEC lesion, TIMP-bound MT5-MMP and active ADAM-10 protein
levels were significantly elevated during the acute degenerative (2d) and early
regenerative (7d) phases of recovery. With TBI+BEC, a similar 2d rise over control
occurred, but was reduced in extent by approximately 28%. Lower enzyme expression
at 2d may limit the amount of MMP/substrate interaction required to promote the
necessary degeneration and clearance of damaged axon terminals following combined
injury. This result is similar to that seen for secreted MMP-3 at 2d, where the TBI+BEC
insult generated a lower level of enzyme than the UEC (Phillips et al., unpublished
observations). By contrast, at the 7d interval, where axonal sprouting and synapse
formation is most rapid, ADAM-10 expression was 25% higher than seen in adaptive
recovery, and remained elevated up to 47% over UEC levels at 15d postinjury. Again,
this result is in agreement with a persistent elevation of MMP-3 protein at 7d in the
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maladaptive TBI+BEC model (Phillips et al., unpublished observations). Together they
support a differential response for MT5-MMP and ADAM-10 between the two models.
Combined injury pathology had a lesser effect on MT5-MMP, which was most
associated with the early periods of debris removal and organization for axonal
sprouting. By contrast, maladaptive plasticity was clearly linked to higher ADAM-10
response and a persistent elevation of the enzyme past the time period when it is
attenuated in the adaptive UEC model. Such persistent MMP elevation under
conditions of failed recovery is in agreement with long-term increase in transcript levels
for secreted MMPs 2, 3 and 9 previously reported for the TBI+BEC model (Phillips and
Reeves, 2001; Kim et al., 2005; Falo et al., 2006).
Another important model difference was observed regarding the expression of
full-length N-cadherin, which showed a significant 15d elevation over control levels
during adaptive UEC recovery. This would be predicted for the phase of
synaptogenesis when nascent synapses are selectively pruned and junction complexes
stabilized by N-cadherin adhesion. A similar elevation of the synaptic protein agrin was
described 7d following UEC, which paralleled the reduction of MMP-3 (Falo et al., 2006;
Falo et al., 2008). With TBI+BEC maladaptive plasticity, full length N-cadherin was
attenuated by 30% at 15d relative to the UEC model, a result predicted from the
observation that active ADAM-10 was elevated at the same time point. A persistent
ADAM-10 proteolysis of N-cadherin at newly developing synapses would limit synaptic
stabilization and possibly alter downstream signals regulating gene transcription critical
to recovery. Notably, this same pattern of persistently elevated enzyme and
significantly reduced substrate was seen with MMP-3 and its synaptic target agrin
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following TBI+BEC (Falo et al., 2006; Falo et al., 2008). Moreover, reduced N-cadherin
and agrin protein expression in the maladaptive model is consistent with the poor
synaptic reorganization seen in earlier ultrastructural studies (Phillips et al., 1994; Falo
et al., 2006).
Model differences were also found with some of the additional forms identified for
each protein. The 100kDa TIMP-1 bound and 80kDa pro-enzyme forms of ADAM-10
were significantly reduced at all three postinjury intervals after UEC, however, they each
returned to control levels at 7d post-TBI+BEC. While the reason for a normalization of
these ADAM forms during the phase of sprouting and synapse formation is not clear, it
may represent a compensatory shift towards latent enzyme expression as a control for
the extent of ADAM-10 activity generated in the maladaptive model. The one case
where a model difference was not observed was the 85kDa form of MT5-MMP which
was significantly reduced at all time intervals for UEC and TBI+BEC, suggesting that
this MT5-MMP form may play a similar role in the adaptive and maladaptive recovery
processes.
Tissue Distribution of Membrane-bound MMPs and N-cadherin after Injury
Tissue localization provides important correlative data for the accurate
interpretation of quantitative changes in MMPs and their target substrates during
reactive synaptogenesis. Based on current literature, MT5-MMP, ADAM-10 and Ncadherin clearly display spatial expression patterns that would favor interaction at the
synaptic interface and support active roles in synaptic reorganization (Jaworski, 2000;
Sekine-Aizawa et al., 2001;, Hayashita-Kinoh et al, 2001; Benson and Tanaka, 1998;
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Monea et al., 2006; Marcinkiewicz and Seidah, 2000; Marcello et al., 2007). Our
immunohistochemical analysis of MT5-MMP, ADAM-10 and N-cadherin support such a
relationship in several ways: 1) the deafferented molecular layer in UEC and TBI+BEC
cases shows elevation of each enzyme and N-cadherin relative to paired controls, 2)
the 7d increase in MMP protein is more profound for the combined insult cases,
correlating with the quantitative blot results, and 3) astrocytes are the primary sites of
tissue localization for all three proteins, with subtle differences in neuronal distribution
noted between MT5-MMP and ADAM-10.
Adaptive and maladaptive synaptogenesis showed several similarities in enzyme
and N-cadherin protein distribution. In each TBI model, dentate MT5-MMP, ADAM-10
and N-cadherin were elevated relative to uninjured controls. Proteins showed principal
localization within reactive astrocytes in the deafferented molecular layer during all
phases of reactive synaptogenesis. This pattern is entirely consistent with our earlier
studies with MMPs 2, 3 and 9, where endogenous glia appear to be the primary site for
production or processing of these enzymes (Phillips and Reeves, 2001; Kim et al.,
2005; Falo et al., 2006). Moreover, secreted MMPs are consistently reported to be
localized within the glia affected by a variety of CNS traumas (Rosenberg, 1995).
Diffuse neuropil localization is also consistent with the proposed high concentration of
these three molecules at synaptic sites either around granule cell (GC) bodies or along
their dendrites. A notable difference in membrane-bound MMP distribution between
models was the stronger intensity of this latter pattern in the combined cases. This was
particularly true for MT5-MMP, which might be explained by it potential role in activation
of MMP-2 within the ML extracellular space. More profound damage in the TBI+BEC
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model would require greater matrix fluidity to facilitate debris removal. Localization of
N-cadherin within reactive astrocytes and throughout the ML supports glial uptake and
processing of its cleaved extracellular domain during a time of increased active ADAM10 expression. Again, the combined maladaptive model showed subtle differences,
with slightly more signal in a diffuse pattern relative to cellular localization than the UEC.
The TBI+BEC model exhibits slow debris clearance (Phillips et al., 1994), suggesting
that perhaps this shift in N-cadherin distribution represents a lesser degree of glial
response to phagocytose the cleaved adhesion protein. Over the 2-15d time course,
we found a similar pattern of MT5-MMP, ADAM-10 and N-cadherin distribution in the
dentate, with the principal difference being relative intensity of signal. This pattern was
consistent with model and temporal differences seen in our WB results. N-cadherin was
the only exception, where, as described above, we can attribute the higher tissue signal
versus lower blot signal to differences in antibody recognition used for the two
experiments. As with our other histological time course studies, the more acute
increases are followed by long-term decreases as synaptogenesis proceeds. Taken
together, these results support local interaction between membrane-bound
MMPs/substrates during synaptic remodeling, a site where glial processes intimately
interface with pre- and post-synaptic membranes (Benson et al., 2000).
Our immunohistochemical results not only illustrate the spatial profile of these
matrix proteins, but also point to a major astrocytic role in their regulation during
reactive synaptogenesis. The data suggests that this role may be different as a function
of membrane-bound MMPs. A primary clue here was the distinct structural appearance
of antibody signal for MT5-MMP and ADAM-10. We found similar punctate somatic and
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process labeling in reactive astrocytes for both MT5-MMP and N-cadherin, supporting a
common link to phagocytosis and internalization after injury. By contrast, ADAM-10
uniformly filled the astrocyte cell bodies and did not directly match with the N-cadherin
pattern. Although most published studies show ADAM-10 localized within neurons,
there is also evidence that ADAM-10 may have an astrocytic origin (Kieseier et al.,
2003; Bandyopadhyay et al., 2006). While this difference is an interesting observation,
our data cannot fully discriminate between the possibilities. It should be noted that our
WB data does show major changes in active enzyme, supporting lytic astrocytic activity
for ADAM-10 as well.
The magnitude and direction of astrocytic response may be dependent on the
severity and complexity of TBI, and therefore influence the level of recovery. Reactive
astrocytes can exhibit detrimental, as well as stimulatory effects on injury-induced
plasticity. Traditionally, reactive astrocytes are proposed to contribute to the formation
of inhibitory glial scars adjacent to damaged tissue, therefore preventing or limiting
recovery postinjury (Liuzzi and Lasek, 1987; Rudge and Silver, 1990). Conversely,
some studies argue that astrocytic scars play a protective role, restricting additional
tissue damage following injury, as well as synthesizing and releasing local
cytokines/growth factors (White and Jakeman, 2008; Su et al., 2009). Reactive
astrocytes also produce and release MMPs to aid in the removal of damaged
tissue/cells from the injured region, a necessary step prior to the regenerative phase of
synaptogenesis. We know that MMP-3 expression during post-UEC synaptogenesis
contributes to adaptive recovery. However, overproduction and release of MMPs could
lead to upregulated activity and additional tissue damage. For example, lytic activity of
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both MMP-3 (Kim et al., 2005) and the gelatinases MMPs 2, and 9 (Phillips,
unpublished results) is persistently elevated during maladaptive synaptic plasticity,
negatively affecting recovery in the TBI+BEC model. In these cases, MMPs are
predominantly located within CNS glia and are likely released to influence
synaptogenesis. Thus, a tight spatial and temporal regulation of MMP expression
appears necessary for adaptive plasticity to occur. Despite their dual role, targeted
manipulation of reactive astrocytes during maladaptive plasticity has potential to
improve recovery by limiting the overexpression and release of MMPs postinjury.
RNA Expression of Membrane-bound MMPs and N-cadherin During Sprouting and
Synaptogenesis
To better understand the profile of postinjury MT5-MMP, ADAM-10, and Ncadherin protein expression, we used microarray and qRT-PCR methods to screen for
transcript changes at 7d after UEC and TBI+BEC. Microarray results from whole
hippocampus and enriched ML samples revealed the greatest change to be in ADAM10 transcript, which occurred following adaptive UEC. In contrast, slightly more modest
shifts were seen after TBI+BEC. Increased ADAM-10 transcript did not appear to differ
between ML and hippocampal samples, further supporting its prominent role in reactive
synaptogenesis. These findings are paralleled by increases in hippocampal ADAM-10
protein expression values at 7d for both models and the persistent rise in the enzyme
at15d following TBI+BEC. Microarray screening of MT5-MMP and N-cadherin failed to
show post-UEC changes in gene expression and only a modest rise in N-cadherin ML
transcript with TBI+BEC. While these results do not specifically match our hippocampal
WB profile, they do provide details regarding the synchrony of transcription and
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translation in these models. No change in ML UEC MT5-MMP and N-cadherin
transcript at 7d suggests that these genes are regulated at either earlier or later time
intervals to produce the protein changes we have observed. In the maladaptive model,
ML gene expression patterns were attenuated, consistent with the slower start for
membrane-bound MMP response and slower lysis of synaptic proteins like N-cadherin.
The strongest cross-model synchrony of transcript and protein change was seen for
ADAM-10, which might be predicted since the 7d time point showed the most increase
in protein expression.
Quantitative RT-PCR analysis of the same 7d ML samples, revealed greater
changes in MT5-MMP, ADAM-10 and N-cadherin mRNA expression, as is commonly
the case when samples are shifted from array to PCR analysis. Elevated ADAM-10
mRNA in both models remains consistent with our hippocampal WB results. Again, this
tight synchrony of protein and mRNA expression for ADAM-10 shows that its up
regulation is important during dentate synaptic reorganization. The principal asynchrony
between message and protein was seen with the combined model MT5-MMP and Ncadherin. As indicated above, we interpret this pattern to mean that our 7d sampling
missed an earlier peak in MT5-MMP transcript. Alternatively, the use of ML for the PCR
may introduce unknown differences when compared to hippocampal WB results. We
also interpret the lack of effect on 7d transcript for N-cadherin in the maladaptive model
as an expected result, since the protein does change at the later 15d time point with
TBI+BEC. It should be noted that reported protein expression was determined from
whole hippocampal samples, while the greatest changes in mRNA expression were
derived from ML samples. The fact that 7d whole hippocampal mRNA analysis showed
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minimal to no change relative to controls tends to support synthesis of these proteins by
non-neuronal cells, such as reactive astroglia concentrated in the deafferented zone, a
conclusion consistent with our immunohistochemical and preliminary in situ
hybridization findings. Taken together, the PCR analysis further supports the
involvement of membrane-bound MMPs in the acute phases of synaptic regeneration,
as well as the notable persistent expression of active ADAM-10 and reduced N-cadherin
during stabilization of nascent synapses.
Role of MT5-MMP, ADAM-10 and N-cadherin in Synaptic Recovery after TBI
The spatial and temporal patterns of MT5-MMP, ADAM-10, and N-cadherin
expression during adaptive and maladaptive recovery provide insight into potential
mechanisms underlying their role in injury-induced synaptogenesis. While membranebound MMPs like MT5-MMP and ADAM-10 may be either directly or indirectly capable
of modifying ECM-cell and cell-cell structure within the CNS, they may also act as
upstream mediators of plasticity. At this time, our view of postinjury mechanisms is
strongly based on evidence that MMP lysis of N-cadherin has downstream effects on
plasticity-related events. The present results show that elevation of active ADAM-10 is
paralleled by decreased full length N-cadherin expression postinjury. Additionally, a
persistent elevation of active ADAM-10 at 15d post-TBI+BEC is correlated with reduced
N-cadherin expression when compared to the pattern in UEC, further suggestive of a
critical ADAM-10/N-cadherin interaction during synaptogenesis. There is evidence that
ADAM-10 and MT5-MMP cleavage of N-cadherin has both extracellular and intracellular
downstream effects that can potentially influence synaptic plasticity (Uemura et al,
2006; Reiss et al., 2005; Monea et al., 2006). For example, in vitro studies show
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ectodomain shedding of N-cadherin releases an N-terminus fragment (NTF) that
promotes neurite outgrowth in cultured neurons (Paradies and Grunwald, 1993; Utton et
al., 2001). Additionally, MMP-driven ectodomain shedding of N-cadherin is required for
its further intracellular cleavage, which releases a 40kDa C-terminus fragment (CFT1),
similar to the form we observed in our WB analysis. The release of CTF1 alters the
structural integrity of the synapse by changing the intracellular binding properties of the
protein, thereby permitting structural synaptic modifications during times of heightened
plasticity (i.e., acute degenerative and regenerative phases of reactive synaptogenesis)
(Jang et al., 2009). Release of intracellular N-cadherin fragments has also been shown
to alter synaptic Ca2+ conductance and therefore affect synaptic function. This Ncadherin fragmentation is linked to changes in submembrane interaction with proteins
such as the AMPA receptor family and p120 catenin, resulting in a decreased Ca 2+
conductance (Silverman et al., 2007; Malenka and Bear, 2004; Brusés, 2006; McCusker
and Alfandari, 2009; Jang et al., 2009). CFT1 undergoes further processing into a
35kDa fragment (CTF2), which can inhibit the AKT signaling pathway, therefore
potentially leading to neuronal death in pathological states (Jang et al., 2009).
Additionally, CTF2 may affect synaptogenesis by binding CREB binding protein (CBP)
and preventing downstream transcription of CREB-dependent genes that are critical for
nervous system function and plasticity (Marambaud et al., 2003; Lonze and Ginty,
2002). Further, CTF2 also associates with the Wnt signaling molecule β-catenin, which
promotes transcription of genes that are important for cell proliferation and survival,
such as cyclin D1, c-myc, c-jun, and N-cadherin (Reiss et al., 2005). Clearly the
literature points to the signaling events produced by the proteolytic processing of N-
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cadherin as critical to the efficient reorganization of the synaptic junction. We believe
our aggregate data provide evidence that this is true, and that the success or failure of
injury-induced synaptic recovery may depend upon MMP directed generation of
substrate fragments at specific phases of synaptogenesis. Indeed, the altered ADAM-10
and N-cadherin expression we observed during the later stages of aberrant injuryinduced synaptogenesis support this conclusion.

SUMMARY
The current study examined MT5-MMP, ADAM-10 and N-cadherin protein and mRNA
expression during adaptive and maladaptive plasticity as a first step in better
understanding the role of these matrix molecules in postinjury recovery. It is clear that
the neuropathology generated by UEC and combined TBI+BEC are different, and
therefore recruit different responses from these membrane-bound MMPs to either foster
or inhibit structural and functional recovery. The results presented here raise several
questions about postinjury mechanisms that may affect MMP regulation, expression,
and, in turn, injury-induced plasticity. Our results implicate MT5-MMP and ADAM-10 as
important enzymes in the plasticity process, potentially through activation of other
proteases or interaction with N-cadherin. Although we show MT5-MMP and ADAM-10
influence on synaptic plasticity in two different TBI models, it remains unclear what
specific event(s) regulate their differential postinjury expression patterns. Future studies
are needed to determine MT5-MMP and ADAM-10 functional activity over the time
course of reactive synaptogenesis. In addition, detailed behavioral and functional
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assessments are necessary to further understand model differences and reveal
possible therapeutic targets to improve synaptic plasticity and recovery following TBI.
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Chapter 3

MMP Inhibition Improves Synaptic Efficacy and Stabilization during
Maladaptive Injury-Induced Synaptogenesis
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ABSTRACT
In our prior studies we have reported that a variety of matrix metalloproteinases
(MMPs) influence the success of reactive synaptogenesis induced by traumatic brain
injury (TBI). The first portion of this dissertation has shown that specific membranebound MMPs, MT5-MMP and ADAM-10, are spatially and temporally correlated with
adaptive synaptic plasticity, specifically the period of recovery when new synapses are
stabilized. The success of this process appears to be linked to reduced MMP levels
and elevated expression of their common substrate, N-cadherin, an adhesion molecule
critical to the organization and stabilization of the synaptic junction. Such observations
suggest that membrane bound MMPs may act in concert with N-cadherin to support
functional recovery seen with adaptive synaptic plasticity. Our earlier studies indicate
that attenuation of secreted MMP activity at 6-7d postinjury improves the structural
integrity of newly formed synapses in the TBI+BEC model of maladaptive
synaptogenesis. Here, we posit that inhibition of membrane bound MT5-MMP and
ADAM-10, targeting their elevation during onset of regenerative axonal sprouting in that
model, will enhance N-cadherin related stabilization of synaptic structure and promote
functional recovery. Adult male rats subjected to TBI+BEC (combined fluid percussion
+ entorhinal lesion insult) were treated with the broad spectrum MMP inhibitor GM6001
(10mg/kg i.p.) or vehicle at 6 and 7d postinjury, targeting both the onset of synapse
reorganization and the period of highest hippocampal MT5-MMP and ADAM-10 protein
expression. Assessment of drug effect was made at 15d postinjury, the period when
these two MMPs and their substrate N-cadherin were most prominently altered during
maladaptive plasticity. Relative to sham-injured controls, GM6001 treatment decreased
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ADAM-10 protein levels and increased in N-cadherin protein expression. Functional
effects of MMP inhibition were also evaluated at 15d postinjury, using brain slices for in
vitro electrophysiological recordings of long-term potentiation (LTP), long-term
depression (LTD), and paired pulse facilitation (PPF) in the Schaffer collateral input to
CA1. This pathway was selected based upon its widespread use as a model for
probing hippocampal synaptic efficacy, and the fact that its components remain intact
following the TBI+BEC insult. Combined injury resulted in the delayed induction of LTP,
which was partially restored with GM6001 treatment. By contrast, LTD failed to show
any drug-related change. Further, PPF trials showed no significant effects of either
injury or drug, suggesting that functional deficits associated with this hippocampal
pathway did not involve defects in pre-synaptic terminals. To assess behavioral
plasticity following MMP inhibition, a subset of injured-untreated and injured-treated
animals were tested for spatial memory performance using the Morris Water Maze. Our
results showed the profound, persistent deficits associated with the TBI+BEC model,
however, GM6001 treatment failed to alter behavioral outcome. Finally, qualitative
ultrastructural analysis of injured animals treated with GM6001 revealed dendritic
cytoarchitecture and synaptic integrity consistent with adaptive synaptic recovery,
supporting the hypothesis that GM6001 MMP inhibition also protects synaptic structure
after TBI. Collectively, these results suggest that membrane-bound MMPs and their
substrate N-cadherin interact during reactive synaptogenesis to influence synapse
stabilization, contributing to enhanced synaptic function following TBI.

140

INTRODUCTION
Two principle features of traumatic brain injury (TBI) are excessive
neuroexcitation and diffuse axonal injury, which lead to neuronal deafferentation in
vulnerable brain regions (Okonkwo and Povlishock, 2003; Povlishock and Katz, 2005).
Injury-induced deafferentation results in reactive synaptogenesis, which serves to
replace degenerated synaptic connections and restore function. This plasticity is
influenced by a number of extracellular matrix (ECM) molecules, including members of
the matrix metalloproteinase (MMP) family and their targeted substrates (Phillips and
Reeves, 2001). MMPs constitute a large family of zinc and calcium dependent
enzymes that are capable of substrate cleavage at cell surfaces, including the majority
of ECM shaping molecules (Rosenberg, 2002). Clearly, MMP proteolytic modification of
cell-ECM and cell-cell connections is critical for the formation and maintenance of
neural circuitry, as well as for synaptic replacement, reorganization, and recovery
following TBI (Sternlicht and Werb, 2001; Treuttner et al., 2005; Falo et al., 2006;
Szklarczyk et al, 2002). While MMPs promote a variety of plasticity processes including
axonal guidance and synaptogenesis during nervous system development and disease,
MMP activity is tightly regulated to avoid the negative consequences of excessive lysis
(Yong et al., 2001).
Our lab has demonstrated MMP involvement in reactive synaptogenesis
following TBI, which suggests an integral MMP role in recovery (Reeves et al., 2003;
Kim et al., 2005; Falo et al., 2006). Studies revealed aberrant MMP protein expression
and activity when the plasticity process is maladaptive. This work contrasts the
adaptive synaptic recovery induced by unilateral entorhinal cortex lesion (UEC) with a
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model which combines moderate central fluid percussion injury and bilateral entorhinal
cortex lesions (TBI+BEC), resulting in poor synaptic recovery. We posit that these
persistent recovery deficits are due, in part, to the unregulated expression and activity of
MMPs within damaged brain regions. Therefore, to improve synaptic recovery and
uncover potential treatment paradigms for human TBI, we have explored the efficacy of
pharmacological MMP inhibition postinjury in producing enhanced synaptic recovery. In
the TBI +BEC model, MMP inhibition with the hydroxyamate compound FN-439 at 6-7d
postinjury reduced spatial learning deficits and improved synaptic cytoarchitecture (Falo
et al., 2006). Interestingly, we also found that FN-439 administration 30 minutes after
UEC attenuated both structural and functional recovery at 7d postlesion (Reeves et al.,
2003). These results suggest that, while regulated MMP expression and activity is
required for successful synaptic recovery, excessive MMP response can attenuate this
recovery and result in maladaptive reorganization following brain injury.
Recently, two membrane-bound MMPs, Membrane-type 5 MMP (MT5-MMP) and
A Disintegrin and Metalloproteinase-10 (ADAM-10), have emerged as important players
in the plasticity process. MT5-MMP and ADAM-10 may influence the outcome of
reactive synaptogenesis by targeting the neuronal adhesion molecule, N-cadherin
(Monea et. al, 2006; Reiss et al., 2005). In the CNS, N-cadherin ligates pre- and postsynaptic elements extracellularly, stabilizes intracellular synaptic structure, and
influences the organization and function of mature synapses (Benson and Tanaka,
1998). MT5-MMP and ADAM-10 are localized in and around synapses, in close
proximity to N-cadherin, permitting concentrated proteolytic activity at synaptic junctions
(Jaworski, 2000; Marcinkiewicz and Seidah, 2000; Takeichi and Abe, 2005). Interaction
142

between MT5-MMP, ADAM-10 and N-cadherin has the potential to influence reactive
synaptogenesis following TBI through modification of synaptic adhesion and
stabilization.
The first study in this dissertation has shown that specific membrane-bound
MMPs, MT5-MMP and ADAM-10, are spatially and temporally correlated with adaptive
synaptic plasticity, specifically the period of recovery when new synapses are stabilized
(Warren et al., 2009). We observed an inverse relationship between levels of enzyme
and substrate in both models, as well as recovery-dependent changes in protein
expression postinjury. Relative to the adaptive UEC model, maladaptive plasticity
showed a reduced MT5-MMP response at 2d postinjury and a persistently elevated
ADAM-10 expression at 15d. Synaptic adhesion protein N-cadherin was reduced at 2
and 7d postinjury, but showed elevation above normal levels of expression at 15d with
adaptive recovery. With maladaptive synaptogenesis, N-cadherin failed to increase at
15d. We conclude that these altered patterns of 2d MT5-MMP and 15d ADAM-10/Ncadherin expression contribute to the poor synaptic recovery seen in the TBI+BEC
model. Further, we posit that the inhibition of MT5-MMP or ADAM-10 activity at 6-7d
postinjury, the interval of its maximum expression, will attenuate enzyme expression
and elevate N-cadherin at 15d after injury. Moreover, these shifts will reduce structural
and functional pathology which characterizes the maladaptive synaptic plasticity of the
TBI+BEC model.
In this present study we investigated the effect of MMP inhibition on MT5-MMP,
ADAM-10 and N-cadherin protein expression by administering the broad-spectrum
MMP inhibitor, GM6001, at 6 and 7d following TBI+BEC insult. Assessment of drug
143

effect was made at 15d postinjury, the period when these two MMPs and their substrate
were most prominently altered during maladaptive plasticity. GM6001 inhibits MMP
activity by chelating zinc at the active site of secreted and membrane-type MMPs,
including MT5-MMP and ADAM-10. Substrate binding is prevented, rendering the
MMPs inactive (Grobelny et al., 1992; Schultz et al., 1992). We chose to use GM6001
in our study based upon its ability to cross the blood brain barrier to inhibit MMPs in vivo
and published evidence for its in vitro inhibition of MT5-MMP and ADAM-10 (Gijbels et
al., 1994; Leib et al., 2000; Bendeck et al., 1996; Monea et al., 2006; Reiss et al., 2005).
We chose to administer GM6001 at 6 and 7d for several reasons: 1) to target the
period where we observed maximal postinjury MT5-MMP and ADAM-10 elevation, 2) to
manipulate MT5-MMP and ADAM-10 activity during the period of axonal sprouting and
3) to match our prior protocols which showed enhanced synaptic recovery with FN-439,
a MMP inhibitor with high selectivity for secreted MMP-3 (Falo et al, 2006). In these
studies we first assessed hippocampal MT5-MMP, ADAM-10 and N-cadherin
expression at 15d postinjury with Western blots. In a parallel set of experiments,
functional effects of MMP inhibition were evaluated with in vitro electrophysiological
recordings of long-term potentiation (LTP), long-term depression (LTD), and paired
pulse facilitation (PPF) in the Schaffer collateral input to CA1. To assess behavioral
plasticity following MMP inhibition, a subset of injured-untreated and injured-treated
animals were tested for spatial memory performance using the Morris Water Maze. At
the end of behavioral assessment, a subset of animals from each group was prepared
for ultrastructural analysis of drug effect on synaptic cytoarchitecture. Our results show
that MMP inhibition significantly affected ADAM-10 and N-cadherin protein expression,
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improved measures of synaptic efficacy, and enhanced the integrity of hippocampal
synaptic ultrastructure.

METHODS
Experimental Animals
Adult male Sprague-Dawley rats (300-400g) were used in this study. Two rats
were housed per cage, with food and water ad libitum, and subjected to a 12 hr darklight cycle at 22°C. All protocols for injury and use of animals were approved by the
Institutional Animal Care and Use Committee of Virginia Commonwealth University.
Rats were randomly divided into three groups and subjected to either: 1) TBI+BEC
injured-untreated (n=25), 2) TBI+BEC injured-GM6001 treated (n=20), 3) TBI+BEC
injured-vehicle treated (n=10), 4) sham-injury (n=25). Animals were allowed to survive
for 15d, at which time subgroups were again randomly selected for biochemical,
electrophysiological or ultrastructural assessment. In all analyses, sham-injured
animals served as paired-controls and results were expressed as percent change from
this group. A subset of injured-treated, injured-untreated and sham-injured rats
underwent behavioral testing (MWM) on days 12-15 postinjury before being sacrificed at
15d.
Surgical Preparation for Central Fluid Percussion TBI
Animals were anesthetized (isoflurane 4% in carrier gas of 70% N2O and 30% O2
delivered via nose cone) and placed in a stereotaxic frame for surgical preparation
24hrs prior to injury. Body temperature was maintained at 37°C using a thermostatic
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heating pad (Harvard Apparatus, Holliston, MA) and physiological parameters (heart
rate, arterial oxygen saturation, breath rate/distension and pulse distension) monitored
throughout surgical preparation using pulse oximetry (MouseOx; Starr Life Sciences,
Oakmont, PA). Rats received a 4.8 mm midline craniectomy midway between bregma
and lambda, exposing but not breaching the underlying dura. Two steel screws were
implanted 1 mm caudal to the coronal suture on the left and 1mm rostral to lambdoidal
suture on the right. A modified Leur-Loc hub (2.6 mm inside diameter) was implanted in
the craniectomy site and fixed with cyanoacrylate adhesive. Dental acrylic was added
around the hub and screws to secure the complex. The scalp was sutured closed to
cover hub and Bacitracin was applied to the wound. Rats were monitored for recovery
and returned to their home cages.
Central Fluid Percussion TBI
Moderate central fluid percussion injury (2.0+0.1 atm) was performed as
described by Dixon et al. (1987). The fluid percussion injury device is made up of a
Plexiglas cylinder (60cm long, 4.5 cm diameter) filled with double distilled water. One
end of the cylinder has a rubber-covered Plexiglas piston mounted on O-rings, and the
opposite end is closed by a metal extra-cranial pressure transducer (Entram Devices,
Inc., model EPN-0300-100A). The end of the metal transducer (5mm tube, 2.6 mm
inside diameter) has a male Leur-loc fitting that connects to the exposed female Leurloc hub implanted in the rat skull. A metal pendulum is dropped from a determined
height that coincides with injury severity, and strikes the rubber-covered piston, forcing
a small fluid injection into the closed cranial cavity, briefly displacing brain tissue. Injury
level is recorded by the extra-cranial transducer, and visualized and reported
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(atmospheres, atm) on an oscilloscope (Tektronix 5111: Beaverton, OR). Twenty-four
hours after surgical preparation, rats were re-anesthetized, connected to the fluid
percussion device through the exposed hub, and subjected to injury. Animals were
monitored for recovery from anesthesia and injury by observation and timing of multiple
reflexes (paw, tail, corneal, righting, pinna), and then returned to their home cages.
Combined Central Fluid Percussion +Bilateral Entorhinal Lesion (TBI+BEC)
Animals that received the combined injury were surgically prepared for fluid
percussion injury, and twenty-four hours later received moderate (2.0+0.1 atm) central
fluid percussion injury. These animals recovered for another twenty-four hour time
period, and were then re-anesthetized and subjected to bilateral entorhinal cortex
lesions (Phillips et al., 1994). Briefly, a small portion of the skull was removed on the
right and lefts sides to expose the dura mater superior to the entorhinal cortex (see
again Appendix A, Fig. A-2). Electrolytic lesions were made by passing a 1.5 mA
current (40 sec each) via 0.2 mm Teflon-insulated wire electrode, positioned 10° to the
perpendicular plane, at eight at eight separate stereotaxic sites: 1.5 mm anterior to the
transverse sinus, and 3, 4, and 5 mm lateral to midline, 2 , 4 and 6mm ventral to the
brain surface for the first two lateral measurements (3 and 4mm) and only 2 and 4mm
ventral to the brain surface for the last lateral measurement (5mm) (see again Appendix
A, Fig. A-1). After lesioning, electrodes were removed, the scalp sutured, and
Bacitracin was applied. Animals were transferred to a recovery cage and monitored for
at least 1 hr to ensure adequate recovery, and were then returned to their home cages.
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MMP Inhibitor (GM6001) Administration
Inhibition of MT5-MMP and ADAM-10 activity was achieved using a commercially
available MMP inhibitor, GM6001 (Millipore, Billerica, MA). This hydroxamate
compound chelates the active site zinc atom within a variety of MMPs, preventing
substrate binding and rendering the enzyme inactive (Grobelny et al, 1992; Schultz et.
al, 1992). Although it targets a broad-spectrum of MMPs, GM6001 has been shown to
inhibit both MT5-MMP and ADAM-10 in vitro (Monea et. al, 2006; Reiss et. al, 2005).
Animals within the TBI+BEC Injured-treated group received GM6001 (10mg/kg i.p.)
once daily, at 6 and 7d postinjury, delivered in vehicle consisting of 4%
carboxymethlycellulose (CMC sodium salt, Sigma, St. Louis, MO) suspension as
described. GM6001 dose, suspension, and delivery was based on previous in vivo
studies which showed effective inhibition of MMPs in neurotrauma models (Wang and
Tsirka, 2005; Sifringer et al., 2007). The timeframe for dosing was selected to coincide
with the period where we observed maximal postinjury MT5-MMP and ADAM-10
elevation. A separate injured-vehicle group received 4% CMC with the same dosing
paradigm to assess effects of vehicle on biochemical outcome. No significant
differences were detected between injured-untreated and injured-vehicle animals (data
not shown), therefore the two groups were combined into one for subsequent
experimental analyses.
Western Blot Analysis
At 15d following injury, a subset of rats (TBI+BEC injured-treated: n=6; TBI+BEC
injured-untreated: n=7-8; sham-injured: n= 8) were subjected to hippocampal protein
analysis. Rat were anesthetized with isoflurane (4% in carrier gas of 70% N2O and 30%
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O2) and quickly decapitated. Whole hippocampi were removed, homogenized in icecold TPER (Pierce), and centrifuged (8,000xg) for 5 min at 4°C. Supernatants were
removed and assayed for protein concentration (Shimadzu UV-160, Shimadzu
Scientific, Columbia, MD; FLUOstar Optima, BMG Labtechnologies, Inc., Durham, NC).
For blot preparation, a 1:5 dilution (5 μg sample:20 μg H2O) of each sample was mixed
with XT Sample Buffer/Reducing Agent (Bio-Rad Laboratories, Hercules, CA) and
heated at 95°C. Proteins were resolved on a 4-12% Bio-Tris gel (Bio-Rad) and
transferred to PVDF membranes. Post-blotted gels were stained and analyzed for even
protein load and transfer. Membranes were washed in dH2O twice and TBS once for 5
min each, and then blocked in 5% milk TBS-Tween (TBS-T) for 1 hour. Membranes
were then probed with primary antibody (MT5-MMP rabbit polyclonal n-terminus:
1:1,000, Abcam, Cambridge, MA; N-Cadherin mouse monoclonal c-terminus: 1:1,000,
BD Transductions Laboratories, San Jose, CA; ADAM-10 rabbit polyclonal c-terminus:
1:1,000, Sigma, St. Louis, MO) in 5% Milk TBS-T. After overnight incubation at 4°C,
blots were washed six times with Milk TBS-T for 5 min each, incubated in secondary
antibody (IgG goat anti-mouse: 1:20,000, Rockland, Gilbertsville, PA; IgG bovine antirabbit: 1:20,000, Santa Cruz, Santa Cruz, CA; ) for 1 hour, and washed six times with
TBS-T for 5 min each. Antibody binding was visualized with enhanced
chemiluminescence substrate, SuperSignal (Thermo Scientific, Rockford, IL).
Immunopositive bands were imaged on the Syngene G:BOX and densitometry was
performed using GeneTools software (Syngene, Frederick, MD). β-actin (mouse
monoclonal: 1:3,000, Sigma, St. Louis, MO) was used as a load control for Western blot
experiments (see again Appendix B, Fig B-8).
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Electrophysiological Recording
A randomly selected subset of rats from TBI+BEC injured-treated (n=9),
TBI+BEC injured-untreated (n=8), or sham-injured (n=12) groups were prepared for in
vitro electrophysiological recording. Each rat was anesthetized with 4% isoflurane for 4
min, and the brain rapidly removed. Coronal 450 μm slices were cut into artificial
cerebrospinal fluid (ACSF; 2-4 ºC) containing (in mM): NaCl 124, KCl 3, MgSO4 2, CaCl2
2, NaH2PO4 1.3, NaHCO3 26, glucose 10; pH 7.4; saturated with 95% O2/5% CO2 gas.
All slices containing the mid-dorsal hippocampus were saved, which yielded 4 to 6
slices per brain. Slices were then transferred to a holding chamber containing
oxygenated ACSF, gradually brought to 34°C, and were allowed to equilibrate under
these conditions for at least 1 h prior to recording. For electrophysiological recording, a
slice was gently transferred from the holding chamber to a submersion-type recording
chamber, and perfused with oxygenated ACSF (34°C) at a rate of 2-3 ml / min.
A bipolar stimulating electrode (teflon-insulated tungsten, with intertip distance
(0.2-0.3 mm) was lowered into the stratum radiatum of CA1 in order to stimulate the
fibers of the Schaffer collateral system. This hippocampal projection was selected for
study in lieu of the perforant path projection to the dentate gyrus, which is bilaterally
ablated in the TBI+BEC model. The Schaffer-collateral projection to CA1 also
represents a downstream component of the hippocampal trisynaptic loop and is often
used for studies of synaptic efficacy after CNS injury. A recording electrode (glass
micropipette filled with ACSF; resistance 6-8 MegOhm) was also placed in the stratum
radiatum, approximately 0.5-0.7 mm medial to the stimulating electrode, to measure the
evoked population excitatory postsynaptic potentials ("field EPSPs" or fEPSPs). The
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initial depth of electrodes was approximately 200 micron below the surface of the slice,
however, fine adjustments were made in the depths of both stimulating and recording
electrodes to achieve maximum fEPSP amplitude.
Unless otherwise noted, stimulation used for evoked potentials was constant
current stimulus-isolated square wave pulses (0.20 msec duration) delivered at one
pulse each 30 sec (0.033 Hz). All evoked field potentials were amplified (bandpass =
d.c. to 5 kHz), digitized at 20 kHz, and stored on hard disk for off-line analysis. For offline quantification of digitized waveforms, fEPSP slopes were measured as rate of
descent over a 0.5 msec interval in the initial negative-going phase of the fEPSP
(ClampFit v.8.2 software, Axon Instruments, Inc., Union City, CA).
An input-output function was generated for each slice by varying stimulus
intensity in ten equal steps from subthreshold level to the stimulus intensity which
evoked a maximum fEPSP. To assure measurement stability, all evoked potentials
were repeated 4 times, at each separate level of stimulation intensity, and statistical
analyses were performed only on the averaged signals.

Following the determination of

the input-output function, three paradigms of neural functional plasticity were
implemented: long-term potentiation (LTP), long-term depression (LTD), and pairedpulse facilitation (PPF).
Stimulus amplitude was adjusted to evoke a fEPSP response which was 50% of
maximum, based on the prior input-output analysis (see above). Using this constant
level of stimulation intensity, a 30 minute period of baseline recording was obtained by
evoking fEPSPs at a stimulus rate of 0.033 Hz. LTP was then induced by theta-burst
high frequency stimulation (HFS) consisting of a total of ten bursts of four pulses at 100
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Hz, with 200 msec separating the onset of each burst. The magnitude of LTP was then
evaluated for a period of 60 minutes, using the same stimulation parameters (0.033 Hz)
as used during the pre-HFS baseline sample. Following the 60 minute period of postHFS monitoring, LTD was induced using 15 minutes of 1 Hz stimulation. The effects of
the 1 Hz stimulation were then evaluated by acquiring responses at the low stimulation
rate (0.033 Hz) for 20 minutes.
A subset of rats (n=6) within each group were further assessed for paired-pulse
facilitation (PPF). In the PPF procedure, two identical stimulus pulses, subthreshold for
target cell discharges (i.e., not evoking population spikes) and separated by either 50,
100, or 150 msec, usually evoke non-identical responses. The second augmented
response has been interpreted as due, in large part, to residual Ca2+ loaded into presynaptic terminals during the first response, which has not been buffered or cleared
prior to the second response (Leung and Fu, 1994). Paired-pulse plasticity was
calculated at each interpulse interval (50, 100, and 150 msec) using the ratio of the
second fEPSP slope to the first (fEPSP2/fEPSP1).
Morris Water Maze Assessment
The Morris Water Maze (MWM) was used to assess spatial memory function as
previously described (Hamm et al, 2001; Phillips et al., 1997). TBI+BEC injured-treated
(n=7), TBI+BEC injured-vehicle (n=8) and sham-injured (n=5) groups were subjected to
4 trials per day for 4 days (12-15d post-injury). In each block of trials, rats were placed
in the pool, facing the wall and commenced testing once from each of the start locations
(north, south, east west ordinates). The order of start locations was randomized and
the hidden goal platform was consistently positioned 45 cm from the outside of the pool
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wall. A digital camera was mounted above to pool to record all trials. For each trial,
rats were given up to 120 sec to find the hidden platform. If the rat failed to reach the
platform after 120 sec, it was placed on the platform for 30 sec, removed from the pool,
and returned to a heated chamber between trials. All trials were separated by 4 min
intervals. A mean daily latency to find the platform (in sec) was calculated for each
animal and group mean comparisons were made as described previously (Phillips et al.,
1997).
Electron Microscopy
At the end of MWM testing (15d postinjury), a subset of rats (n=3/injured group)
were randomly selected for qualitative EM analysis. Rats were anesthetized with a
lethal dose of sodium pentobarbital (90 mg/kg, i.p.) and perfused with 0.9% NaCl
followed by mixed aldehyde fixative (4% paraformaldehyde and 0.2% glutaraldehyde) in
0.1M Phosphate Buffer (PB), pH 7.2. Brains were then removed and stored in buffer
overnight at 4°C. Coronal vibratome sections (40 μm) containing the hippocampus and
dentate gyrus were collected in 0.1M PB and prepared for EM processing as previously
described (Phillips et al., 1994). Briefly, sections were first placed in 1% osmium (in
0.1M PB, pH 7.2), processed in resin and flat-embedded on plastic slides. After curing,
hippocampi were excised and a series of semi-thin (0.5µm) and ultrathin (silver, 600Å)
sections cut on a Leica EM UC6i ultramicrotome (Leica Microsystems, Wetzlar,
Germany). The semi-thin sections were photographed as a guide for ultrastructural
sampling. Ultrathin sections were collected on membrane-coated slotted grids and
observed on a Jeol JEM-1230 electron microscope equipped with a Gatan UltraScan
4000SP CCD camera. A series of 5,000 x images were collected at regular intervals
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across the dorso-ventral extent of CA1 radiatum and the dentate molecular layer for
subsequent qualitative cytoarchitectural analysis.
Statistical Analysis
For Western blot data, results were expressed as percent of control and group
means calculated. Changes in protein expression were first evaluated for significance
by comparison of relative optical density measures within TBI+BEC injured-untreated
and injured -treated samples to that of paired sham-injured control cases. Subsequent
comparisons were also made for optical density measures between TBI+BEC injureduntreated and injured-treated cases. The effects of injury and drug treatment on protein
level were determined using the Student‟s t-test.
Electrophysiological results were evaluated with mixed-model ANOVAs, using
the MANOVA software routines in SPSS v. 11.5, with between-subjects factor of
analytic group (uninjured control, TBI+BEC (untreated), and TBI+BEC (treated)). In
LTP analyses, the repeated measures factor was time relative to application of the highfrequency stimulation (theta-burst), and in PPF analyses the repeated measures factor
was interpulse interval. Contrasts between specific groups were evaluated using simple
effects based on planned comparisons (Keppel, 1991; Levine, 1991).
For behavioral measures, group means were first analyzed using ANOVA, with
specific group differences evaluated using the Fisher Least Significant Difference test.
A probability of less than 0.05 was considered statistically significant for all experiments.
All results are reported as mean + SEM.
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RESULTS
Physiological Measurements
During surgical preparation and lesioning, all animals were monitored for heart rate (350
+ 20bpm), arterial oxygen saturation (> 93%), breath rate (45 + 5bpm), pulse distention
(15 + 5µm), and breath distention (12 + 5µm) with pulse oximeter (MouseOx; Starr Life
Sciences, Oakmont, PA). Surgical procedures on all experimental animals produced no
significant change in these physiological measures.

Western blot analysis
Effect of MMP Inhibition on MT5-MMP, ADAM-10 and N-cadherin Protein Expression
In order to test the effect of MMP inhibition on MT5-MMP, ADAM-10 and Ncadherin expression during the period of synapse stabilization, we sampled
hippocampal protein extracts at 15d postinjury. We specifically targeted GM6001
treatment at the 6-7d postinjury interval to affect the period when enzyme levels are
highest and N-cadherin substrate decreased. The primary 80 kDa MT5-MMP
expression at 15d was neither significantly affected by GM6001 treatment when
compared with injured vehicle cases, nor was it different from sham-injured controls
(104.55 + 9.75, p=0.65) (Fig. 3.1). These results suggest that MT5-MMP protein
expression was not a major player at 15d postinjury, consistent with our prior Western
blot results. However, we did observe a significant drug effect on active 70 kDa ADAM10 protein expression at 15d postinjury relative to injured-untreated animals (Fig. 3.1).
Injured-untreated cases showed an increase (230.78 ±30.41, p<0.001), while injuredtreated cases were not different from controls (109.74 ±14.86, p=0.64). Further, when
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injured-untreated and injured-treated were directly compared, there was a 48%
reduction in 70 kDa ADAM-10 following GM6001 which proved to be significant
(p<0.01). While 15d full length N-cadherin (130 kDa) within the injured groups was not
different from sham-injured controls (p=0.15), GM6001 treatment significantly elevated
130 kDa N-cadherin in the injured-treated animals when compared with the injuredvehicle cases at 15d (injured-untreated: 88.69 + 5.47 p=0.24; injured-treated: 122.29 +
12.87; p<0.05) (Fig. 3.1). Notably, the relative expression of MT5-MMP, ADAM-10 and
N-cadherin in the GM6001 treated TBI+BEC cases was now similar to that seen at 15d
following UEC, shifting the profile toward that present during adaptive synaptic plasticity.
Further, these results show that GM6001 administration at the time of sprouting
and synapse formation selectively affects ADAM-10 during synapse stabilization phases
of synaptogenesis. Moreover, significant increase in N-cadherin after GM6001
treatment supports a direct enzyme/substrate interaction between ADAM-10 and Ncadherin during this synapse stabilization.
Blot signal for the additional forms of MT5-MMP (85 kDa), ADAM-10 (100 kDa,
80 kDa) and the 40 kDa N-cadherin fragment following GM6001 treatment was not
different from that of the injured-vehicle group at 15d postinjury (data not shown).
These results indicate that MMP inhibition did not affect the expression of these
additional forms of MT5-MMP, ADAM-10 and N-cadherin.
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Figure 3.1 Comparison of MT5-MMP, ADAM-10 and N-cadherin Hippocampal
Protein Expression in TBI+BEC-untreated and TBI+BEC GM6001-treated animals
at 15d. Values expressed as percent of sham controls. GM6001 treatment at 6 and 7d
postinjury significantly decreased ADAM-10 and increased N-cadherin protein
expression relative to injured-untreated group when measured at 15d.There was no
change noted between groups for MT5-MMP (MT5) expression. Representative blots
shown below. I=Injured; S=Sham (control); Injured-Vehicle n=7-8, Injured-Treated n=6,
Sham n=8; *p<0.05, **p<0.01
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Electrophysiology
Effect of MMP Inhibition on Long-Term Potentiation and Long-Term Depression
Application of the theta-burst high-frequency stimulation (HFS) generally
elevated fEPSP slopes during the 60 minute post-HFS period. Example evoked
waveforms from each group are shown in Fig. 3.2, illustrating potentials acquired during
pre-HFS baseline period, and during the post-conditioning period. Also illustrated is the
fEPSP measurement, taken early in the downstroke of the fEPSP. In comparison to
fEPSP measurements based on peak amplitude, a slope measurement early in the
fEPSP waveform is less affected by population spikes. As indicated in Fig. 3.2, the
standardized current intensity (50% of maximum, based on input-output functions)
evoked moderate fEPSP waveforms, having small population spikes, or lacking them
altogether. After HFS, the evoked fEPSPs often developed large population spikes (see
example, marked „p.s.‟ in Fig. 3.2). Within the LTP literature, there is a widespread
agreement that the „early-slope‟ measurement approach reflects current fluxes initiated
by the population EPSP, prior to contamination by target cell discharges.
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Figure 3.2 Representative field potentials evoked in the Schaffer collateral
afferent input to CA1. Traces are shown from a sham control rat, from a TBI+BEC
(vehicle) rat, and from a TBI+BEC (GM6001-treated) rat. A sample waveform is shown
during the baseline recording period, prior to the application of high frequency
stimulation (HFS) used to induce LTP, and from 10 min and 60 min after HFS. Within
each row stimulus current was held constant. The method of measuring the initial
fEPSP slope is illustrated in two of the baseline waveforms. In addition to usually
increasing fEPSP slope, HFS often also induced a population spike (p.s.) which
persisted during the post-HFS recording period

160

161

In uninjured control rats, the HFS trains induced a significant 58.0+8.6% increase
in fEPSP slope, when averaged across the 60 minute post-HFS monitoring period
(p<0.001). However, as measured at 15 d after the TBI+BEC injury, LTP was weak and
quite variable. Again averaging across 0-60 minutes post-HFS, the TBI+BEC
(untreated) group exhibited a 36.1+15.5% elevation of fEPSP slope, but this narrowly
missed significance (p=0.077). In contrast HFS induced a significant 45.8+10.8%
average increase in TBI+BEC (treated) rats (p<0.01). Figure 3.3 panel A shows, mean
fEPSP slope measurements, normalized to pre-HFS baseline, for each group. These
results indicated that the HFS was effective in inducing a functional plasticity: a
significant 58% and 46% enhancement for controls and injured-treated rats,
respectively, and a (non significant) 36% change in injured-untreated rats. A separate
issue was whether these magnitudes of LTP were statistically different among the three
groups. As a first approach to this question, we analyzed whether the mean fEPSP,
averaged over entire 60 minutes of post-HFS monitoring, was significantly different
among the three groups. This analysis indicated that there were no statistically
significant differences among any of the three groups (p=0.198), probably due to the
highly variable responses in rats subjected to TBI+BEC.
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Figure 3.3 Effects of TBI+BEC injury and GM6001 treatment on LTP and LTD. (A).
Rats with TBI+BEC injuries showed weak and highly variable LTP, significantly below
control levels during the first 15 minutes post-conditioning (Period 1 (P1) interval). Time
of application of high-frequency stimulus (HFS) trains is marked with filled arrow.
Injured rats treated with GM6001 exhibited a level of LTP intermediate between the
control and injured-untreated groups. LTD (induction time marked with open arrow) was
not significantly altered by injury or GM6001 treatment. ). For clarity data points are
averages of 2-minute epochs. (B) Mean level of LTP was significantly suppressed in
injured rats from 0-15 min post-HFS (p<0.05). LTP in GM6001-treated rats was not
different from control levels. No significant injury or drug effects were observed from
16-60 minutes post-HFS (P2).
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Inspection of Figure 3.3 panel A, suggested a possible systematic difference
among groups during the first 15 minutes post-HFS. Specifically, the rate of post-HFS
response increases in the injured-untreated group tended to be retarded in comparison
to the control and to injured-treated groups. Accordingly, analyses were also conducted
separately for this early period (Period 1 = 0-15 minutes post-HFS), and for P2=16-60
minutes post-HFS. While this division is arbitrary, for theoretical reasons it is useful to
explore indications that injury or drug treatments may preferentially impact activitydependent plasticity at early stages. For example, and as discussed below, molecular
cascades and structural modifications, initiated by HFS, may be quite labile during the
early phases of plasticity, and especially susceptible to neuropathological conditions
during this time. Analyses targeted at period P1, revealed that the average LTP
induced in TBI+BEC (untreated) rats was significantly below that of uninjured control
rats (p<0.05) (see Figure 3.3 panel B). In contrast, during this same interval (0-15
minutes post HFS) the level of LTP in TBI+BEC (treated) rats was not different from
uninjured controls (p=0.183), or from TBI+BEC (untreated) rats (p=0.323). To the
extent that a significant effect of injury was only observed in the TBI+BEC (untreated),
and not in the TBI+BEC (treated), groups, these results are consistent with a
neuroprotective effect of GM6001 on LTP induction under these injury conditions.
However, any neuroprotective benefit was limited to this early interval, because no
statistically significant differences were noted among the groups during 16-60 minutes
post-HFS (see Figure 3.3 panel B).
Although application of the low-frequency (1 Hz) stimulation appeared to induce
some degree of long-term depression (LTD), the mean fEPSP slopes in all groups
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trended back to the potentiated level during the 20 minutes of LTD monitoring (75-95
minutes in Figure 3.3 panel A). Although the TBI+BEC (untreated) group exhibited an
especially unstable pattern during this interval, statistical analyses did not reveal any
significant between-group differences of mean fEPSP slopes, induced by the LTD
procedure.
Effect of MMP Inhibition on Paired-Pulse Facilitation
Studies of LTP have documented the involvement of multiple postsynaptic
mechanisms including specific kinase activities, translocation and modification of AMPA
receptors, morphological changes to spines and postsynaptic densities, protein
synthesis, and gene activation. Less evidence has accumulated for a presynaptic role
in LTP induction (e.g., reviewed by Malenka and Bear, 2004), although important
questions remain in this area. Because N-cadherin participates in the linkage and
stabilization of presynaptic terminals with postsynaptic structures, it is useful to consider
if TBI+BEC injury, and GM6001 treatment, alter presynaptic functional plasticity in a
manner comparable to their effects on LTP. To approach this issue we also
implemented the paired-pulse facilitation (PPF) procedure. While a postsynaptic role in
this form of short-term plasticity cannot be entirely ruled out, there is a substantial
consensus that, using low levels of stimulus current as presently implemented, PPF is
predominantly mediated presynaptically. Multiple authors have interpreted the
augmentation of the second response to reflect residual Ca2+ loaded into presynaptic
terminals during the first response (Lomo, 1971; Creager et al., 1980; Zucker, 1989;
Leung and Fu, 1994).
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In the present study, all groups showed a similar pattern of responses to the
paired stimulus presentations. An example set of paired fEPSPs, obtained from a
control rat, are shown in Fig. 3.4 panel A. Note the similar amplitude and waveform of
the first field potential in each pair. This was expected because 30 seconds were
allowed to pass between each paired pulse presentation. This permitted a recovery of
the ionic status of the presynaptic compartment, presumably including a return of
intracellular calcium to basal levels. Note also that the amplitude and waveform of the
second field potential in each pair were contingent on the interpulse interval, with the
greatest augmentation of fEPSP2 seen at an interval of 50 msec. Stimulus currents
were held constant during this procedure, set individually for each slice to ensure that
fEPSP1 was stimulated below the threshold for a population spike. However, it was
commonly observed that a population spike was visible in fEPSP 2, especially at 50 and
100 msec intervals (see example „p.s.‟ in Fig. 3.4 panel A).
At interpulse intervals of 50 msec, fEPSP2 was elevated over fEPSP1 by an
average of 69.55+7.30%, for all slices tested. The mean magnitude of PPF, at the 50
msec interpulse interval, ranged from 81.92+13.82% (injured untreated) to
59.47+14.52% (injured-treated), with controls showing an intermediate 67.24+9.46%.
However, these differences did not reach statistical significance. All groups showed the
predicted pattern of decreased PPF as interpulse interval was increased to 100, and
then to 150 msec (Fig. 3.4 panel B). However, the same lack of statistically significant
group differences were noted also at these longer intervals, with overall PPF
magnitudes of 51.69% and 33.16% observed at 100 and 150 msec, respectively.
Taken together, analysis of the PPF data indicated that neither the TBI+BEC injury nor
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Figure 3.4 Effects of TBI+BEC injury and GM6001 treatment on PPF. (A)
Representative paired-pulse waveforms for interpulse intervals 50, 100, and 150 msec,
from a sham-injured control rat. Dotted portion of waves abbreviates period between
evoked responses. In the PPF protocol, stimulus current is set below threshold for
population spikes (first response in each pair). Characteristically, the second response
is augmented (steeper descent of fEPSP), and a population spike is often induced at
interpulse intervals of 50 or 100 msec (p.s. in example). (B) Mean paired-pulse ratios
(fEPSP2 / fEPSP1) for the analytic groups exhibited similar decreases as interpulse
interval was increased from 50 to 150 msec. Neither the TBI+BEC injury, nor the
GM6001 treatment, was associated with a statistically significant effect on PPF
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the GM6001 compound significantly altered this form of short-term plasticity (p=0.482).
Morris Water Maze Testing
MMP Inhibition and Cognitive Behavioral Outcome
Cognitive performance of injured-untreated and injured-treated animals was
assessed at 12-15d postinjury using the Morris Water Maze (Morris et al., 1981) task
(Fig. 3.5). Group latencies (measured in seconds) to locate the hidden platform were
analyzed using ANOVA, which revealed significant differences in main effect of group
(p<0.001). Following ANOVA analysis Fisher Least Significant Difference (LSD) tests
were conducted to determine specific group differences. Post Hoc analysis using the
Fisher LSD test indicated significant differences between injured-untreated and sham
groups, as well as between injured-treated and sham groups (p<0.001). GM6001
treatment at 6-7d postinjury failed to produce significant differences in performance
between the injured-untreated and injured-treated groups (p=.294). These results
indicate that the GM6001 dosing used in this study, while altering ADAM-10 and Ncadherin expression and affecting the induction of LTP, did not significantly improve
spatial memory deficits associated with maladaptive plasticity.
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Figure 3.5 Effect of TBI+BEC injury and MMP Inhibition on Cognitive Recovery.
Spatial learning and memory was assessed using the Morris Water Maze task. Pretrained sham-injured (open circle), injured-vehicle (black square) and injured-treated
(gray triangle) groups underwent testing on days 12-15 postinjury. Average latency to
goal scores (measured in seconds) for each group are presented across postinjury
testing days. Injured-vehicle and injured-treated animals displayed significantly longer
latency to goal times when compared to sham-injured animals at all postinjury day
intervals, indicating an injury effect. However, MMP inhibition by GM6001 treatment
(i.p., 10 mg/kg, 6 and 7d postinjury) did not improve cognitive recovery in the injuredtreated group when compared to sham control. p<0.001.
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Ultrastructural Analysis
MMP Inhibition and Hippocampal Synaptic Structure
Following MWM assessment, a subset of15d postinjury untreated and GM6001
treated animals were prepared for ultrastructural analysis. Qualitative observations of
ultrathin sections from both dentate gyrus molecular layer and CA1 stratum radiatum
revealed differences in dendritic and synaptic cytoarchitecture between the two groups.
Injured-untreated animals showed evidence of persistent hippocampal dendritic and
synaptic pathology (Fig. 3.6). Their dendrites were of small diameter, irregular in form
and often containing disrupted cytoskeleton. Synapses appeared immature, with
thinned post-synaptic densities and atypically large separation at the synaptic cleft. In
contrast, GM6001 treated animals displayed dendritic and synaptic cytoarchitecture
more consistent with control 15d postinjury cases. Overall, treated cases appeared to
have larger diameter dendrites, with intact cytoskeletal networks. Synaptic profiles
revealed well-developed junctions, with mature pre-and post-synaptic organization.
Although qualitative in nature, these observations do suggest that MMP inhibition during
the initiation of sprouting and synapse formation can foster a shift toward the generation
of normal synaptic structure in a model of maladaptive synaptic recovery. While these
observations do not follow the absence of GM6001 effect on cognitive outcome, they do
compliment our 15d protein and electrophysiological analyses, which show that the
MMP inhibitor increases expression of the neuronal adhesion molecule N-cadherin and
elicits a reversal of field potential deficits during the induction of LTP.
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Figure 3.6 Effect of TBI+BEC injury and GM6001 Treatment on Dendritic and
Synaptic Cytoarchitecture at 15d. Ultrastructural profiles of the dentate molecular
layer and hippocampal CA1 stratum radiatum following vehicle (A/C) or GM6001 (B/D)
treatment. Qualitative assessment of GM6001 cases (B/D) suggest increased dendritic
integrity, with larger diameters and more intact cytoskeleton. Synapses appeared more
frequently and had normal structural organization (see inset arrows) when compared to
vehicle (A/C). The GM6001 profile is consistent with our 15d observations of increased
expression of N-cadherin and partial restoration of CA1 LTP following MMP inhibition.
Bar = 2µm.
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DISCUSSION
The current study examined the effects of MMP inhibition on MT5-MMP, ADAM10, and N-cadherin protein expression, synaptic function, synapse cytoarchitecture and
cognitive recovery in the TBI+BEC model of maladaptive plasticity. Following injury,
the broad-spectrum MMP inhibitor GM6001 was administered on days 6 and 7
postinjury, targeting both the onset of synaptic reorganization and the period of most
elevated MT5-MMP and ADAM-10 expression. Assessment of drug effect was made by
comparing injured-treated and injured-vehicle animals at 15d survival, when stabilization
of regenerated synapses begins. Our results showed that GM6001 treatment produced
the following: 1) a reduction in ADAM-10 and increase in N-cadherin hippocampal
protein expression, generating a profile similar to that found at 15d post-UEC, 2) an
enhancement of synaptic efficacy, evidenced by effects on the early induction phase of
LTP, and 3) improved structural reorganization of dendritic and synaptic
cytoarchitecture. In the present experimental design, GM6001 MMP inhibition failed to
produce improvement in cognitive performance. Collectively, this study provides
evidence that targeted MMP inhibition promotes a more adaptive environment for
reactive synaptogenesis, thereby improving postinjury recovery in the maladaptive
condition. In following sections, we will discuss how these results support a prominent
role for membrane bound MMPs and N-cadherin in the enhancement of functional and
structural synaptic recovery.
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MMP Inhibition and Protein Expression
Western blot (WB) analysis at 15d postinjury, the onset of synapse stabilization,
revealed that MMP inhibition produced differences in hippocampal ADAM-10 and Ncadherin protein expression. When injured-treated and injured-vehicle groups were
compared, drug treatment significantly decreased ADAM-10 protein by 48%, while Ncadherin was significantly elevated by 38%. This resulted in a pattern of relative
expression which matched that of the adaptive UEC described in the previous chapter,
supporting the hypothesis that appropriate balance of MMP/substrate interaction is key
to the final stabilization of regenerated synapses. While we have studied the effects of
other MMP inhibitors (e.g., FN-439) on behavioral and structural outcome in the
combined model (Falo et al., 2006), this is the first study to show that MMP inhibition
has a direct effect on the expression of membrane bound MMPs and N-cadherin during
the stabilization phase of synaptogenesis. These results are also consistent with prior
studies in our laboratory which show that manipulation of recovery in the combined
model alters the expression of MMPs. For example, postinjury administration of the
NMDA antagonist MK-801 significantly reduced MMP-2 activity and MMP-3 protein
expression (Phillips and Reeves, 2001; Falo et al., 2006).
Our WB results also revealed differential effects of GM6001 on the two
membrane bound MMPs. Here, MMP inhibition failed to affect the TIMP-2 bound MT5MMP protein expression at 15d post-TBI+BEC. This result might be explained by the
fact that a majority of MT5-MMP signal was seen at 80 kDa, consistent with TIMP2/MT5-MMP binding at the catalytic site, likely in the context of proMMP-2 activation.
This arrangement would then act to hinder GM6001 binding and inhibition. While MT5177

MMP protein expression remained unchanged at 15d, our current interpretation of
MT5-MMP response is supported by prior findings showing shifts in hippocampal MMP2 protein after TBI+BEC, similar to our observed MT5-MMP changes (Phillips and
Reeves, 2001). Based on the concomitant elevation MT5-MMP and MMP-2 at 2-7d
postinjury, targeting earlier time points for MMP inhibition of MMP-2 would be warranted
to provide further evidence for this proposed relationship, as well as further delineate
specific MMP role in postinjury recovery. Taken together, these data support our
proposed role for MT5-MMP as an activator of proMMP-2 during the earlier phases of
injury-induced synaptogenesis.

Our WB results show that MMP inhibition can

significantly affect protein expression following injury in a TBI model of maladaptive
plasticity, and promote a molecular environment similar to that found with adaptive
plasticity.
One important consideration for interpretation of our results would be how
inhibition of MMP activity leads to changes in protein expression following injury.
Postinjury MMP inhibition may influence protein expression by reducing the capacity for
MMPs to modify ECM and cell to cell connections. Such modification would affect the
initiation of a number of signaling pathways which regulate cell survival and death, often
through altering gene transcription and protein translation. In the context of this study,
persistent ADAM-10 lysis of synaptic N-cadherin between 7-15d postinjury may be
linked to anoikis, or cell death by loss of cell anchorage (Grossman, 2002). Inhibition of
this ADAM-10 activity would reduce cleavage of synaptic N-cadherin, maintain synaptic
contact, attenuate loss of anchorage, and potentially allow for a more stable
transcriptional regulation of ADAM-10 and N-cadherin expression in surviving cells.
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Inhibition of MMPs has also been shown to decrease downstream neuronal
degeneration and improve recovery in other neurotrauma models, potentially by limiting
excessive loss of cell anchorage and preventing anoikis (Ashi et al., 2000; Wang and
Tsirka, 2005; Zhao et al., 2006; Sifringer et al., 2007). Additionally, injury-induced
alteration of ECM and cell to cell connections can provide feed forward signals that
influence downstream pathways within the cell and lead to MMP upregulation (Conant
and Gottschall, 2005). For example, post-ischemic alterations of hippocampal ECM-cell
contacts have been shown to trigger intracellular signaling by protein focal adhesion
kinase, pp125FAK, which leads to upregulation of MMP-2 and -9 (Zalewska et al, 2003).
Potentially, increased MMP expression may lead to continued alteration in ECM/cell
interaction, activation of these signaling pathways, and further MMP upregulation. In
the context of our Chapter 2 results, this endogenous feedback mechanism may have
mediated the injury-induced increases in active ADAM-10 expression that were
observed over the postinjury time course. Therefore, postinjury inhibition of MMP
activity may further decrease ECM/cell alterations, thereby limiting the effects of
downstream signaling through such pathways. This may explain our observations that
GM6001 decreased ADAM-10 protein expression at 15d postinjury. Finally, MMP
inhibition may influence N-cadherin expression through β-catenin, which can indirectly
decrease N-cadherin protein upon its release from the cadherin/catenin complex and
subsequent nuclear translocation to act as a transcription factor (McCusker, 2009). Our
results suggest that MMP inhibition may help to maintain β-catenin submembrane
binding in the cadherin/catenin complex, therefore limiting its release to affect a down
regulation of N-cadherin. The result would be enhanced synapse stabilization. While
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MMP inhibitors are designed to limit protease activity, our results provide further
evidence they can also influence the process of injury-induced synaptogenesis through
downstream regulation of the expression of plasticity-associated proteins, and therefore
improve recovery.
MMP Inhibition and Synaptic Functional Recovery
In order to examine the effect of MMP inhibition on recovery of synaptic function
we conducted a series of in vitro electrophysiological experiments including assessment
of LTP, LTD and PPF. We chose to record the synaptic response in CA1 stratum
radiatum following Schaffer Collateral fiber stimulation. This choice was made for two
reasons: 1) the absence of a homotypic perforant path projection in the combined
animals subjected to BEC insult and 2) the presence of synaptic reorganization in CA1
dendrites following cFPI alone. Results from these experiments showed an injury effect
on the capacity for LTP during the first 15 minutes (P1) following conditioning stimulus.
These experiments were the first in vitro assessment of LTP, LTD and PPF in the
TBI+BEC model and were consistent with our prior in vivo studies showing persistent
deficits in the capacity to elicit LTP up to 15d postinjury (Reeves et al., 1997). A key
finding in the present electrophysiological assessments was that the GM6001 treatment
partially restored the injury-induced LTP deficit noted in the first 15 minutes postconditioning. This suggests that dampening of MMP activity during the 6-7d period of
sprouting and synapse formation can improve synaptic function in the context of
maladaptive plasticity. While this was the first investigation to examine the effects of
MMP inhibition on TBI+BEC synaptic efficacy, the consequences of postinjury MMP
inhibition on synaptic function have been examined in the UEC model of adaptive
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plasticity. In that study, the MMP inhibitor FN-439 was applied at 30 min after lesion
and outcome assessed at 7d postinjury (Reeves et al., 2003). Results showed a
reduced capacity to elicit LTP and aberrant spatial reorganization of synapses along
deafferented dendrites when compared to vehicle controls. In contrast to MMP
inhibition at 7d, the latter study suggests that acute inhibition of MMPs during the
degenerative phase of synaptogenesis can reduce functional recovery, even within an
adaptive environment. Similarly, non-injured (naïve) hippocampal slices treated with
FN-439 failed to produce LTP induction and maintenance, further suggesting that
inhibition of MMPs under normal conditions is also detrimental (Meighan et al., 2007).
Thus, our collective data support a key role for MMPs in shaping the environment
around reorganizing synapses to foster their growth, as well as support stabilization for
synaptic efficacy in the new circuits generated. The findings also clarify the requirement
for increased MMP activity during the more acute postinjury periods and the subsequent
attenuation of this activity as synapses mature and regain their functional status.
In addition to LTP, we also investigated the effect of GM6001 treatment on LTD
and PPF. Despite observing significant changes in LTP, we found no group differences
in LTD and PPF measurements. Interestingly, PPF abnormalities have been observed
within the central (Reeves et al., 2000) and lateral (Cao et al., 2006) fluid percussion
(cFPI, lFPI), persisting for up to seven to nine days postinjury, respectively. Such model
differences show that pathophysiological processes influencing pre-synaptic plasticity
are altered when cFPI is combined with targeted deafferentation in the TBI+BEC model.
This result provides further support for our hypothesis that neuroexcitation insult and
deafferentation are interactive in the context of maladaptive synaptic reorganization.
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Collectively, these electrophysiological data suggest that postsynaptic vulnerability may
be a preferential contributor to deficits in synaptic efficacy following TBI+BEC. Further,
by documenting that these deficits can be attenuated with MMP inhibition, we provide
support for the hypothesis that MMPs and their synaptic substrates participate in the
recovery of functional synapses following TBI.
The current LTP findings with GM6001 treatment point to several possible
mechanisms by which MMPs might affect functional recovery during reactive
synaptogenesis. One such LTP-associated synaptic mechanism may involve the
adhesive and stabilization roles of N-cadherin. N-cadherin functions extracellularly to
bind pre- and post-synaptic elements and establishing intracellular connections to
stabilize the synapse and permit efficient function (Takeichi and Abe, 2005). Pre- and
post-synaptic adhesion is essential for synaptic growth, maturation and resistance to
disassembly (Bozdogi et al., 2004). Based on these roles, N-cadherin is linked to
synapse potentiation and plasticity during early and late LTP (E-LTP, L-LTP), where in
vitro blocking N-cadherin results in the failure to produce LTP induction and/or
maintenance (Tang et al., 1998; Bozdogi et al., 2000). The current study shows that
MMP inhibition mediates increased N-cadherin expression and attenuates E-LTP
induction deficits at 15d after TBI+BEC insult. All LTP monitoring conducted in this
study, and certainly the P1 period, would fall within the E-LTP phase which may last for
~1 to 3 h (Blitzer et al., 2005). Recall that, following GM6001 treatment 15d N-cadherin
protein expression in TBI+BEC is very similar to what was seen at that time interval
after UEC, a period which represents the onset of the synaptic stabilization. Similar
levels of N-cadherin protein in these two groups suggests the potential for similar
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maturation and stabilization of hippocampal synapses. Therefore, N-cadherin may
directly influence the successful synapse stabilization or synaptic efficacy during E-LTP.
An additional N-cadherin associated mechanism that may be enhanced by MMP
inhibition involves modification of the post-synaptic density (PSD) during E-LTP. E-LTP
does not require new protein synthesis, but rather, relies on modification and reorganization of existing synapses using available stored proteins (Malenka and Bear,
2004; Issac et al., 1995; Liao et al., 1995). Modifications made to existing synapses
include the trafficking and placement of additional AMPA receptors into the PSD, which
is regulated by N-cadherin in cultured neurons, therefore indicating a link between
structural and functional plasticity (Bredt and Nicoll, 2003; Malenka and Nicoll, 1999;
Nuriya and Huganir, 2006). Based on current literature, the interaction between AMPA
receptors and N-cadherin appears to enhance synaptic efficacy as measured by LTP.
Our finding of functional improvement, associated with increased hippocampal Ncadherin following GM6001 treatment, would be consistent with prior reports of an Ncadherin role in receptor and PSD stabilization. A preservation of N-cadherin function,
after GM6001 treatment, conceivably permitted enhanced synaptic transmission and
LTP-associated plasticity in our maladaptive model.
In addition to its role in post-synaptic density organization and function, Ncadherin affects synaptic Ca2+ conductance through other binding partners at the
synapse. In the previous chapter, we provided evidence that MMP lysis of the Ncadherin extracellular domain mediates the cleavage and release of an intracellular
~35-40 kDa cytoplasmic tail fragment-1 (CTF1). This 40 kDa N-cadherin fragment was
detected in both the UEC and TBI+BEC models. Although we did not find significant
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change in this fragment with GM6001 treatment, it is important to consider its possible
influence on Ca2+ conductance on synaptic function. The intracellular release of CTF1
can indirectly affect Ca2+ conductance by interacting with one of its binding partners,
p120 catenin, which subsequently releases and activates RhoA. Through interaction
with myosin-actin cytoskeleton, soluble, active RhoA ultimately decreases synaptic Ca 2+
influx through action on voltage activated Ca2+ channels (VACC) (Marrs et al., 2009).
Therefore, extensive lysis of N-cadherin by a persistently activated ADAM-10 can serve
as an upstream mediator of RhoA signaling, leading to decreased Ca 2+ conductance
and attenuated synaptic efficacy. Our LTP results suggest that MMP inhibition may limit
N-cadherin cleavage, thereby preventing RhoA driven decrease in synaptic Ca2+ influx,
and decreasing the injury-induced deficits seen during P1 of our LTP trials. Although
the exact mechanism(s) are yet to be established, the relationship between N-cadherin
and synaptic function is well established and further supported by our present molecular
and electrophysiological data.
MMP Inhibition and Cognitive Recovery
One of the principal concerns following TBI is the presence of persistent
cognitive impairment. To study the effect of MMP inhibition on cognitive recovery
following injury, we used the Morris Water Maze (MWM) task, which is a reliable and
sensitive measurement of cognitive function following TBI (Hamm, 2001). In these
experiments, we did find a significant injury effect on MWM performance during 12-15d
postinjury trials. Impaired latency to find the goal platform in the injured-vehicle group
was consistent with our published studies (Phillips et al., 1994; Phillips and Reeves,
2001; Falo et al., 2006). However, using the present GM6001 treatment paradigm we
184

were unable to detect a drug effect on MWM performance. These results are in
contrast to a prior TBI+BEC study where the MMP inhibitor FN-439 showed improved
spatial learning over a five day trial period, utilizing both acute (1-2d) and delayed (6-7d)
treatment paradigms (Falo et al., 2006). It is interesting that both studies applied MMP
inhibitor at 6-7d postinjury, but only FN-439 showed attenuation of cognitive deficits.
Both GM6001 and FN-439 inhibit MMPs through a common mechanism of binding
divalent ions critical to engaging the active site of the enzyme. They do, however,
exhibit specificity for different MMP family members. The FN-439 compound targets
collagenase, gelatinase and stromelysin, while GM6001 more broadly inhibits a wide
range of MMPs, inclusive of the MT-MMP family group. This difference in specificity
may account for the presence or absence of behavioral effects in the MWM test, which
would suggest that more specific targeting of MMPs is a better approach than using a
general profile inhibitor. Unfortunately, no such inhibitor targeting membrane bound
MMPs has been developed to test this possibility.
Despite the challenges of inhibitor specificity, we did find a positive relationship
between GM6001 treatment and the modest reversal of injury-induced deficits within the
inductive phase of LTP. Since LTP may serve as a cellular model for learning and
memory, and the MWM task tests functional aspects of memory, the emergence of a
reversal in LTP deficit with MMP inhibition supports the interaction between MMP
function and behavioral recovery. The failure to detect attenuation of MWM deficits in
our experimental paradigm may indicate that a more careful dose/delivery study is
needed. For example, shifting to intra ventricular rather than intra peritoneal would
likely improve delivery and facilitate any drug effect on CNS structures. It is also
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important to recognize that while the hippocampus is an essential structure for the
processing of learning and memory, MWM tested behavior involves the coordination of
multiple nervous system circuits.
MMP Inhibition and Synapto-Dendritic Reorganization
Finally, we examined the effect of MMP inhibition on synaptic ultrastructure in the
stratum radiatum of the hippocampal CA1 field and the dentate molecular layer at 15d
postinjury. Sampling from each area allowed us to compare dendritic and synaptic
cytoarchitecture in the region subjected to electrophysiological recording, as well as the
principal deafferented zone undergoing reactive synaptogenesis. In the injured-vehicle
animals we found abnormalities in synaptic structure that were consistent with
maladaptive plasticity as previously described for the TBI+BEC model (Phillips et al.,
1994; Falo et al., 2006). For example, injured-vehicle animals exhibited damaged
dendrites, as well as atrophied and disorganized synaptic profiles in both the stratum
radiatum and outer molecular layer when compared to control tissue. These
observations are consistent with our prior TBI+BEC studies showing persistent axodendritic pathology and abnormal synaptic reorganization at 15d postinjury (Phillips et
al., 1994; Gordon et al., 1996; Phillips and Reeves, 2001; Falo et al., 2006). By
contrast, injured-treated animals exhibited robust reorganization of synaptic structure,
with larger, well organized supportive dendrites. Post synaptic densities were larger
and more complex in structure, often abutting axon terminals with well-organized presynaptic vesicles at the membrane surface. Although we did not use quantitative
methods for analysis, we did observe that synapses appeared to be more abundant
following MMP inhibition. Similar cytoarchitectural changes in synapse structure have
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been reported following TBI+BEC treatment with the MMP inhibitor FN-439 (Falo et al.,
2006).
The synapto-dendritic reorganization described here provides a structural
correlate to the positive effects of MMP inhibition on synaptic function and support
MMPs as mediators of improved outcome under conditions of maladaptive plasticity.
Our collective results suggest that such inhibition stabilized synaptic structure which
contributes to improved induction of LTP and synaptic efficacy after TBI+BEC. Again,
these structural improvements can be directly linked to the functional properties of Ncadherin at the synaptic interface. N-cadherin mediates specific post-synaptic density
organization and synaptic stabilization through AMPA receptor placement and actin
cytoskeleton anchorage, respectively, each of which support the capacity for LTP
(Nuriya and Huganir, 2006; Togashi et al., 2002; Lilien et al., 1999). Quantitative EM
analysis of CA1 dendrites in hippocampal slices transfected with mutated N-cadherin
constructs also revealed significantly smaller dendritic spines and post-synaptic
densities and reduced spine stability, further illustrating N-cadherin‟s role in synaptic
structural organization (Mendez et al., 2010). Our results support a role for N-cadherin
in structural synaptic recovery. They tie together elevated MMP activity, N-cadherin
lytic fragment production and intracellular signaling to alter synapse structure during
maladaptive plasticity. Importantly, MMP inhibition at the onset of this process appears
to facilitate structural recovery by generating a more adaptive environment for
synaptogenesis.
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SUMMARY
We have shown that MMP inhibition at 6 and 7d postinjury significantly alters the
expression of hippocampal ADAM-10 and N-cadherin protein at 15d survival in the
TBI+BEC model of maladaptive plasticity. This inhibition shifted the expression of
ADAM-10 and N-cadherin to the pattern seen during adaptive plasticity. Targeted MMP
inhibition also reversed deficits in LTP induction and stabilized synapto-dendritic
integrity. However, the same treatment paradigm had no effect on cognitive
performance. While these results suggest that MMP inhibition during reactive
synaptogenesis promotes structural and functional recovery, there are important
limitations to be considered. Foremost, GM6001 is a broad-spectrum MMP inhibitor,
affecting multiple soluble and membrane-bound MMPs. Although we were able to show
that ADAM-10 expression was altered by GM6001 treatment, we did not provide
evidence that its enzyme activity was blocked by the compound. Moreover, the effects
observed could be due to inhibition of other MMPs as well. Therefore, for future studies
it will be important to specifically target ADAM-10 or MMPs activated by MT5-MMP
(e.g.-MMP2) in order to directly link these enzymes to adaptive synaptic recovery.
Further investigation is also needed to better define the molecular mechanisms that
regulate MT-MMP expression and activity, as well as identify the downstream effects of
their proteolytic products on the process of reactive synaptogenesis.
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Chapter 4

General Discussion
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DISCUSSION
Summary of Results
Chapters 2 and 3 presented the protein and mRNA profiles of membrane-type
MMPs, MT5-MMP and ADAM-10, along with a shared substrate N-cadherin, within adult
rat hippocampus following TBI. Expression profiles were compared in two models of
TBI, one exhibiting adaptive synaptic plasticity (UEC) and the other maladaptive
synaptic plasticity (TBI+BEC). We also presented the effects of MMP inhibition on
molecular, electrophysiological, behavioral and structural outcome at 15d following
TBI+BEC. MMP inhibition targeted elevated MT5-MMP and ADAM-10 expression
during the axonal sprouting and synapse formation period of synaptogenesis.
Collectively, our results provide evidence that membrane-bound MMPs and their
constitutive substrates (e.g.-N-cadherin, pro-MMP-2) are influence both adaptive and
maladaptive plasticity in a time and injury-dependent manner. Inhibition of membranebound MMPs during maladaptive plasticity leads to change in their protein expression
and improved outcome with respect to synaptic efficacy and structure. Therefore,
targeted MMP inhibition has the potential to translate maladaptive plasticity into a more
adaptive process, facilitating an improved recovery.
In Chapter 2, MT5-MMP, ADAM-10 and N-cadherin expression was shown to
differ between adaptive and maladaptive models of TBI as a function of postinjury
survival, suggesting that their role(s) in the process are temporally regulated.
Comparison of model profiles shows that MT5-MMP plays a more acute role during the
degenerative and regenerative phases (2 and 7d) of injury-induced synaptogenesis,
potentially through interaction with TIMP-2 and activation of proMMP-2. Our results
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suggest that ADAM-10 is the preferred protease targeting N-cadherin during the phase
of synapse reorganization and stabilization (7 and 15d) postinjury. Protein analysis at
15d after TBI+BEC specifically showed a temporal correlation between a persistent
increase of ADAM-10 and decreased N-cadherin expression, contrasting with the
opposite pattern of expression in adaptive UEC plasticity. Changes in hippocampal
protein expression in both models were consistent with the pattern seen using
immunohistochemistry, where signal increase was greater over the deafferented
dentate molecular layer (ML), principally within reactive astrocytes. These results
suggest a role for reactive astrocytes in the synthesis and/or processing of MT5-MMP,
ADAM-10 and N-cadherin following injury. Synthesis of MT5-MMP by reactive
astrocytes is further supported by our preliminary 7d in situ hybridization results,
showing MT5-MMP mRNA signal within reactive astrocytes of both adaptive and
maladaptive models. Finally, microarray results suggested the greatest change in
ADAM-10 transcript post-UEC and TBI+BEC, matching our maximally elevated WB
ADAM-10 protein expression between 7-15d postinjury. Preliminary quantitative RTPCR (qRT-PCR) analysis on the same 7d ML samples revealed elevated ADAM-10
mRNA in both models and decreased N-cadherin transcript post-TBI+BEC. These 7d
changes in ML mRNA track with ADAM-10 and N-cadherin protein expression during
maladaptive plasticity. Taken together, MT5-MMP, ADAM-10 and N-cadherin protein
and mRNA profiles revealed time and recovery-dependent changes which were
correlated with extent of recovery. Such results led us to investigate the effect of MMP
inhibition on not only protein expression, but also synaptic structure and function postTBI+BEC.
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The results presented in Chapter 3 demonstrated that the significant effect of
MMP inhibition on ADAM-10 and N-cadherin protein expression likely influenced
improvements in synaptic structure and function at 15d post-TBI+BEC. MMP inhibition
by GM6001 at 6 and 7d after TBI+BEC targeted the period with greatest elevation of
MT5-MMP and ADAM-10 protein, as well as the onset of axonal sprouting and synaptic
reorganization. Our results showed that MMP inhibition had no effect on 15d
hippocampal MT5-MMP expression, but significantly decreased ADAM-10 and
increased N-cadherin expression, thereby shifting their profiles to those observed at 15d
post-UEC. Changes in ADAM-10 and N-cadherin expression were accompanied by
improvement in the capacity to induce hippocampal long-term potentiation (LTP), but
failed to correlate with improved spatial learning and memory performance by injuredtreated animals. Further, MMP inhibition improved dendritic and synaptic structure
within the hippocampus and dentate gyrus at 15d post-TBI+BEC. Given the importance
of N-cadherin to synapse stabilization, these improvements in synaptic function and
structure could be influenced by a shift to increased N-cadherin expression following
MMP inhibition. Collectively, the novel results presented in Chapters 2 and 3 are
supported by the current literature and indicate roles for membrane-bound MMPs like
MT5-MMP and ADAM-10, as well as N-cadherin in synaptic plasticity and recovery
following TBI.
Roles of Membrane-Bound MMPs in Synaptogenesis
Due to their transmembrane position, membrane-bound MMPs serve a unique
role in neuroplasticity by interacting with both cellular and extracellular substrates, often
at very focused sites along the cell surface. Our results show that membrane-bound
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MMPs, MT5-MMP and ADAM-10: 1) are expressed at high levels within the
hippocampus under injury conditions that induce synaptogenesis, 2) are normalized in
expression by 15d during adaptive synaptogenesis, 3) exhibit a time course of
expression which is consistent with MMPs secreted during adaptive and maladaptive
plasticity, 4) are highly localized to reactive astrocytes, not microglia, following injury,
and 5) may influence postinjury recovery through individual interaction with TIMP2/proMMP-2 and N-cadherin, respectively. The results presented in Chapters 2 and 3
are further supported by current literature that shows that MT5-MMP and ADAM-10 are
highly expressed and active during development and disease processes that involve
plasticity.
Our study investigated postinjury tissue expression and localization of MT5-MMP
and ADAM-10 in the hippocampus, a structure known for its ability to exhibit properties
of neuroplasticity. We showed a protein and mRNA expression of membrane-bound
MMPs which is consistent with reported expression during CNS development. In the
developing brain, hippocampal MT5-MMP and ADAM-10 are found primarily in neuronal
axonal growth cones and/or dendritic spines, with some evidence of ADAM-10 glial
localization. Based on these patterns, MT5-MMP and ADAM-10 are thought to facilitate
the outgrowth of neurites and the formation of synapses (Hayashita-Kinoh et. al, 2001;
Sekine-Aizawa et. al, 2001; Bernstein et al., 2003; Marcinkiewicz and Seidah, 2000).
Specifically, in vitro developmental studies have shown that MT5-MMP and ADAM-10
are involved in neurite outgrowth through proteoglycan cleavage and axonal guidance
through interaction with ephrin, respectively (Hayashita-Kinoh et al., 2001; Hattori et al.,
2000). ADAM-10 is highly involved in Notch signaling which influences neurogenesis,
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axonal and dendritic growth, synaptic plasticity, and neuronal death during both nervous
system development and disease (Lathia et al., 2008). Additionally, MT5-MMP has
been shown to facilitate the re-organization of Aβ fibers within the spinal cord following
in vivo sciatic nerve injury (Komori et al., 2004). Together, these studies and our
current results show that membrane-bound MT5-MMP and ADAM-10 are critical to
success of the plasticity process in both developing and adult nervous systems.
Elevation of hippocampal MT5-MMP and ADAM-10 expression during reactive
synaptogenesis does show some similarity to that of their secreted counterparts
following TBI. For example, protein analysis revealed an acute upregulation of MT5MMP and ADAM-10 at 2 and 7d post-UEC and TBI+BEC. MT5-MMP mRNA was
moderately elevated at 7d for each model. These results indicate that MT5-MMP and
ADAM-10 are temporally correlated with the degradation and regeneration of synapses
during both adaptive and maladaptive plasticity. However, it is important to note that
during adaptive recovery, MT5-MMP and ADAM-10 return to control levels by 15d. This
shift in expression indicates that as adaptive plasticity proceeds into the synapse
stabilization phase, high levels of membrane-bound MMPs are not required, perhaps
due to a reduced need for local ECM and cell-cell modification. In previous studies we
have shown similar 2-7d increases of MMP-2, -3, and -9 protein and mRNA for both
models, however, these secreted MMPs were normalized to control expression by 15d
(Phillips and Reeves, 2001; Kim et al., 2005; Falo et al., 2006). We also observed
persistent elevation of ADAM-10 protein up to 15d post-TBI+BEC. Prior studies also
show a persistent elevation of MMPs 2, 3 and 9 after TBI+BEC insult, but for this
secreted MMP it occurs at 7d, not 15d (Falo et al., 2006). We have also shown 2 and

194

7d increases in MMP-2 and -9, and elevations in both MMP-2 mRNA and activity 7d
following TBI+BEC (Phillips and Reeves, 2001). Other investigators have also shown
elevation of secreted MMPs during plasticity in models of neurotrauma, including
controlled cortical impact, lateral fluid percussion injury, olfactory bulb lesion, and
cerebral ischemia (Wang et al., 2000; Truettner et al., 2005; Costanzo et al., 2006;
Costanzo and Perrino, 2008; Romanic et al., 1998; Fujimoto et al., 2008). The fact that
secreted and membrane-bound MMPs show similar expression patterns suggests that
they each have important roles in postinjury recovery. However, the precise role(s) may
be further dictated by their cellular localization and distribution.
Our current study showed pronounced upregulation of membrane-bound MT5MMP and ADAM-10 in reactive astrocytes, not microglia. Astrocytic localization of
secreted MMPs (i.e.-MMP3) has been shown in our previous studies as well (Kim et al.,
2005; Falo et al., 2006). While soluble MMPs are released from astrocytes over a more
diffuse area within the ECM, our current results suggest that membrane-bound MT5MMP and ADAM-10 are primarily found within the membranes of ML reactive
astrocytes. Localization and up regulation of MMP mRNA and protein within astrocytes
are supported by several published in vitro and in vivo studies. For example,
lipopolysaccaride (LPS) stimulated cultured astrocytes produce active MMP-2 and
proMMP-9 protein (Gottschall and Yu, 1995; Rosenberg et al., 2001). LPS stimulated
cultured astrocytes also express varying levels of mRNA for MMP-2, -3, -9, -10, -11, 12, -13 and MT1-MMP (Wells et al., 1996). Other studies show that, following in vivo
spinal cord injury peri-lesion reactive astrocytes express MMP-1 (Buss et al., 2007).
MMP-2, -3 and -9 display a temporal upregulation in reactive astrocytes following
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middle cerebral artery occlusion (MCAO) in rats (Rosenberg et al., 2001). Additionally,
ADAM-10 was found to be constitutively expressed in reactive astrocytes in multiple
sclerosis patients (Kieseier et al., 2003). While our immunohistochemical results
identified reactive astrocytes as sites of MT5-MMP and ADAM-10 localization, they
failed to show MT5-MMP and ADAM-10 co-localization with microglial markers (CD-11,
IBa-1), which is consistent with other CNS inflammation and injury studies (Toft-Hansen
et al., 2007; Kieseier et al., 2003). Therefore, our results suggest that reactive
astrocytes likely function as the primary sites for synthesis and recycling of MT5-MMP
and ADAM-10, thus directly affecting the organization of the ECM during injury-induced
synaptic plasticity.
Finally, the present study suggests that, of the two membrane-bound MMPs
examined, N-cadherin may be preferentially targeted by ADAM-10 during the later
stages of reactive synaptogenesis. In vitro studies indicate that N-cadherin can be
processed by either MT5-MMP or ADAM-10 (Monea et al., 2005; Reiss et al., 2006).
However, our in vivo results reveal temporal correlates between the levels of ADAM-10
and N-cadherin which suggest that their specific interaction during the phase of synapse
stabilization is critical to synaptic recovery after TBI. Conversely, we found evidence for
the principal expression of MT5-MMP as a TIMP-2 bound form following injury, opening
the possibility that it may play a different role in the synaptogenic process. Specifically,
TIMP-2 bound MT5-MMP may function to activate proMMP-2 (Sternlicht and Werb,
2001; Nagase et al., 2006), supporting synapse organization at local sites along the
dendritic membrane. The reduction of its expression during the later stages of adaptive
synaptogenesis points to a lesser role for MT5-MMP in N-cadherin processing during
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synapse stabilization. Thus, the current study provides evidence that distinct
enzyme/substrate relationships may exist for membrane-bound MMPs during the
course of reactive synaptogenesis.
Understanding Maladaptive Synaptic Plasticity
How do our current findings add to what is already known about maladaptive
plasticity following TBI? While previous studies have examined secreted MMPs in the
UEC and TBI+BEC models, this is the first study to show that maladaptive plasticity may
be influenced by membrane-bound MMP/substrate interaction, specifically during
periods of synapse stabilization and maturation. ADAM-10, rather than MT5-MMP,
emerged as the prominent player in the maladaptive response, persistently elevated up
to 15d. Despite different responses at 15d, MT5-MMP and ADAM-10 were both
similarly elevated at the acute postinjury intervals, much like the secreted MMPs MMP
2, 3 and 9. This common elevation of expression suggests that both secreted and
membrane-bound MMPs contribute to different phases of reactive synaptogenesis. We
posit that increased ADAM-10 expression and activity at 15d post-TBI+BEC prevents Ncadherin-dependent stabilization and organization of nascent synapses, resulting in a
maladaptive form of synaptic plasticity. This is supported by our EM analysis in Chapter
3, which shows reversal of synaptic pathology after MMP inhibition. N-cadherin is also
directly linked to both post-synaptic density (PSD) organization and synaptic adhesion,
therefore proteolysis of N-cadherin would disrupt PSD structure, commonly seen in
synapse pathology (Malenka and Nicoll, 1999; Takeichi and Abe, 2006; Nuriya and
Huganir, 2006). The role of ADAM-10/N-cadherin in the generation of maladaptive
plasticity is also supported by our observation that deficits in LTP induction can be
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attenuated when MMPs are inhibited, particularly given that attenuation is temporally
correlated increased in N-cadherin expression. These improvements in synaptic
structure and function are consistent with earlier studies which showed that synapse
reorganization develops concurrently with the re-emergence of LTP following UEC
lesion (Reeves and Steward, 1986). Based on these observations, we conclude that
maladaptive plasticity is generated, in part, by ADAM-10 and N-cadherin synaptic
interaction, and that MMP inhibition has potential to prevent these impairments.
Potential benefits of MMP inhibition on Recovery
Results presented in Chapter 3 suggest the potential application of MMP inhibition
as a treatment to improve maladaptive plasticity. Our results provide evidence that
broad-spectrum MMP inhibition (GM6001) can alter expression of membrane-bound
MMPs like ADAM-10, affecting the tissue level of its synapse-related substrate Ncadherin. Inhibition of enzyme activity may also reduce expression of MMP genes
through a feedback mechanism which limits proteolysis of ECM-cell and cell-cell
contacts, stimulating intracellular signaling pathways which alter downstream
transcription and protein expression (Conant and Gottschall, 2005). In the TBI+BEC
model this would offer the benefit of returning MMP protein levels to those more in line
with adaptive recovery. We also report that deficits in the early induction phase of LTP
were attenuated with GM6001 treatment. Other studies also show that MMP inhibition
can affect hippocampal LTP following injury. MMP inhibition by FN-439 at 30 min
postinjury suppressed the emergence of LTP when compared to controls, suggesting
that inhibition of MMPs at an inappropriate postinjury period can be detrimental, even
within an adaptive environment (Phillips and Reeves, 2001). A similar negative effect of
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FN-439 on LTP was found using normal hippocampal slices, where both induction and
maintenance were impaired (Meighan et al., 2007). Taken together with our data, these
results suggest that the role of MMPs in synaptic activity is complex, and that the
application of MMP inhibitors must be considered in the context of both time postinjury
and tissue condition. The benefits of MMP inhibition during maladaptive plasticity were
further strengthened by the observation that GM6001treatment improved dendritic and
synaptic cytoarchitecture within the hippocampus. However, we were unable to show
that MMP inhibition translated into improvements in cognitive performance in the MWM.
This result emphasizes the importance of optimizing dose and delivery in order to
confirm whether or not the physiological and structural improvements are translatable
into behavioral protection. The inclusion of MMP inhibition in future studies will be
discussed below. Our results have shown the beneficial effects of MMP inhibition on
the expression of and potential interaction between ADAM-10 and N-cadherin, and
synaptic structure and function. In addition to altering membrane-bound MMP/substrate
expression and interaction, TBI and MMP inhibition can modify the downstream
extracellular and intracellular signaling pathways involved in synaptic plasticity.
Signaling Pathways and Plasticity
Interaction between MMPs and their substrates is known to influence
downstream signaling pathways to regulate neuroplasticity. Our study suggests that
ADAM-10 and N-cadherin interact at the synaptic membrane, and that TIMP-2 bound
MT5-MMP may potentially function as an activator of proMMP-2 at the same location.
In the case of membrane-bound MMPs, interaction with substrates occurs at the cell
membrane, often involving the cleavage and release of an extracellular molecular
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fragment of their substrate. MMPs which perform this lysis are termed sheddases. This
cleavage generates intracellular fragments as well, peptides that can influence
downstream signaling to affect plasticity following TBI. These pathways are well
characterized in vitro. They can involve the shedding of an N-terminal N-cadherin
fragment (NTF) by ADAM-10, which leads to γ-secretase cleavage and release of the
intracellular 40 kDa C-terminus fragment (CFT1) (Reiss et al., 2005; Uemura et al.,
2006; Kohutek et al., 2009). CTF1 can also undergo further calpain proteolysis into a
35 kDa fragment (CTF2) (Jang et al., 2009). Each of these fragments has been shown
to be involved with downstream regulation of neuroplasticity. For example, ADAM10/MMP-mediated cleavage and release of NTF promotes neurite outgrowth in cultured
cells (Paradies and Grunwald, 1993; Utton et al., 2001). Based on our results, the
production of NTF by ADAM-10 sheddase activity may permit modulation at the
synapse and promote collateral sprouting of spared axons into the damaged region
during injury-induced synaptogenesis. In addition to NTF, release of other intracellular
N-cadherin fragments has been implicated in synaptic function and plasticity.
Recall that, in Chapter 2, we demonstrated the presence of an N-cadherin 40
kDa intracellular protein fragment in both adaptive and maladaptive models. While a
significant decrease in the 40 kDa fragment was observed only at 2d post-UEC, the
presence of this fragment indicates that intracellular N-cadherin lysis occurred in both
adaptive and maladaptive models. This 40 kDa fragment likely represents CTF1,
generated through NTF production by ADAM-10. Increased CTF1 may mediate several
downstream pathways invoked by injury-induced synaptogenesis. For example, the
production of CFT1 influences synaptic structural stability and synaptic Ca2+
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conductance (Brusés, 2006; McCusker and Alfandari, 2009). Synapse structure is
disrupted when CTF1 is released from the membrane due to the breakdown of Ncadherin/catenin/cytoskeleton connections, which are necessary to provide structural
stability to the synapse (Jang et al., 2009). Our results suggest that persistent ADAM10 may be an upstream regulator of the production and release of CTF1. In this way,
MMPs may direct the evolution of abnormal synaptic cytoarchitecture which we
documented in hippocampal stratum radiatum and dentate molecular layer after
TBI+BEC insult.
Structural instability can also lead to the failure of synaptic function. Extracellular
cleavage of N-cadherin by MMPs and the intracellular release of CTF1 not only alter
connections to the actin cytoskeleton, but also change the relationship N-cadherin and
subcellular PSD proteins, including AMPA receptors and p120 catenin. When binding
between N-cadherin and these proteins changes, Ca2+ conductance is altered. These
downstream effects may help to explain the injury-induced deficits we observed in our
LTP experiment. N-cadherin has been found to mediate the placement and positioning
of AMPA receptors into the post-synaptic membrane, which is necessary for synaptic
transmission and activation of NMDA receptors which results in Ca2+ influx (Silverman
et al., 2007; Malenka and Bear, 2004). During the early induction phase of LTP, AMPA
receptors are inserted into the post-synaptic membrane, strengthening the synaptic
response. Here we showed LTP deficits at 15d post-TBI+BEC, a time when high
ADAM-10 levels were matched with decreased full length N-cadherin. Following MMP
inhibition, full length N-cadherin was increased, along with a reduction in LTP deficit.
Restoration of intact N-cadherin may have facilitated AMPA receptor membrane
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placement, therefore increasing Ca2+ conductance and improved synaptic efficacy.
Neuronal Ca2+ conductance may also be altered when p120 catenin dissociates from
RhoA and binds the juxtamembrane domain (JMD) of CTF1. In this series of events,
intracellular cleavage of N-cadherin produces a form of the molecule which recruits and
binds to p120 catenin, releasing RhoA. Free RhoA is activated upon release from p120
catenin and can then modulate voltage activated Ca2+ channels (VACC) in both preand post-synaptic sites. Through interaction with myosin-actin cytoskeleton, soluble,
active RhoA ultimately decreases synaptic Ca2+ influx (Marrs et al., 2009). Although the
mechanism is different from N-cadherin/AMPA receptor interaction, CTF1/p120 catenin
interaction has similar downstream effects on Ca2+ conductance which would also
support a decrease in synaptic efficacy after TBI+BEC and our observed effects on
LTP.
While we were unable to visualize hippocampal N-cadherin fragments smaller
than 40 kDa following injury, it is important to consider the role that such fragments may
play in neuroplasticity after TBI. Current literature shows that CTF1 can be further
processed into a 35 kDa fragment (CTF2), which also may affect synaptogenesis
through interaction with CREB and β-catenin (Reiss et al., 2005; Marambaud et al.,
2003; McCusker and Alfandari, 2009). CTF2 binds CREB binding protein (CBP),
targeting it for degradation, therefore interfering with downstream transcription of CREBdependent genes. Many of these genes are critical for CNS plasticity, such as c-fos,
synapsin I, K+ channels and the alpha subunit of Ca2+/calmodulin-dependent kinase II
(Marambaud et al., 2003; Lonze and Ginty, 2002; Deisseroth et al., 1996).
Additionally, CTF2 associates with the Wnt signaling molecule, β-catenin, promoting
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transcription of genes important for cell proliferation and survival, as well as synaptic
plasticity: cyclin D1, c-myc, c-jun, and N-cadherin (Reiss et al., 2005; McCusker and
Alfandari, 2009). CFT2-dependent action on transcription of any of these plasticityassociated genes could play a role in synaptic reorganization following TBI. Clearly,
both extracellular and intracellular N-cadherin fragments generated by ADAM-10 are
capable of altering trauma-induced synaptic plasticity through different signaling
pathways. While the role of MT5-MMP appears to be less clear, some reasonable
predictions as to its effect on reactive synaptogenesis can be made based on our
current results.
Our Western blot (WB) results showed that MT5-MMP was not detectable in its
active 58 kDa form, but rather, predominantly seen as an 80 kDa band, likely bound to
its endogenous inhibitor TIMP-2. As previously mentioned, MT5-MMP is capable of
binding toTIMP-2 in a complex with proMMP-2. The formation of this complex occurs at
the cell membrane, where the binding of TIMP-2 inhibits any catalytic activity of MT5MMP, the enzyme functioning as a docking station. TIMP-2 possesses a C-terminal
domain with a high affinity for the HLD domain of proMMP2. The proMMP-2 “substrate”
docks to the C-terminus of TIMP-2 and forms the ternary complex (Strongin et. al, 1995;
Maskos and Bode, 2003). The binding of these three proteins is insufficient to activate
proMMP-2, thus an adjacent TIMP-free MT5-MMP is needed to initiate the first proMMP-2 cleavage. Following the initial cleavage, an additional MMP-2 molecule
removes the remaining propeptide domain from the intermediate MMP-2 to yield a
mature and fully-active MMP-2 molecule (Deryugina et. al, 2001). This series of
downstream events is initiated by the placement of MT5-MMP into the cell membrane.
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Based on results from our lab and others, all components of the MT5-MMP/TIMP2/proMMP-2 complex are found to be expressed in astrocytes (Conant and Gottschall,
2005). This molecular localization and proximity further supports their interaction and
possible influence on plasticity within the deafferented molecular layer. Our lab has
previously demonstrated increases in MMP-2 gene expression and activity in the injured
hippocampus, as well as increased localization of MMP-2 in the deafferented molecular
layer 2 and 7d following both UEC and TBI+BEC (Phillips and Reeves, 2001). This data
is consistent with our the hypothesis that a significant increase in hippocampal MT5MMP expression at 2 and 7d postinjury may result in formation of the MT5MMP/TIMP2/MMP-2 complex and local MMP-2 activation.
The results presented in this dissertation add to our understanding of how
membrane-bound MMPs and N-cadherin might influence the efficacy of synaptic
plasticity following TBI. Interpretation of these results in the context of TBI
neuropathology and recovery did reveal possibilities for targeting MMP inhibition in
developing new therapies to improve postinjury recovery. While many of our initial
questions were answered, new ones arose during our investigation. The following
section describes some of these questions and the future studies which could address
them.
Future Directions
In our lab group the overall research goal is to gain greater understanding of TBI
pathophysiology and design treatment paradigms translatable to the clinic for improved
patient recovery and rehabilitation. This study expands our current understanding of
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synaptic recovery and reveals that membrane-bound MMP/substrate interaction can
positively or negatively influence this process following TBI. Our results provide
evidence that spatio-temporal changes in MT5-MMP, ADAM-10 and N-cadherin
expression correlate with functional and structural recovery, and differ in effect
depending on the plasticity conditions. However, additional investigation is needed to
confirm two missing aspects of MMP involvement: 1) to fully characterize MT5-MMP,
ADAM-10, and N-cadherin mRNA expression, and 2) to confirm injury-dependent
differences in proteolytic activity for these membrane-bound MMPs. To further examine
the specific cellular localization of ADAM-10, MT5-MMP and N-cadherin we plan to use
EM immunohistochemical techniques. We also plan to take a closer look at MMPrelated molecular mechanisms guiding neuroplasticity and identify additional
manipulations to more specifically inhibit MT5-MMP and ADAM-10. These future
studies are needed to confirm the findings in the current study.
Although we have profiled hippocampal MT5-MMP, ADAM-10, and N-cadherin
protein expression over the time course of reactive synaptogenesis, we have yet to fully
document the transcript profiles of these genes. Our preliminary 7d qRT-PCR results
provide useful information about mRNA expression in enriched ML samples, pointing to
larger model shifts in ADAM-10 and N-cadherin transcription at the tissue site of
synaptogenesis. Nevertheless, it will be important to examine mRNA expression at
later postinjury intervals in order to further dissect the persistent ADAM-10 expression in
the maladaptive model of TBI. Also, our results failed to show pronounced model
differences in MT5-MMP mRNA expression, suggesting that we need to investigate
MT5-MMP transcription at more acute postinjury periods.
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Measurement of MT5-MMP and ADAM-10 proteolytic activity is also needed to
fully understand the relationship between enzyme expression and function during
postinjury recovery. Unfortunately, no commercial assays specific for either MT5-MMP
or ADAM-10 are currently available. While we were able to assess the active 70 kDa
ADAM-10 with Western blots, this only confirms the expression of active enzyme, not its
endogenous activity. Nevertheless, we have worked with a commercial supplier of
enzyme assays in an attempt to measure ADAM-10 specific lysis using hippocampal
tissue samples from our models. The assay tested was designed for cultured cells and
did not show the same specificity in extracts from fresh brain. A feasible indirect option
for exploring MT5-MMP activity would be to first measure MMP-2 lysis in our samples.
Changes in MMP-2 activity would further support the postulated role of MT5-MMP as a
facilitator of proMMP-2 activation. While less quantitative in nature, gel zymography
methods have been used to assay membrane-bound MMP activity (Wang, 2004), which
is another option. In future studies, we will continue to investigate the different options
for accurate measurement of MT5-MMP and ADAM-10 proteolytic activity.
In addition to above directions, we will focus on molecular mechanisms involving
membrane-bound MMPs which might influence the postinjury plasticity process. For
example, we are currently investigating the role of β-catenin in postinjury gene
transcription. N-cadherin lysis by ADAM-10 results in intracellular processing of Ncadherin fragments and the release of binding partner β-catenin, leading to its nuclear
translocation and altered gene transcription of plasticity pathways (McCusker and
Alfandari, 2009; Reiss et al., 2005; Lyuksyutova, AI et al., 2003; Yu and Malenka, 2003;
Gogolla et al., 2009). Our preliminary studies with hippocampal β-catenin protein show
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a significant decrease of full-length (94 kDa) β-catenin and an increase in detection of
fragments (90 and 75 kDa) across all post-TBI+BEC times (See Appendix Fig E-1).
Interestingly, in molecular layer enriched samples, this pattern of fragment generation
was detected only at the acute 2d postinjury interval (See Appendix Fig E-2). These
results show that hippocampal β-catenin protein lysis occur throughout the time course
of reactive synaptogenesis, with pronounced increases in a 75 kDa form. Overall,
maladaptive recovery produces greater change in β-catenin at 2 and 7d postinjury,
generating more of the 75 kDa fragment. Notably, these shifts are spatio-temporally
correlated with elevation of ADAM-10 and reduction of N-cadherin. For future studies
we posit that ADAM-10 proteolysis of N-cadherin alters β-catenin binding within the
post-synaptic site, resulting in the generation of fragments which are translocated to the
cell nucleus as transcription factors, targeting genes associated with synaptic plasticity.
In the context of this β-catenin hypothesis, we will investigate changes in transcript and
protein expression of plasticity associated genes. Manipulation of these molecules or
the mechanism by which they act will also support our current findings.
In Chapter 3 we showed that broad-spectrum MMP inhibition improved synaptic
structure and function in the maladaptive TBI+BEC model. While these effects were
modest, we believe that inhibition of membrane-bound MMPs remains an important
area of study with clinical relevance, not only for TBI, but also for additional pathologies
that involve MMPs. We have traditionally used broad-spectrum MMP inhibitors,
including FN-439 and GM6001, when characterizing MMP activity and role during injuryinduced plasticity. A chief issue with these drugs is the lack of specificity for individual
MMPs. Specific MT5-MMP and ADAM-10 inhibitors were not commercially available for
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use in the present experiments. In the interim, new inhibitors have been developed that
preferentially target ADAM-10. In several studies, the compound GI254023X has been
shown to block in vitro ADAM-10 induced shedding of N-cadherin, L1, Fas-ligand,
Pcdhγ, VE-cadherin, and CX3CL1 (Ludwig et al, 2005; Hoettecke et al., 2010;
Hundhausen et al, 2003; as reviewed in Pruessmeyer and Ludwig, 2009). Specific
pharmacological inhibitors of MT5-MMP have yet to be developed, therefore future
MT5-MMP studies in TBI may involve knock down experiments employing siRNA or
transgenic approaches. In a preliminary study, we have applied MT5-MMP siRNA in
vivo 24h prior to UEC and successfully reduced injury-induced elevations in MT5-MMP
protein at the 2d postinjury (Phillips, unpublished data). Additionally, both ADAM-10
and MT5-MMP knockout mice are commercially available for use in neuropathology
research and will be a useful tool for TBI as well (Komori et al, 2003; Folgueras et al.,
2009; Postina et al., 2004).
In addition to broad-spectrum MMP inhibition, we have used established
neuroprotective treatments to determine their effect on MMP expression and activity.
Drugs such as MK-801(NMDA antagonist) show tandem neuroprotection and altered
expression of secreted MMPs (Phillips and Reeves, 2001; Falo et al., 2006). We will
use such agents in future studies to determine how membrane-bound MMPs and their
synaptic substrates respond to protective therapies. In the case of MT5-MMP activation
of proMMP-2, we have already shown that MK-801 treatment results in reduction of
MMP-2 activity at 7d post-TBI+BEC. Based on this data, we would predict that
postinjury treatment with MK-801 may also result in significant effects on ADAM-10 and
N-cadherin expression and/or function. Such experiments will further identify specific
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role(s) of membrane-bound MMPs MT5-MMP and ADAM-10 and their substrates during
injury-induced plasticity. Lastly, regardless of the method or target of manipulation, it is
imperative to develop the appropriate dosing and delivery paradigm. Therefore, future
manipulations will first require more complete pharmacological studies to characterize
treatment response along the synaptogenic time course. This approach is particularly
important with respect to our MWM experiments, where, using a single dosing paradigm
for GM6001, we failed to detect significant effects on cognitive performance.
Final Remarks
Collectively, the series of experiments presented in this dissertation give greater
insight into the role of membrane-bound MMPs and their substrates during synaptic
plasticity induced by TBI. Through characterization and manipulation of these
molecules, we also broadened our understanding of the process of maladaptive
synaptic plasticity, and developed additional questions for future studies. Our lab
continues to test the importance of matrix molecules such as MMPs in the process of
synaptic recovery. We strive to develop treatment options that prevent the persistent
impairments that ensue following TBI and promote successful recovery.
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Figure A-1 Unilateral Entorhinal Cortex Lesion Stereotaxic Sites. Coronal section
of rat brain with stereotaxic lesion sites indicated by black circles at 3, 4, and 5mm
lateral to midline.
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Figure A-2 Craniectomy Sites and Fluid Percussion Injury Device. (A) Craniectomy
site (black) for central fluid percussion injury hub placement (located midway between
bregma and lambda); Right and left craniectomy sites (red) for bilateral entorhinal cortex
lesions (superior to entorhinal cortex).
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Figure B-1 Co-migration of MT5-MMP and TIMP-2 in Protein Analysis.
Representative gel blots illustrating co-migration of TIMP-2 with MT5-MMP within gel
system, indicating potential MT5-MMP/TIMP-2 binding in hippocampal tissue.
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Figure B-2 Hippocampal Protein Expression of Additional MT5-MMP Forms
following UEC. Values expressed as percent of contralateral hippocampus over 2, 7,
and 15d postinjury time intervals. As indicated in Chapter 2, UEC insult produced
significant increases in 80 kDa MT5-MMP (MT5) at 2 and 7d, however, an additional
minor 85 kDa form was observed to decrease across all postinjury time intervals. 2d:
n=7; 7d: n=4; 15d n=6. *p<0.05, **p<0.01, ***p<.001.
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Figure B-3 Hippocampal Protein Expression of Additional ADAM-10 Forms
following UEC. Values expressed as percent of contralateral hippocampus over 2, 7,
and 15d postinjury time intervals. As indicated in Chapter 2, UEC insult induced a
significant increase in 70 kDa ADAM-10 protein expression at 2 and 7d with a reduction
to levels not different from controls at 15d. By contrast, 100 kDa and 80 kDa forms
showed significant reductions across all postinjury time intervals. 2d: n=4; 7d: n=5; 15d
n=4. *p<0.05, **p<0.01.

267

Figure B-4 Hippocampal Protein Expression of Additional N-cadherin Forms
following UEC. Values expressed as percent of contralateral hippocampus over 2 and
15d postinjury time intervals. As indicated in Chapter 2, UEC insult produced a
significant reduction at 2d for both 130 kDa and 40 kDa forms, and 15d elevation for the
130kDa form. The 40 kDa form was not measurable at 7d, therefore this time interval
was not represented. 2d: n=7; 15d n=6. *p<0.05, **p<0.01.
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Figure B-5 Hippocampal Protein Expression of Additional MT5-MMP Forms
following TBI+BEC. Values expressed as percent of sham controls over 2, 7, and 15d
postinjury time intervals. As indicated in Chapter 2, TBI+BEC induced a significant
increase in 80 kDa MT5-MMP (MT5) protein expression at 2 and 7d, with reduction to
levels not different from controls at 15d. By contrast, the additional 85 kDa form
showed significant reduction across all postinjury time intervals. Injured=I, Sham=S; 2d:
I=10, S=8; 7d: I=16, S=10; 15d I=8, S=7; *p<0.05, **p<0.01, ***p<0.001.
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Figure B-6 Hippocampal Protein Expression of Additional ADAM-10 Forms
following TBI+BEC. Values expressed as percent of sham controls over 2, 7, and 15d
postinjury time intervals. As indicated in Chapter 2, TBI+BEC produced a significant
increase in 70 kDa ADAM-10 over all postinjury time intervals. By contrast, 100 kDa
and 80kDa showed a significant reduction at 2d only, and levels not different from
controls at 7 and15d. Injured=I; Sham=S; 2d: I=6, S=8; 7d: I=7, S=9; 15d I=7, S=8;
*p<0.05, **p<0.01, ***p<0.001.
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Figure B-7 Hippocampal Protein Expression of Additional N-cadherin Forms
following TBI+BEC. Values expressed as percent of sham controls over 2, 7, and 15d
postinjury time intervals. As indicated in Chapter 2, TBI+BEC produced a significant
reduction at 2 and 7d in the 130 kDa form and levels not different from control in the 40
kDa form across all postinjury time intervals. Injured=I; Sham=S; 2d: I=9, S=8; 7d: I=1516, S=10; 15d I=7, S=3-8; *p<0.05.
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Figure B-8 Representative β-actin load control for Western blot Analysis. β-actin
(42kDa) was selected as a load control for TBI+BEC Western blot analysis in Chapters
2 and 3. Representative samples from 2, 7, and 15d TBI+BEC blots show a typical
pattern indicative of even loading in injured (I) and sham control (S) lanes across all
postinjury time intervals.
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Figure B-9 Downstream Intracellular Signaling as a Result of N-cadherin
Processing by ADAM-10. Schematic representation of ADAM-10 induced N-cadherin
ectodomain shedding at the synaptic interface. N-cadherin processing and
fragmentation may have downstream influence on ion conductance, structural integrity
of the synapse, and β-catenin and CREB driven gene transcription. These events may
potentially affect the plasticity process and recovery following TBI.
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Figure C-1 Molecular Layer Localization of ADAM-10 with GFAP at 2 and 15d
following UEC. Confocal overlay images showing ADAM-10 (green) and GFAP (red)
co-localization (yellow) in ipsilateral (injured) and contralateral (control) dentate
molecular layers at 2 and 15d postinjury. In ipsilateral images note increased ADAM-10
signal filling reactive astrocytes throughout molecular layer at 2d. By 15d, signal is
concentrated in the outer molecular layer. Contralateral side shows ADAM-10
localization within non-reactive astrocytes, but with a much reduced level of signal. 40X
magnification.
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Figure C-2 Molecular Layer Localization of ADAM-10 with GFAP at 2 and 15d
following TBI+BEC. Confocal overlay images showing ADAM-10 (green) and GFAP
(red) co-localization (yellow) in combined-injured and sham dentate molecular layers at
2 and 15d survival. Note increased ADAM-10 signal filling reactive astrocytes
throughout molecular layer at 2d postinjury. As in the UEC, ADAM-10 signal is
concentrated in the outer molecular layer at 15d post-TBI+BEC. Sham shows reduced
ADAM-10 signal within non-reactive astrocytes throughout molecular layer. 40X
magnification.
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Figure C-3 Molecular Layer Localization of MT5-MMP with GFAP at 2 and 15d
following UEC. Confocal overlay images showing MT5-MMP (green) and GFAP (red)
co-localization (yellow) in ipsilateral (injured) and contralateral (control) dentate
molecular layers. In the ipsilateral side, note increased outer molecular layer signal at
2d and 15d. MT5-MMP is clustered within reactive astrocyte cell bodies and extends
into the glial processes. Neuronal labeling is seen as punctate signal in granule cell
bodies and throughout molecular layer neuropil. At 15d ipsilateral and contralateral
overlays show similar signal intensity and profile for MT5-MMP, despite differences in
astrocytic response. MT5-MMP granule cell signal will need further confirmation with
neuronal antibody markers. 40X magnification.
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Figure C-4 Molecular Layer Localization of MT5-MMP with GFAP at 2 and 15d
following TBI+BEC. Confocal overlay images showing MT5-MMP (green) and GFAP
(red) co-localization (yellow) in injured and sham dentate molecular layers. In injured
images, note increased in cluster-like MT5-MMPsignal within reactive astrocyte cell
bodies and out into selective processes, as well as punctate signal throughout
molecular layer and over granule cell bodies at 2d. At 15d injured and sham overlays
show similar signal intensity and profile for MT5-MMP, despite the difference in
astrocytic response. MT5-MMP granule cell signal will need further confirmation with
neuronal antibody markers. 40X magnification.
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Figure C-5 Molecular Layer Localization of N-cadherin with GFAP at 2 and 15d
following UEC. UEC confocal overlay images showing N-cadherin (green) and GFAP
(red) co-localization (yellow) at 2 and 15d in ipsilateral (injured) and contralateral
(control) dentate molecular layers. In ipsilateral images note increased N-cadherin
signal filling reactive astrocytes throughout molecular layer at 2d and concentrated in
the outer molecular layer at 15d. UEC contralateral side shows N-cadherin localization
within non-reactive astrocytes, but with much reduced signal. 40X magnification.
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Figure C-6 Molecular Layer Localization of N-cadherin with GFAP at 2 and 15d
following TBI+BEC. Confocal overlay images showing N-cadherin (green) and GFAP
(red) co-localization (yellow) at 2 and 15d injured and sham dentate molecular layers.
In 2d injured images, note increased N-cadherin signal primarily within reactive
astrocyte cell bodies, as well as punctuate signal throughout molecular layer. At 2d,
sham shows a much reduced N-cadherin signal and less reactive astrocytic labeling,
although neuropil punctuate profile is similar. At 15d injured and sham overlays show
similar signal intensity and profile for N-cadherin, despite the moderate difference in
astrocytic response. Punctate N-cadherin signal is also visible throughout the molecular
layer at 15d in both injured and sham. 40X magnification.
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Figure C-7: Representative Minus Primary Controls for ADAM-10, MT5-MMP and
N-cadherin immunostaining with GFAP. 7d UEC injured examples of tissue
processed without the primary antibody show an absence of signal. Overlay images are
representative of tissue for all immunohistochemical experiments in the study. From top
to bottom: MT5-MMP/GFAP; ADAM-10/GFAP; and N-cadherin/GFAP confocal overlay
images. 40X magnification.
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Figure C-8 Representative Molecular Layer Localization of MT5-MMP, ADAM-10,
and N-cadherin with microglial markers CD-11/Iba-1. Co-localization of MT5-MMP
with CD-11, and ADAM-10 and N-cadherin with Iba-1 in TBI+BEC injured tissue. Note
no MT5-MMP, ADAM-10 and N-cadherin signal within molecular layer microglia
following injury. MT5-MMP/ADAM-10/N-cadherin (green), CD-11/Iba-1 (red); 40X
magnification.
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Fig. D-1 Molecular layer Co-localization of MT5-MMP RNA transcript with GFAP 7d
post-UEC. Confocal images showing single channel MT5-MMP anti-sense ribroprobe
(red) and reactive astrocytic marker GFAP (green) and overlay (yellow). Note increased
co-labeling in outer molecular layer, primarily within astrocytic processes. 40X
magnification.
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Figure E-1 Hippocampal Protein Expression of β-catenin following TBI+BEC.
Values expressed as percent of sham controls. Significant increase of 90 kDa and 75kD
β-catenin forms was seen at all time points, with significant decrease in 94 kDa at 2 and
7d. Greatest change in expression was found in the 75 kDa form, peaking at 7d.
Representative blots shown below. I=Injured; S=Sham. 2d: Injured n=5, Sham n=3; 7d:
Injured n=9, Sham n=4; 15d: Injured n=4, Sham n=3. *p<0.05.
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Figure E-2 Molecular Layer Protein Expression of β-catenin following TBI+BEC.
Values expressed as percent of sham controls. Significant increase in 75 kDa form and
decrease in 94 kDa form was seen only at 2d. No significant changes in β-catenin
expression were found at 7 and 15d. A measurable 90 kDa form was not detectable in
ML samples. Representative blots shown below. I=Injured; S=Sham; n-values: 2d I=4,
S=6; 7d I=4, S=4; 15d I=3, S=3; *p<0.05.A
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